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From Research to the Real World
Chapter 1
General introduction
10
ment of T2DM. The key recommendations for the 
management of T2DM centre on lifestyle manage-
ment (diet, weight control, smoking cessation and 
physical activity), optimal control of blood glucose 
and blood pressure (BP), screening and treatment 
of retinopathy, neuropathy and nephropathy and, 
when necessary, referral to specialist services.18–23 
The ADA/EASD guidelines provide treatment 
goals for HbA1c (≤53 mmol/mol), systolic BP 
(≤140 mmHg) below which it is thought the risk 
of complications is as low as possible.18,19 Cur-
rently, the guidelines also underline the necessity 
to personalize HbA1c goals, taking into account 
several, modifiable and non-modifiable risk fac-
tors, such as diabetes duration and the presence 
of complications, resulting in less or more strin-
gent HbA1c goals.  
The ‘grounds’ of the current treat-
ment guidelines
To understand the background of the current 
guidelines, it is necessary to know on which theo-
ry they are grounded. 
The current guidelines are mostly based on the 
outcomes of randomized clinical trials (RCTs). 
Four major RCTs are mainly representable for 
the grounds of the current guidelines; the Diabe-
tes Control and Complications Trial (DCCT),24 
the United Kingdom Prospective Diabetes Study 
(UKPDS)25,  Action to Control Cardiovascular 
risk in Diabetes (ACCORD) study,26  and the 
Action in Diabetes and Vascular Disease (AD-
VANCE)27 study. 
From these trials, three concepts concerning 
T2DM management arose on which the guidelines 
heavily rely; 
1.  The lower, the better
2.  The earlier, the better
3.  Personalized care
The lower, the better
Treatment goal setting in T2DM management ini-
tially came from the DCCT and the UKPDS study, 
that aimed to prove the benefit of tight blood glu-
cose control.24,28 Although tight glucose control 
was already thought to be beneficial in terms of 
prevention of developing complications, these tri-
als proved the hypothesis for the first time.
Diabetes Mellitus
Diabetes Mellitus is a chronic metabolic disorder, 
characterized by increased blood glucose levels. 
The two clinically most common and important 
types of diabetes mellitus are Type 1 Diabetes 
Mellitus (T1DM) and Type 2 Diabetes Mellitus 
(T2DM). 
T1DM is caused by insulin deficiency following 
destruction of the insulin-producing pancreatic 
beta cells. It presents mostly in childhood, but 25% 
of the patients diagnosed with T1DM are adults.1 
T2DM is the most common type of diabetes with 
about 90% of the patients having T2DM.2,3 The dis-
ease is characterized by deficient beta-cell func-
tion, hyperglycemia, insulin resistance and relative 
impairment of insulin secretion.4,5 It is a common 
disorder worldwide with a prevalence that has 
risen substantially over the years,2,4,6,7 mainly con-
tributable to the increasing prevalence of people 
with obesity and a sedentary lifestyle.8 
In 2000, 171 million (2.8%) people were estimated 
to have diabetes, and it is thought that this number 
will increase to an impressive number of 366 mil-
lion (4.4%) patients in 2030.2,3 
This thesis focuses on T2DM and its complications.
Complications of Type 2 Diabetes  
Mellitus
Due to the harm that hyperglycemia (and fre-
quently in combination with hypertension) poses 
on the body and its vascular system, T2DM pa-
tients are at increased risk of developing a large 
array of complications.9 Roughly, the vascular 
complications can be divided into microvascular 
(diabetic retinopathy, nephropathy, and neuropa-
thy) and macrovascular complications (i.e. car-
diovascular disease [CVD]; hypertension, heart 
failure). Furthermore, T2DM is associated with 
the occurrence of deteriorated cognitive func-
tioning,10 cancer and cancer mortality,11–15 CVD 
mortality as well as all-cause mortality.16,17
Current treatment guidelines of 
Type 2 Diabetes Mellitus
To lower the risk of complications resulting from 
T2DM, the American Diabetes Association (ADA) 
and the European Association for the Study of 
Diabetes (EASD)18,19 provide, yearly updated, ev-
idence-based recommendations on the manage-
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with higher, probably longstanding blood glucose 
levels at baseline,31 suggesting that the body could 
remember long periods of hyperglycemia.  Fur-
thermore, strict glycemic control from the start 
of T2DM management was beneficial on the long-
term. 
These results validated the experimental evidence 
that early metabolic environment is remem-
bered32 and therefore gave credit to the concept;
“The earlier, the better”
Personalized care
The ACCORD26 and the ADVANCE27 studies 
aimed to provide evidence for the concept “the 
lower is really better”, failed to do so but did 
show that “one size does not fit all” T2DM pa-
tients.
Within the ACCORD study, including mostly 
older T2DM patients with a longer diabetes dura-
tion as compared to the UKPDS, patients within 
the very strict glycemic control group (HbA1c 
<6%) showed a reduced risk of neuropathy and 
microalbuminuria, but no change in risk of retin-
opathy.33,34 Furthermore, an increased risk of all-
cause and CVD mortality was observed in T2DM 
patients with very strict glycemic control, causing 
the study to eliminate early.26 
However, subgroup analyses showed that patients 
within the intensive glycemic control group with 
HbA1c levels ≤8.0% at baseline had a significantly 
reduced risk of developing CVD complications, 
whereas those with very poor glycemic control 
(HbA1c >8%) had an increased CVD risk. Anoth-
er difference in the effect of very strict glycemic 
control was observed in patients without prior 
CVD, who had a significantly reduced risk of CVD 
complications whereas those with prior CVD at 
baseline did not. 
Within the ADVANCE study, microalbuminuria, 
but not CVD nor retinopathy, was significantly 
reduced in the intensive glycemic control (HbA1c 
<6.5%) subgroup.27,35 Subgroup analyses further 
showed that the benefit of intensive control was 
greater in patients younger than 65 years. 
With these subgroup analyses, the ACCORD and 
the ADVANCE studies were the first to show 
that not every T2DM patient has the same risk 
The DCCT was the first to compare intensive 
treatment with conventional treatment.24  Since 
this study aimed at T1DM, it will not be further 
discussed here. 
Evidence for T2DM came from the UKPDS trial. 
Newly diagnosed T2DM patients were randomly 
assigned to either conventional (diet only) or in-
tensive treatment.28,29 In addition, hypertensive 
T2DM patients were randomized to “tight” or 
“less tight” blood pressure (BP) control to show 
the benefits of lowering BP.25
Patients within the intensive treatment group 
showed a risk reduction of 25% for any microvas-
cular complication28 but a benefit in terms of mor-
tality or cardiovascular events was only shown in 
overweight patients treated with metformin.29 
Although the UKPDS trial did not show a clear 
benefit in terms of cardiovascular events or mor-
tality, a positive association was shown from the 
observational study following the UKPDS.21 Each 
1% reduction in  HbA1c value decreased the risk 
of any complication or diabetes related mortality 
by 21% and of all-cause mortality by 14%. 
The association between HbA1c and the rate of 
complications showed a positive linear relation-
ship,21,24,28 and as no threshold of HbA1c was iden-
tified below which the risk of complications no 
longer decreased, the first concept arose; 
“The lower, the better”
The earlier, the better
The concept of a glucose “legacy effect” (initially 
called “memory effect”) emerged from the Steno 
and DCCT trials on the effect of strict glycemic 
control in retinopathy in patients with insulin-de-
pendent diabetes and background retinopathy.30 
From the outcome of these trials came the con-
cept that the body could essentially “remember” 
long periods with high blood glucose, and this was 
called the “memory effect.” This term was later 
substituted by “legacy effect” when the results of 
the ten-year follow-up of the UKPDS study were 
issued.25 In T2DM, all data available on the legacy 
effect were generated from the UKPDS study. 
The UKPDS trial also showed that patients with 
lower glucose levels at baseline developed less 
complications over time as compared to people 
12
Study populations
Diabetes Care System
The Diabetes Care System (DCS) organizes man-
aged diabetes care with contracted health care 
providers in the region of West-Friesland in The 
Netherlands, a region with about 200,000 inhabit-
ants, representative of a Caucasian population. All 
general practitioners in the region refer a patient 
to the DCS as soon as he/she is diagnosed with 
T2DM. In the period between 1998 and 2011, 
9849 T2DM patients with varying diabetes dura-
tions entered the DCS in different years.36 Start-
ing at diabetes diagnosis, patients receive an an-
nual extended diabetes assessment at the DCS 
in addition to the diabetes care offered by the 
patients’ GPs. Patients have a central role in their 
care and self-management is stimulated by provid-
ing education and information programs. Moreo-
ver, individual care plans are discussed with the 
patient and patients are encouraged to make their 
own choices with respect to treatment options 
and lifestyle behavior.44
Due to the open and dynamic nature of the co-
hort, the number of patients decreases every year 
due to loss to follow-up, referral or death. In ad-
dition, ‘newer’ patients who enter the cohort at 
a later stage, have a shorter follow-up duration. 
For each patient, the year of entry to the DCS 
was considered to be the baseline measurement 
(T1).36 
The DCS consists of a large care cohort of T2DM 
patients treated within primary care. 
The DCS has a long-term and well-characterized 
follow-up and offers the opportunity to study the 
effect of current blood glucose and BP goals and 
risk factors on diabetic retinopathy and other 
outcomes of T2DM in a real-world setting.
Hoorn Study
The Hoorn study is a population-based cohort 
study on glucose metabolism. It started in 1989, 
when 3553 individuals aged 50-74 years were invit-
ed to participate. Eventually, 2484 (70%) Caucasian 
individuals participated. Within this cohort, two 
75-g oral glucose tolerance tests were performed 
to determine the glucose tolerance status.45 
Follow-up measurements in subsamples of the 
original cohort were conducted in 1996-1998, 
and that very strict glycemic control can be harm-
ful in some T2DM patients, whereas it might be 
beneficial in others. This was a major contribution 
to the concept;
 
“Personalized care”
The linking but missing pin -  
Evidence from the real world
As outlined, the guidelines are merely based on 
outcomes of RCTs. However, patients included in 
RCTs generally do not reflect the clinical T2DM 
population and represent only a highly selected 
patient group defined with detailed inclusion and 
exclusion criteria.36 
Therefore, it is perhaps not surprising that cross-
sectional studies within clinical care show that 
only 40-60% of the T2DM patients meet the rec-
ommended blood glucose37–40 and/or blood pres-
sure41–43 targets. Thus, the current guidelines do 
not fit all clinical T2DM patients. It has already 
been acknowledged that “the lower, the better” 
and “the earlier, the better” do not pose benefi-
cial effects for each T2DM patient and the ten-
dency towards “personalized care” is necessary 
to reach adequate multifactorial diabetes manage-
ment for each T2DM patient. However, to reach 
this, a greater understanding of the effect of cur-
rent blood glucose and BP goals and risk factors 
on outcomes of T2DM in a real-world setting is 
required. Long-term real-world data derived from 
T2DM patients treated within regular diabetes 
care are scarce. As a consequence, personalized 
care cannot be implemented and the question 
“what works for whom and in what context?” 
remains yet to be unanswered. 
Main objective
This thesis comprises a number of real-world stud-
ies and tries to complement the current guidelines 
by providing a step towards personalized care. 
The main objective of this thesis is to reach a 
greater understanding of the variation in current 
glucose and BP goal attainment rates and its as-
sociation with risk factors on diabetic retinopa-
thy and other complications of T2DM in a real-
world setting. 
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1999-2001 and 2007-2009. Individuals received 
an extensive range of measurements, including 
ophthalmologic examinations,46 echocardiogra-
phy47 and cognitive function tests.10 Furthermore, 
all participants were followed with respect to 
cause-specific mortality.48 To assess the pres-
ence of retinopathy, fundus photography was 
performed with mydriasis of both eyes with 0.5% 
tropicamide and 2.5% phenylephrine eye drops. 
One photograph was centred on the macula 
and the other nasally with the optic disc one 
diameter from the temporal edge. A 45 degrees 
CR5 nonmydriatic retinal camera (Canon, Tokyo, 
Japan) was used. All photographs were graded 
according to the Eurodiab classification score,49 
in which grade 0 is “no retinopathy,” grade 1 is 
“minimal nonproliferative retinopathy,” grade 2 is 
“moderate nonproliferative retinopathy,” grade 
3 is “severe nonproliferative or preproliferative 
retinopathy,” grade 4 is “photocoagulated retin-
opathy” and grade 5 is “proliferative retinopathy”. 
In each patient the ‘worst’ eye was graded for 
retinopathy.
Outline of thesis
In the first part of this thesis (chapter 2-7), sub-
groups of T2DM patients and its relation to out-
comes are identified. Subgroups with distinct tra-
jectories of  HbA1c (chapter 2 and 3) and systolic 
blood pressure (chapter 5) are identified. Fur-
thermore, subgroups of patients at increased risk 
of cancer and all-cause mortality (chapter 4), left 
ventricular dysfunction (chapter 6) and cognitive 
impairment (chapter 7) are explored. 
In the last part of this thesis (chapter 8), the sec-
ond step towards personalized care is set by in-
troducing and validating a personalized screening 
model to screen for diabetic retinopathy. 
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Chapter 2
Distinct HbA1c trajectories in a type 2 
diabetes cohort
I Walraven, MR Mast, T Hoekstra, APD Jansen, AAWA van der Heijden, SP Rauh, 
F Rutters, E van ‘t Riet, PJM Elders, AC Moll, BCP Polak,  JM Dekker, G Nijpels
Acta Diabetologica 2015 Apr;52(2):267-75.
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more, long-term cumulative effects of hyperglyce-
mia are known to be associated with an increased 
risk of all-cause and cardiovascular mortality.4,5 
The current ADA/EASD guidelines6 for the man-
agement of T2DM recommend HbA1c levels of 
≤ 53 mmol/mol (≤ 7.0%) in patients with early 
T2DM or a relatively long life expectancy. Al-
though most patients respond adequately to glu-
cose-lowering therapy,7 T2DM has a heterogene-
ous character. Not every patient may benefit from 
the same type of glucose management and there 
may be certain patients for whom different care 
strategies and less stringent HbA1c targets are 
appropriate. Therefore, the current ADA/EASD 
guidelines6 also placed emphasis on a more per-
sonalized care approach where higher  goals are 
accepted in patients not likely to reach an HbA1c 
≤ 7.0 % (≤ 53 mmol/mol). 
These guidelines were merely based on outcomes 
of randomized clinical trials (RCTs).6 However, 
patients included in RCTs do not reflect the gen-
eral T2DM population and represent only a highly 
selected patient group defined with detailed in- 
and exclusion criteria. Long-term clinical data de-
rived from patients who were treated within reg-
ular diabetes care are scarce. As a consequence, 
clinical characteristics of T2DM patients with gly-
cemic control trajectories that are distinct from 
achieving the recommended  HbA1c target are 
inadequately studied. Latent class growth mod-
eling (LCGM) is an innovative statistical method 
used to determine those subgroups (classes) of 
patients with distinct HbA1c trajectories.8 Iden-
tifying those classes may help to characterize 
patients for whom personalized care strategies 
are needed to reach a more ‘tailor made’ HbA1c 
target. 
The Diabetes Care System (DCS) West-Friesland 
in The Netherlands consists of a large primary 
care cohort of T2DM patients. The DCS has a 
long-term and well-characterized follow-up and 
offers the opportunity to identify classes of gly-
cemic control trajectories, which is the primary 
aim of this study. Second, we assessed which 
characteristics are associated with membership 
in identified classes and whether different classes 
are associated with varying risks of developing mi-
crovascular complications. 
Abstract
Aims: To identify subgroups of type 2 diabetes 
mellitus (T2DM) patients with distinct HbA1c 
trajectories. Subgroup characteristics were deter-
mined and the prevalence of microvascular com-
plications over time was investigated.
Study Design and Setting: Data from a 
cohort of 5,423 T2DM patients from a managed 
primary care system was used (mean follow-up 
5.7 years (range 2-9 years)). Latent Class Growth 
Modeling (LCGM) was used to identify subgroups 
of patients with distinct HbA1c trajectories. 
Multinomial logistic regression analyses were con-
ducted to determine which characteristics were 
associated with different classes. 
Results: Four subgroups were identified. The 
first and largest subgroup (83%) maintained 
good glycemic control over time (HbA1c ≤ 53 
mmol/mol), the second subgroup (8%) initially 
showed severe hyperglycemia, but reached the 
recommended HbA1c target within two years. 
Patients within this subgroup had significantly 
higher baseline HbA1c levels but were otherwise 
similar to the good glycemic control group. The 
third subgroup (5%) showed hyperglycemia and 
a delayed response without reaching the rec-
ommended HbA1c target. The fourth subgroup 
(3.0%) showed deteriorating hyperglycemia over 
time. Patients within the last two subgroups were 
significantly younger, had higher HbA1c levels and 
a longer diabetes duration at baseline. These sub-
groups also showed a higher prevalence of retin-
opathy and microalbuminuria. 
Conclusion: Four subgroups with distinct 
HbA1c trajectories were identified. More than 
90% reached and maintained good glycemic con-
trol (subgroup one and two). Patients within the 
two subgroups that showed a more unfavorable 
course of glycemic control, were younger, had 
higher HbA1c levels and a longer diabetes dura-
tion at baseline.
 
Introduction
Strict glycemic control is essential in managing pa-
tients with type 2 diabetes mellitus (T2DM). The 
risk of developing both micro- and macrovascular 
complications increases considerably as glycated 
hemoglobin A1c levels (HbA1c) rise.1-3 Further-
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the baseline measurement (T1). Due to the open 
and dynamic nature of the cohort, the number 
of patients decreased every year due to loss to 
follow-up, referral or death. In addition, ‘newer’ pa-
tients who entered the cohort at a later stage, had 
a shorter follow-up duration. 
Figure 1 presents a flowchart of the included study 
population. To be able to perform latent class 
growth modeling, all T2DM patients (n = 5,423) 
with a minimum follow-up of two years were se-
lected. Patients that were excluded because they 
had less than two years of follow-up (n=4,426) 
had a significantly lower   HbA1c (-0.1%), lower 
BMI (-0.31 kg/m2), lower total cholesterol (-0.3 
mmol/L), higher age  (+5.3 years), higher systolic 
blood pressure (+3.2mmHg) and a lower diastolic 
blood pressure (-2.2mmHg) at baseline. 
 
Research Design and Methods 
An observational cohort study was performed 
with data from the Diabetes Care System (DCS) 
West-Friesland, described in detail elsewhere.9 
In short, the DCS organizes managed diabetes 
care with contracted health care providers in 
the region of West-Friesland in The Netherlands, 
a region with about 200,000 inhabitants, repre-
sentative of a Caucasian population. All general 
practitioners in the region refer a patient to the 
DCS as soon as he/she is diagnosed with T2DM. 
Study population 
In the period between 1998 and 2011, 9849 T2DM 
patients with varying diabetes durations entered 
the DCS in different years. For each patient, the 
year of entry to the DCS was considered to be 
Figure1. 
Flowchart of included patients within the DCS.
Confirmation of diabetes Year of onset of diabetes 
was obtained by self-report. Furthermore, T2DM 
was considered confirmed if at least one of the fol-
lowing criteria was present: 1) one or more clas-
sic symptoms (excessive thirst, polyuria, weight 
loss, hunger or pruritus) and (fasting plasma glu-
cose ≥ 7.0 mmol/l or random plasma glucose 11.1 
mmol/l); 2) at least two elevated plasma glucose 
levels on different occasions (fasting glucose ≥ 7.0 
mmol/l or random plasma glucose ≥ 11.1 mmol/l).  
The presence of the abovementioned criteria was 
investigated by the GP and was most of the times 
regarded as the year of onset of diabetes. When 
the confirmation of diabetes and self-reported 
year of onset of diabetes differed, the reason for 
the difference was investigated.
Drop-outs were identified as those lost to follow-
up due to death, referral and migration.
1998-2011: 9849 T2DM patients 
5423 T2DM patients with follow-up ≥ 2 years 
 
Follow-up < 2 years; 4138 
 
 3 years 
5313 
4 years 
4708 
5 years 
4153 
6 years 
3558 
7 years 
3082 
8 years 
2634 
9 years 
2185 
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Retinopathy From 1998 until 2000, fundus photog-
raphy of both eyes was performed yearly with 
a Kowa Pro Fundus camera with a green filter 
(Kowa Optical Industry, Torrance, CA). Black and 
white, 35-mm photographs were taken 30 min 
after mydriasis with 0.5% tropicamide and 2.5% 
phenylephrine eye drops. From the beginning of 
2000 until 2004, fundus photography of both eyes 
was performed with a nonmydriatic Canon CR5 
camera (Canon Inc., Tokyo, Japan). From 2004, fun-
dus photography of both eyes was performed us-
ing a nonmydriatic Topcon TRC NW 100 camera 
(Topcon, Tokyo, Japan)9. All participants were ex-
amined using 45-degree fundus photographs. One 
photograph was centred on the macula and the 
other nasally with one optic disc diameter from 
the temporal side. All photographs were graded 
by an experienced ophthalmologist according to 
the EURODIAB classification score,11 in which 
grade 0 is “no retinopathy,” grade 1 is “minimal 
nonproliferative retinopathy,” grade 2 is “mod-
erate nonproliferative retinopathy,” grade 3 is 
“severe nonproliferative or preproliferative retin-
opathy,” grade 4 is “photocoagulated retinopathy,” 
and grade 5 is “proliferative retinopathy.” In the 
DCS, EURODIAB grades 4 and 5 were combined 
and considered to be grade 4.
Statistical analysis
Baseline characteristics are presented as propor-
tion, mean (± SD) or median (interquartile range) 
in the case of a skewed distribution. 
Latent Class Growth Modeling (LCGM) was used 
to identify classes of patients with distinct tra-
jectories of HbA1 cover time.8 LCGM is a type 
of cluster analysis used to group patients into an 
optimal number of classes, each with a unique tra-
jectory of HbA1c over time, by modeling hetero-
geneity over the course of time. To determine the 
optimal number of classes, the stepwise forward 
approach was taken starting with a model with 
one developmental pattern. Then, one class at a 
time was added. The model fit was assessed with 
posterior probabilities (where probabilities > 0.8 
are recommended and a probability closer to 1 
indicates a better classification) and by the Bayes-
ian Information Criterion (BIC) (where a lower 
BIC indicates a better fit). The BIC considers the 
likelihood of the model as well as the number of 
HbA1c level was assessed yearly with a DCCT 
standardized reversed-phase cation exchange 
chromatography (HA 8160 analyzer, Menarini, 
Florence, Italy). The HbA1c level was detected 
by a dual-wavelength colorimetric (415-500). The 
intra-assay coefficient of variation (CV) was 0.6% 
at a mean level of 4.9% and the inter-assay CV was 
0.8 % at a mean level of 5.5%. 
Measurements
Fasting glucose was measured yearly in venous 
plasma by the glucose-oxidase method (Gluco-
quant/hexokinase/G6P-DH; Boehringer-Mannhe-
im, Mannheim, Germany).  
Weight and height were measured yearly (while 
patients were barefoot and wearing light clothing). 
BMI was calculated by weight in kilograms divided 
by the height in meters squared.
Systolic and diastolic blood pressure were measured 
three times on the right arm after five minutes 
of rest in a seated position, using a random-zero 
sphygmomanometer (Hawksley-Gelman, Lancing, 
Sussex, UK); from 2003 on, an oscillometric de-
vice was used (Colin Press-Mate BP-8800, Komaki 
City, Japan; from 2009 on, Welch Allyn ProBP 3400, 
Skaneateles Falls, NY, USA). 
Total cholesterol level was measured using enzy-
matic techniques (Boehringer Mannheim, Man-
nheim, Germany). 
Current medication use Use of metformin, sulfo-
nylureas (SU) derivates and insulin was obtained 
by yearly self-report. Information on medication 
use was compared with data from the PHARMO 
Network, which is a comprehensive record link-
age system in which drug dispensing data in a 
regional/national catchment area are linked to a 
registry of hospital discharge diagnoses and other 
registries.
Microvascular complications
Urinary albumin-creatinin ratio (UACR) in mg/
mmol was determined yearly in an overnight, 
first-voided urine sample. Urinary albumin was 
measured by rate nephelometry (Array Protein 
System; Beckman Coulter, Fullerton, CA) with an 
assay threshold of 2 mg/L. Urinary creatinin was 
measured using a modified Jaffé test. 
Microalbuminuria was considered present if UACR 
> 2.0 mg/mmol. 
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who entered the DCS before 2006.
Second, patients in our cohort had varying diabe-
tes durations at baseline. To investigate whether 
diabetes duration at baseline influenced the con-
struction of classes in our cohort, we further con-
ducted LCGM analyses in a subsample of newly 
diagnosed T2DM patients (diabetes duration ≤ 
one year, N=2861). 
The LCGM analyses were conducted with Mplus 
5.21, MLwin 2.25 was used to conduct binomial 
mixed modeling and further analyses were per-
formed with SPSS 20.0. 
 
Results
Baseline characteristics Table 1 presents baseline 
characteristics of the cohort and of classes identi-
fied with LCGM. 5,423 T2DM patients (mean age 
61 years, 53% male, mean HbA1c level 58 mmol/
mol) with a mean follow-up duration of 5.7 years 
(range two to nine years) were included.
parameters in the model. A lower BIC implies a 
better fit of the model, where a difference of at 
least 10 points is regarded as a sufficient improve-
ment.8
The final number of classes was based on a low 
BIC score, good probabilities (> 0.8) and clinically 
relevant differences between classes. 
Baseline characteristics of classes were assessed 
and differences (mean (± SD), proportion or 
median in the case of skewed distribution) were 
tested using ANOVA (continues variables), Chi-
square tests (categorical variables). Overall p-val-
ues for between group differences are reported. 
Subsequently, a model was created using multi-
nomial logistic backward regression analysis. In 
this analysis, we assessed which available patient 
and disease determinants at baseline were asso-
ciated with membership in classes different than 
the reference class. The glycemic control class 
that reached the recommended  HbA1c target 
(≤ 53 mmol/mol) was regarded as the reference 
class. In the first step, all potential determinants 
of membership (all determinants that were avail-
able, those included in our baseline table) were 
analyzed separately and co-linearity was tested by 
assessing correlations. Linearity of the relation-
ship between determinants and the outcome was 
tested with the Hosmer & Lemeshow-test. In the 
second step, all determinants with p-values < 0.10 
were entered simultaneously using the backward 
elimination method, leading to a model that in-
cluded only significant (p < 0.05) determinants. 
Associations of class membership with develop-
ment of retinopathy (EURODIAB grade 1 to 5), 
microalbuminuria and medication use during fol-
low-up were examined by constructing plots and 
graphically comparing differences between classes. 
Statistical significant differences were tested using 
a binomial mixed modeling approach, accounting 
for both individual and time levels. 
Sensitivity analyses In 2006, new Dutch guidelines 
for the management of T2DM were adopted and 
glycemic targets were lowered from HbA1c lev-
els of 60 mmol/mol to 53 mmol/mol.12 To inves-
tigate whether time-dependent trajectories due 
to guideline alterations were present, sensitivity 
analyses were performed by conducting LCGM 
analyses in a subsample of the cohort, i.e. in those 
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Table 1.
Baseline characteristics according to different classes of HbA1c
Cohort Good 
glycemic 
control
Fast 
respon-
ders
Insuffi-
cient 
glycemic 
control
Bad 
respon-
ders
Overall 
P-value
N (%) 5423 (100) 4508 
(83.1)
444 (8.2) 284 (5.2) 187 (3.4) -
Entry (yr) 2003 (3.5) 2004 (3.5) 2003 (2.9) 2002 (3.2) 2002 (3.0) <0.001
Drop-out (%) 522 (9.6) 416 (9.2) 53 (11.9) 33 (11.6) 20 (10.7) 0.101
Follow-up (yr) 5.7 (2.3) 5.6 (2.3) 6.9 (2.3) 6.0 (2.4) 7.1 (1.6) <0.001
Sex (% male) 2902 
(53.3)
2355 
(52.2)
268 
(60.4)
162 
(60.4)
117 
(62.6)
<0.001
Age (yr) 60.6 (11.6) 61.2 (11.3) 58.9 (12.3) 56.9 (11.7) 55.4 (13.9) <0.001
Diabetes  
duration (yr)
1.0 
(0.2 to 3.6)
1.0 
(0.2 to 3.3)
0.3 
(0.1 to 1.3)
4.1 
(0.9 to 8.8)
1.4 
(0.3 to 5.7)
<0.001
HbA1c (mmol/mol) 57.8 (19.7) 52.3 (13.9) 98.7 (15.1) 75.7 (18.0) 62.9 (17.5) <0.001
Fasting glucose 
(mmol/L)
8.6 (3.2) 8.1 (3.0) 11.7 (3.5) 10.8 (3.4) 9.3 (2.7) <0.001
BMI (kg/m2) 30.1 (5.4) 29.9 (5.2) 29.6 (5.6) 31.6 (6.9) 31.1 (5.0) <0.01
Systolic blood pres-
sure (mmHg)
142.8 
(20.9)
143.3 
(20.6)
140.3 
(20.8)
140.3 
(22.4)
140.8 
(23.1)
0.114
Diastolic blood pres-
sure (mmHg)
81.4 (11.0) 81.1 (10.1) 82.3 (11.0) 82.8 (11.6) 82.9 (11.0) <0.01
Hdl cholesterol 
(mmol/L)
1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) <0.01
Total cholesterol 
(mmol/L)
5.3 (1.2) 5.2 (1.2) 5.6 (1.4) 5.6 (1.2) 5.3 (1.2) 0.052
 * statistically significantly (p <0.05) different from the good glycemic control class. Abbreviations; yr: year, BMI: Body Mass Index: 
UACR: urinary albumin-to-creatinin ratio, SU: sulfonylureas
Four classes with distinct trajectories of HbA1c 
levels were identified (Figure 2). A four-class solu-
tion was found to be the best model according 
to the criteria described in the statistical analysis 
section. From class 1,  the BIC continued to de-
crease more than 10 points with the addition of 
each class (98486, 97146, 96590, 96142 and 95864, 
respectively). Until the fifth class, posterior prob-
abilities remained above 0.80. The addition of a 
fifth class lowered the posterior probabilities in 
one class below 0.80 and did not result in identifi-
cation of a useful class for clinical practice. 
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Figure 2. 
Trajectories of HbA1c according to different classes identifi ed by LCGM.
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The largest class (83.1% of the patients were clas-
sifi ed in this group) showed a stable pattern of 
good glycemic control (HbA1c level ≤ 53 mmol/
mol) over time and was therefore named the good 
glycemic control class, the second class (8.2%) ini-
tially showed severe hyperglycemia (mean HbA1c 
level 99 mmol/mol), then adequately responded 
to glucose management and reached the target 
HbA1c level of ≤ 53 mmol/mol within two years of 
follow-up. For the purposes of the current study, 
this class was named the fast responders class. The 
third class (5.2%) initially showed hyperglycemia 
(mean HbA1c level 76 mmol/mol) during the fi rst 
three years, showed insuffi cient respons to glu-
cose management and did not reach the recom-
mended HbA1c target and was therefore named 
the insuffi cient glycemic control class. The fourth 
class (3.4%) did not respond to glucose manage-
ment and showed deteriorating hyperglycemia 
during follow-up and was therefore named the bad 
responders class (Figure 2). 
Compared to the good glycemic control class, 
classes two to four were signifi cantly younger, had 
a longer duration of diabetes (with the exception 
of the fast responders class, that had a shorter 
duration of diabetes) and more patients entered 
the DCS during the earlier years of the study (Ta-
ble 1). Drop-out rates did not differ across the 
different classes. 
Determinants of identifi ed classes Table 2 shows 
the results of the multinomial logistic regression 
analysis. Patients within the fast responders class 
had signifi cantly higher baseline HbA1c levels, but 
were otherwise similar to the good glycemic con-
trol class. Patients within the insuffi cient glycemic 
control class and the bad responders class had 
signifi cantly higher baseline HbA1c levels, a longer 
duration of diabetes and were younger. Patients 
within the insuffi cient glycemic control class fur-
ther had signifi cantly higher BMI levels as com-
pared to patients with good glycemic control. 
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Table 2. 
Multivariate regression analyses determining characteristics of different classes, compared to class 1  
(good glycemic control).
Model 1 Model 2
Class 2 (fast responders) versus class 1
Female 0.76 (0.51 to 1.11)
HbA1c (mmol/mol) 6.60 (5.60 to 7.76)* 6.41 (5.64 to 7.29)*
Diabetes duration (yr) 0.98 (0.89 to 1.09)
Age (yr) 1.02 (1.01 to 1.04)*
Total cholesterol (mmol/L) 1.12 (0.96 to 1.30)
BMI (kg/m2) 1.04 (1.00 to 1.04)*
Class 3 (insufficient glycemic control) versus class 1
Female 0.75 (0.55 to 1.03)
HbA1c (mmol/mol) 2.86 (2.55 to 3.20)* 2.88 (2.61 to 3.17)*
Diabetes duration (yr) 1.61 (1.45 to 1.79)* 1.54 (1.41 to 1.68)*
Age (yr) 0.98 (0.96 to 0.99)* 0.98 (0.96 to 0.99)*
Total cholesterol (mmol/L) 1.15 (1.01 to 1.31)*
BMI (kg/m2) 1.06 (1.03 to 1.09)* 1.06 (1.03  to 1.08)*
Class 4 (bad responders) versus class 1
Female 0.64 (0.45 to 0.91)*
HbA1c (mmol/mol) 1.59 (1.41 to 1.79)* 1.70 (1.53 to 1.89)*
Diabetes duration (yr) 1.20 (1.08 to 1.33)* 1.21 (1.11 to 1.33)*
Age (yr) 0.97 (0.95 to 0.98)* 0.96 (0.95 to 0.98)*
Total cholesterol (mmol/L) 1.12 (0.97 to 1.30)
BMI (kg/m2) 1.03 (1.00 to 1.07)*
Estimates are odds ratios with 95% confidence intervals. A * indicates a significant association (P<0.05). Model 1 shows the multivari-
ate model including determinants with p-values <0.10. Model 2 shows the final model after backward selection, including variables 
with p-values <0.05. Nagelkerke Rsquare is 0.56.
Microvascular complications Figure 3 shows the 
presence of microvascular complications (retin-
opathy and microalbuminuria) over time, stratified 
for the different classes. Retinopathy and microal-
buminuria over time were statistically significant 
more prevalent in classes two to four, compared 
to the good glycemic control class. The bad re-
sponders class showed an increasing prevalence 
of microalbuminuria over time, while other class-
es either showed a stable or diminishing preva-
lence over time. 
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Figure 3. 
Prevalence of retinopathy (A) and microalbuminuria (>2.0mg/mmol) (B) according to different classes of HbA1c. 
SU-derivates and had the lowest utilization of in-
sulin over time. The insuffi cient glycemic control 
class and the bad responders class had a similar 
pattern of medication use and in both groups 80% 
of the patients used insulin at nine years. 
 
Medication use Figure 4 shows the medication 
trajectories of the different classes of glycemic 
control during follow-up. Use of any diabetes 
medication increased over time in all classes. Pa-
tients within the good glycemic control and the 
fast responders class mainly used metformin and 
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Sensitivity analyses showed that in the cohort in-
cluding only those patients who entered the DCS 
before 2006, the fast responders class disappeared 
and two classes showed sustained or deteriorat-
ing hyperglycemia over time (Figure 5). 
 
Figure 4. 
Proportion of metformin, SU or insulin usage according to different classes of HbA1c. 
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Figure 5. 
Classes with distinct trajectories of HbA1c in a subsample of patients who entered the cohort before 2006 .
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Sensitivity LCGM analyses of newly diagnosed 
T2DM patients showed HbA1c classes identical 
to the classes within the total study population 
(data not shown). 
Discussion
This study identifi ed four classes of T2DM pa-
tients with distinct trajectories of glycemic con-
trol during a mean of 5.7 years of follow-up; a 
good glycemic control class, a fast responders 
class, an insuffi cient glycemic control class and 
a bad responders class. Higher  HbA1c levels, a 
longer diabetes duration and younger age at base-
line were associated with a more unfavourable 
course of glycemic control over time.  
To our knowledge, this is the fi rst study identify-
ing classes with distinct trajectories of glycemic 
control in a clinical T2DM cohort. Existing studies 
have calculated a ‘one size fi ts all’ average HbA1c 
trajectory or have not used longitudinal measure-
ments of HbA1c levels.13-17 Considering the het-
erogeneous character of T2DM, the assumption 
that one homogenous trajectory represents the 
whole T2DM patient group may be too simplistic. 
Our classes represent glycemic control hetero-
geneity within primary diabetes care more accu-
rately. 
The good glycemic control class and the fast 
responders class represent the ‘healthiest’ and 
therefore most desirable classes from a clini-
cal perspective. These classes represent the vast 
majority (91.3%) of the total cohort, indicating 
that most patients are likely to reach the recom-
mended HbA1c target in the context of managed 
primary diabetes care. This proportion is higher 
than that resulting from a recent observational 
study from the United States (U.S.),18 in which 
almost half of the U.S. T2DM patients did not 
meet the recommended HbA1c target. It is also 
higher as compared to Europe, where about 60% 
reaches HbA1c levels of < 7.5%.19-21 The present 
study population consists of a well treated group 
of T2DM patients, who were treated according to 
a managed care plan in the DCS. Starting at diabe-
tes diagnosis, patients receive an annual extended 
diabetes assessment at the DCS in addition to 
the diabetes care offered by the patients’ GPs. 
Patients have a central role in their care and self-
management is stimulated by providing education 
and information programs. Moreover, individual 
care plans are discussed with the patient and pa-
tients are encouraged to make their own choices 
with respect to treatment options and lifestyle 
behavior.22 The organization of care within the 
DCS may be an important reason why the in-
cluded patients are so well controlled. Therefore, 
these results might not be generalizable to other 
populations where glucose levels are controlled 
to a lesser extent. However, the clinical character-
istics of patients who reached the recommended 
HbA1c target and characteristics of those who 
did not, are comparable to other observational 
studies.19-21 Therefore, it is likely that the identi-
fi ed trajectories also exist in other T2DM popula-
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of macrovascular complications, neuropathy, life-
style, treatment intensification and treatment ad-
herence in the different classes. Year of onset of 
diabetes was obtained by self-report, which might 
have led to less precise information on year of 
onset of T2DM. However, T2DM was only con-
sidered present when the criteria as described in 
the methods section were met, which were in-
vestigated by the GP. Therefore, and considering 
the relatively short diabetes duration at baseline, 
it is unlikely that the use of self-reported year of 
onset of type 2 diabetes influenced our findings. 
Another limitation is that HbA1c levels were only 
measured once a year. This might have led to less 
precise construction of the classes. However, as 
the HbA1c levels were quite stable throughout 
time, it is unlikely that missing intermediate in-
formation on HbA1c levels resulted in different 
trajectories. 
Furthermore, the proportion of medication use 
might be an underestimation, since information 
about medication use was obtained via self-
reporting. However, comparison of the diabetes 
medication with data from the PHARMO net-
work showed an almost complete agreement. 
Therefore the degree of underestimation is prob-
ably negligible. 
The use of LCGM as a method to define classes 
with distinct trajectories has some limitations. The 
first limitation concerns the complexity and flex-
ibility of the model. There are numerous, some-
what arbitrary, choices to make and each decision 
could potentially influence the final number of 
classes. Furthermore, the extraction of the classes 
from the data does not prove the existence of 
multiple subgroups, but is a simplification of real-
ity, which should be kept in mind when conducting 
LCGM. However, an advantage of LCGM is that 
categorization is not based on subgroups deter-
mined a-priori, but on trajectory characteristics 
of HbA1c derived from the data. Further, LCGM 
is focused on relationships among individuals, and 
makes it possible to categorize them in homog-
enous subgroups.8
Strengths of this study include its large sample size 
with a short T2DM duration at baseline, standard-
ized measurements of T2DM related risk factors 
and complications. The study was longitudinal in 
tions, probably with dissimilar proportions across 
classes. Nonetheless, the existence of the identi-
fied classes needs to be confirmed in other clini-
cal study populations. 
Patients in the insufficient glycemic control class 
and the bad responders class included relatively 
more patients with a longer diabetes duration and 
who entered the DCS during the earlier years of 
the study. Sensitivity analyses showed that the fast 
responders class was not present in the group 
of patients who entered the DCS before 2006. 
Our findings confirm the results of previous stud-
ies18,23 and may indicate that the proportion of 
patients with bad or insufficient glycemic control 
decreased during more recent years due to ear-
lier referral and improved glucose management. 
Our findings are in accordance with other stud-
ies24-30 that reported an association between de-
teriorating glycemic control and an increased risk 
of microvascular complications. The fast respond-
ers class consisted mainly of newly diagnosed 
diabetes patients and had a higher baseline preva-
lence of microvascular complications compared 
to the good glycemic control class. Nevertheless, 
the prevalence of microvascular complications in 
the fast responders class immediately decreased 
following tight glycemic control. These findings 
confirm that strict glycemic control in newly di-
agnosed T2DM patients has a beneficial effect 
on a patient’s risk of developing microvascular 
complications. This study did not investigate the 
pathways underlying hyperglycemia and the risk 
of developing microvascular complications. One 
suggested pathway is that hyperglycemia induces 
pathogenic mechanisms, such as systemic low-
grade inflammation, oxidative stress and micro- 
or macrovascular endothelial dysfunction which 
itself are associated with micro- and macrovascu-
lar complications in individuals with T2DM.24,31,32
A limitation of our study is that selective drop-
outs may have occurred. However, since the pro-
portion of dropouts did not differ across classes, 
it is unlikely that the occurrence of selective 
dropouts influenced the construction of classes 
within our cohort. Another limitation is that we 
did not have information on the development 
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nature, with nine years of follow-up and multiple 
measurements of HbA1c from each participant, 
allowing identification of HbA1c trajectories. 
To conclude, four classes with distinct trajectories 
of glycemic control were identified in a Dutch 
population of 5,423 T2DM patients. More than 
90% reached the recommended HbA1c target and 
had a low prevalence of microvascular complica-
tions during an average of 5.7 years of follow-up. 
Patients within the insufficient glycemic control 
and the bad responders class had an increased 
prevalence of microvascular complications over 
time. These findings may be the first step towards 
personalized care and confirm that strict glycemic 
control, especially in newly diagnosed T2DM pa-
tients below the HbA1c target of ≤53 mmol/mol 
diminishes a patient’s risk of developing microvas-
cular complications. Patients with a longer dura-
tion of diabetes and a younger age before initiation 
of glucose management may require personalized 
care strategies to achieve tailor-made glycemic 
control and to decrease the risk of developing mi-
crovascular complications. 
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Introduction 
The guidelines of the American Diabetes Associa-
tion (ADA) and the European Association for the 
Study of Diabetes (EASD) for the management 
of type 2 diabetes  (T2DM) recommend target 
HbA1c levels of ≤ 53 mmol/mol (7.0% DCCT) in 
the majority of diabetes patients.1,2 
Most T2DM patients require insulin treatment in 
the course of the disease to achieve these HbA1c 
targets.3,4 During the first six months following 
insulin initiation glycemic control improves the 
most, with little further improvements, despite 
changes in insulin regimen, thereafter.5 
Several studies have shown that higher initial 
HbA1c levels, higher age, lower BMI, and a basal 
bolus insulin regimen at the time of insulin ini-
tiation predict a favourable response (HbA1c < 
58 mmol/mol, or reduction by > 1%) to insulin 
therapy within one year.6,7 However, these stud-
ies were retrospective and had a short follow up 
(maximum of 2 years).6-8
The most widely used insulin regimens are either 
using mixed insulins or basal insulin preparations. 
These don’t appear to differ in efficacy, but may 
differ in terms of adverse effects (e.g. hypoglyce-
mia) and complexity.9 RCTs have their limitations 
as they are often performed in relatively healthy 
T2DM patients and with a short follow up. 
For clinical practice it is important to under-
stand which factors affect the response to insulin 
therapy on the long term. Longterm data allowing 
analyses of factors that affect glycemic control in 
patients treated with insulin are scarce. Moreo-
ver, distinct trajectories of HbA1c levels after the 
start of insulin have never been described. Treat-
ment strategies may be improved and the care 
for the patients can be individualized when these 
predictors are available. 
The aim of the current study was to identify sub-
groups of T2DM patients with distinct HbA1c tra-
jectories after the start of insulin treatment and 
factors associated with reaching and sustaining the 
target  HbA1c level ≤ 53 mmol/mol (7% DCCT). 
Research Design and Methods 
Study population 
An observational cohort study was performed 
with data from the West-Friesland Diabetes Care 
System (DCS), described in detail elsewhere.10,24 
Abstract
Aims: The current ADA/EASD guidelines for the 
management of type 2 diabetes mellitus (T2DM) 
recommend HbA1c levels of ≤ 53 mmol/mol. 
About 25% of all T2DM patients initiate insulin 
to reach this target. However, trajectories of the 
HbA1c levels after initiation of insulin have never 
been described and not much is known about 
characteristics associated with reaching and re-
maining the HbA1c target. The aim of the current 
study was to identify subgroups of T2DM patients 
with distinct  trajectories after the start of insu-
lin treatment and factors associated with reach-
ing and sustaining the target HbA1c level (≤ 53 
mmol/mol). 
Study Design and Setting: The study popu-
lation comprised 798 T2DM patients out of a 
cohort of 9849 T2DM patients who entered the 
Diabetes Care System (DCS) in the Netherlands 
between 1998 and 2011. Inclusion criteria for this 
study: aged ≥ 40 year, initiated insulin during fol-
low up after reaching a HbA1c level of ≥ 53 mmol/
mol, and a follow up ≥ 2 years after initiating insu-
lin. Latent Class Growth Modelling (LCGM) was 
used to identify trajectories of HbA1c after the 
initiation of insulin. Cox regression analyses were 
used to determine which characteristics were 
associated with reaching and sustaining target 
HbA1c ≤ 53 mmol/mol. 
Results: Four HbA1c trajectories were identi-
fied: class 1 (3.8%) showed a gradual increase in 
HbA1c over time, class 2 (3.3%) showed a de-
crease in HbA1c during follow-up and class 3 
(5.1%) showed a good response to insulin. Class 
4 (87.8%) showed stable HbA1c levels around 58 
mmol/mol. 
174 patients (21.8%) reached and sustained 
the target HbA1c level. Higher HbA1c levels at 
time of insulin initiation (HR 0.80 (95% CI 0.68 
to 0.92)) and advanced age at baseline (HR 1.03 
(95% CI 1.02 to 1.05)) were associated time to 
reach and sustain the HbA1c target.  
Conclusions: 21.8% of the patients reached 
HbA1c levels ≤ 53 mmol/mol after insulin initia-
tion. Low HbA1c levels and higher age at the start 
of insulin were associated with a shorter time to 
reach the   HbA1c target. Initiating insulin earlier, 
may improve the likelihood of achieving and sus-
taining glycemic control.
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Measurements
HbA1c levels were assessed with a DCCT stand-
ardized reversed-phase cation exchange chroma-
tography (HA  8160 analyzer, Menarini, Florence, 
Italy). The  HbA1c was detected by a dual-wave-
length colorimetric (415-500). The intra-assay 
coefficient of variation (CV) was 0.6% at a mean 
level of 4.9 % and the inter-assay CV 0,8% at a 
mean level of 5.5%.
Weight and height were measured annually (while 
patients were barefoot and wearing light clothes). 
BMI was calculated by dividing weight (kg) by the 
square of height (m). Weight change was calcu-
lated by subtracting the weight at end of follow up 
from the weight at the start of insulin.
Blood pressure was measured annually. Systolic 
blood pressure (SBP) was measured three times 
on the right arm after five minutes of rest in a 
seated position using a random-zero sphygma-
nometer (Haksley-Gelman, Lancing, Sussex, UK). 
From 2003 on an oscillometric device was used 
(Colin Press-Mate BP-8800C, Komaki City Japan 
after 2011 a Welch Allyn ProBP 3400, Skaneateles 
Falls, NY, USA).
Fasting glucose was measured in venous plasma 
by the glucose-oxidase method (Glucoquant/
hexokinase/G6P-DH; Boehringer-Mannheim, 
Mannheim, Germany).  
Triglycerides, total and HDL-cholesterol were de-
termined from fasting blood samples by enzymat-
ic techniques (Boehringer-Mannheim, Mannheim, 
Germany). 
All measurements were performed at the clinical 
chemistry laboratory of the Westfries Gasthuis. 
Microalbuminuria was considered present if 
UACR > 2.0 mg/mmol. 
Retinopathy (fundus photography of both eyes 
was performed yearly) was measured from 1998 
until 2000, with a Kowa Pro Fundus camera with 
a green filter (Kowa Optical Industry, Torrance, 
CA). Black and white, 35-mm photographs were 
taken 30 min after mydriasis with 0.5% tropi-
camide and 2.5% phenylephrine eye drops. From 
the beginning of 2000 until 2004, fundus photog-
raphy of both eyes was performed with a non-
mydriatic Canon CR5 camera (Canon Inc., Tokyo, 
Japan). From 2004, fundus photography of both 
eyes was performed using a nonmydriatic Topcon 
TRC NW 100 camera (Topcon, Tokyo, Japan).10,24 
Briefly, the DCS organizes the diabetes care in 
the region of West-Friesland in the Netherlands, 
a region with about 200,000 inhabitants and rep-
resentative for a Dutch or a Western-European 
population.11 Almost all T2DM patients in this re-
gion participated in the DCS. 
The DCS uses a managed care plan for T2DM 
patients with contracted health care providers in 
the region and is responsible for the quality of dia-
betes care. The service provided by DCS encom-
passes the care provided by patient’s primary care 
physician (PCP) according to the Dutch treatment 
guidelines for T2DM, an annual assessment includ-
ing HbA1c monitoring and patient education by 
DCS nurses and dieticians. Results of the annual 
visit and protocol driven therapeutic treatment 
recommendations are conveyed to each patient’s 
PCP.12 Patients entered the DCS in different years 
and with different diabetes durations. For each 
patient, the year of entry was considered as the 
year of initiating insulin (T0). The DCS maintains 
anonymized computer records. All patients were 
informed and agreed on the use of these records 
for research purposes.
Study participants
In the study period between 1998 and 2011, 9849 
T2DM patients entered the DCS in different years. 
For the current study, all 798 patients, who initiat-
ed insulin during follow up after reaching a HbA1c 
level of ≥ 53 mmol/mol (at least two HbA1c levels 
≥ 53 mmol/mol), aged 40 years and over, using oral 
glucose lowering agents preceding the initiation of 
insulin, with a follow up of at least 2 years after 
initiation of insulin were extracted from the DCS. 
Confirmation of diabetes and diabetes 
duration
The date of diabetes diagnosis was self reported 
and confirmed in the records of the PCP if at least 
one of the following was reported: 1) one or more 
classic symptoms plus one fasting plasma glucose 
≥ 7.0 mmol/l) or random plasma glucose 11.1 
mmol/l; 2) at least two elevated plasma glucose 
concentrations on different occasions (fasting 
glucose ≥7.0 mmol/l or random plasma glucose ≥ 
11.1 mmol/l) in the absence of symptoms. Diabe-
tes duration was calculated from the date of dia-
betes diagnosis until the date of insulin initiation.
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lower BIC indicates a better fit) and with posteri-
or probabilities (where probabilities > 0.8 are rec-
ommended and a probability closer to 1 indicates 
a better classification).14,24 Also, the usefulness and 
clinical interpretation of each new derived class 
was assessed. The usefulness was assessed by 
considering the number of patients in each class 
(hereby rejecting small classes consisting of less 
than 1% of the total study population). The final 
number of classes was based on a low BIC score, 
good probabilities ( > 0.8), and clinically relevant 
differences between classes.24 
The demographic characteristics, HbA1c, BMI, 
systolic blood pressure, fasting glucose, choles-
terol, triglycerides, retinopathy, microalbuminuria, 
and diabetes duration at baseline were assessed. 
The mean differences in weight gain for partici-
pants in each class was calculated, as well as the 
percentage of oral co-medication users in each 
class besides insulin. Finally the percentage of 
prevalent retinopathy at the end of follow up in 
each class was assessed. 
Differences of the here above described variables 
between the trajectories were tested with One 
Way ANOVA and post hoc Bonferroni tests for 
mean levels, with Chi-square tests for propor-
tions and Kruskal – Wallis test for median levels 
in the study population. 
Subsequently, an associative model was made us-
ing multinomial logistic backward regression anal-
ysis. The glycemic control class that reached the 
most stable HbA1c levels (around 58 mmol/mol) 
was regarded as reference class (class 4). In this 
analysis, we assessed which patient characteristics 
(e.g. BMI, total cholesterol, diabetes duration, PCP 
organisation and HbA1c) at insulin initiation were 
associated with membership from classes dif-
ferent than the reference class. All determinants 
with p-values < 0.10 were entered simultaneously 
using the backward elimination method, leading 
to a model including only significant (p < 0.05) 
determinants. All analyses were adjusted for age 
and gender. Data were presented as Odds Ratios 
(OR) with a 95 % confidence interval (CI).24
Reaching and sustaining the target HbA1c. The pro-
portion of diabetes patients who reached the gly-
cemic target was calculated. A Cox proportional 
All participants were examined using 45-degree 
fundus photographs. One photograph was cen-
tred on the macula and the other nasally with 
one optic disc diameter from the temporal side. 
All photographs were graded by an experienced 
ophthalmologist according to the EURODIAB 
classification score system.13
PCP organisation. Diabetes management differs 
across PCP practices, in terms of initiation of in-
sulin (PCP/DCS) and the employment of a nurse 
practitioner (NP) for diabetes management (NP/ 
no NP). Therefore, PCP organisations were cat-
egorized into three types: involvement of a NP in 
diabetes management; involvement of a NP and 
insulin initiation transferred to DCS; no NP and 
insulin initiation transferred to DCS.  At any time, 
the PCP organisation can send a patient to the 
DCS for the initiation of insulin. Patients choose a 
PCP based on of the geographical location of the 
PCP, not on the basis of the involvement of a NP 
in the PCP organization.
Information on medication use was obtained 
yearly from self-reporting. The information on 
medication use was controlled using data from 
pharmacy registries (PHARMO Network). The 
PHARMO Network is a comprehensive record 
linkage system in which drug dispensing data for 
regional catchment areas are linked to a registry 
of hospital discharge diagnoses and other regis-
tries in the Netherlands.
Statistical Analysis 
HbA1c levels over time
To analyse HbA1c levels over time in response 
of insulin treatment, latent class growth modelling 
(LCGM) was used.  LCGM is a type of cluster 
analysis used to group patients into an optimal 
number of classes, each with a unique trajectory 
of HbA1c over time, by modeling heterogeneity 
in the time course.14,15,24 Each class has its own 
growth parameters (i.e. intercept, slope). To de-
termine the optimal number of classes, a stepwise 
forward approach was taken, starting with a mod-
el with one developmental pattern. Then, one class 
at a time was added. The optimal model is a model 
where individuals within a class are most similar 
to each other and most different to individuals in 
other classes. The model fit was assessed by the 
Bayesian Information Criterion (BIC) (where a 
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(HR) with a 95 % confidence interval (CI). P-values 
lower then 0.05 were considered statistically sig-
nificant. 
Due to the suggestion of less stringent goals 
in older patients and patients with a history of 
severe hypoglycemia and advanced complica-
tions,16-18 we repeated the Cox regression analy-
sis described above for patients with HbA1c ≥ 58 
mmol/mol instead of HbA1c ≥ 53 mmol/mol.
The LCGM analyses were conducted with Mplus 
5.21, further statistical analyses were performed 
with SPSS for Windows (version 20.0, SPSS Inc., 
Chicago, IL).
Results 
Figure 1 shows the disposition of the T2DM popu-
lation in this study. From the 9849 T2DM patients 
participating in the DCS, 798 T2DM patients initi-
ated insulin with a mean follow-up of 5.3 year (SD 
2.8, range 12.3). No patients return to treatment 
with OGA after the initiation of insulin.
hazards model was used to determine which 
characteristics (i.e. BMI, PCP organisation, SBP, 
baseline HbA1c, diabetes duration) were associ-
ated with reaching and sustaining on the target 
of HbA1c ≤ 53 mmol/mol. All analyses were ad-
justed for age and gender. All determinants with 
p-values < 0.10 were entered simultaneously us-
ing the backward elimination method, leading to a 
model including only significant (p < 0.05) deter-
minants. The time to reach the target is defined as 
the time of insulin initiation until the time of an 
HbA1c value ≤ 53 mmol, and sustaining on this 
target or end of the follow up period.
The proportional hazards assumption, i.e. the 
constant hazard ratio over time, was evaluated by 
comparing estimated log-log survival curves for 
all covariates. All assessed log-log survival plots 
graphically showed two parallel lines, indicating no 
violation of the assumption. All continuous varia-
bles were divided into quartiles to check whether 
these variables met the proportional hazard as-
sumption. Data were presented as Hazard Ratios 
Figure 1. 
Flowchart of included patients.
 
1998 – 2011: 8308 T2DM patients 
1555 T2DM patients using insulin 
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Class 3 (41 patients) comprised patients who had 
HbA1c levels starting at 89 mmol/mol that were 
decreasing during the years and the HbA1c stabi-
lized around 55 mmol/mol. The largest decrease 
in HbA1c was during the 2nd and 3rd year of fol-
low up. 
The largest class (class 4, 701 patients) consisted 
of patients who had stable HbA1c levels during 
follow up. The HbA1c level sustained around the 
58 mmol/mol.
HbA1c trajectories 
Figure 2 shows the trajectories of HbA1c over 
ten years for the four identifi ed classes: 
Class 1 (30 patients) shows a steadily increasing 
HbA1c from a high baseline level (67 mmol/mol) 
to 93 mmol/mol after three years, following the 
initiation of insulin therapy. 
Class 2 (26 patients) comprised patients who had 
HbA1c levels starting at 95 mmol/mol that were 
decreasing during the years to 60 mmol/mol after 
10 years. 
Figure 2 
Trajectories of HbA1c over ten years in four classes of type 2 diabetes patients after initiation of insulin.
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Table 1 
Differences in baseline characteristics between classes of HbA1c trajectories following initiation of 
insulin therapy in type 2 diabetic patients.
Total DCS 
population
Class 1 Class 2 Class 3 Class 4
N 798 30 26 41 701
Baseline
Age (yr) 64.2 ± 10.4 58.5 ± 10.6* 57.9 ± 9.8* 63.1 ± 12.7 64.7 ± 10.2
Male (%) 50.5 40.0 73.1 51.2 50.1
Diabetes duration (yr) 8.1 
(5.0 – 12.0)
7.5 
(4.2 – 12.7)
8.0 
(4.4 – 11.1)
7.4 
(4.2 – 11.4)
8.2 
(5.2 –12.1)
HbA1c (mmol/mol) 63 ± 1.3 67 ± 1.2* 95 ± 1.2* 89 ± 1.2* 59 ± 0.9
BMI (kg/ m2) 30.8 ± 5.4 32.3 ± 6.0 31.5 ± 6.2 30.3 ± 5.8 30.8 ± 5.3
SBP (mmHg) 145.4 ± 20.4 136.5 ± 17.2* 137.3 ± 21.9 140.3 ± 17.8 146.4 ± 20.4
Fasting glucose (mmol/L) 8.8 ± 2.7 9.8 ± 3.3* 12.1 ± 4.8* 11.6 ± 3.7* 8.4 ± 2.3
Total cholesterol 
(mmol/L)
4.7 ± 1.1 5.3 ± 1.0* 4.7 ± 1.2 4.7 ± 1.1 4.7 ± 1.1
HDL cholesterol 
(mmol/L)
1.18 ± 0.3 1.24 ± 0.3 1.10 ± 0.4 1.13 ± 0.3 1.19 ± 0.3
Triglycerides (mmol/L) 1.88 ± 1.2 2.32 ± 1.6* 2.00 ± 0.8 2.20 ± 1.6* 1.83 ± 1.1
Metformin use  (%) 72.3 73.3 61.5 68.3 72.9
SU use (%) 75.4 63.3 57.7 73.2 76.7
Any Retinopathy  (%) 8.0 13.3 23.1 12.2 7.0
Grade 1 Retinopathy (%) 4.9 3.3 11.5 7.3 4.6
Grade 2 Retinopathy (%) 1.0 3.3 3.8 0 0.9
Grade 3 Retinopathy (%) 0.9 3.3 7.7* 2.4 0.4
Grade 4 Retinopathy (%) 1.3 3.3 0 2.4 1.1
Microalbuminuria  (%) 19.7 20.0 23.1 24.4 19.3
Drop out  (%) 11.3 3.3 15.4 14.6 11.3
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Total DCS 
population
Class 1 Class 2 Class 3 Class 4
End of follow up
Follow up (yr) 5.3 ± 2.8 5.6 ± 2.7 5.4 ± 3.0 5.3 ± 2.7 5.3 ± 2.8
Mortality  n (deaths per 
1000 person years of 
observation)
18.4 11.8 14.6 7.6 19.4
Weight differences (kg) 1.3 ± 6.0 1.3 ± 10.0 -0.4 ± 10.5 4.2 ± 7.5* 1.2 ± 5.5
Any Retinopathy (%) 9.1 6.7 26.9 12.2 8.4
Grade 1 
Retinopathy (%)
4.8 3.3 11.5 4.9 4.6
Grade 2 Retinopathy (%) 1.6 0 3.8 2.4 1.6
Grade 3 Retinopathy (%) 0.9 0 7.7* 0 0.7
Grade 4 Retinopathy (%) 1.9 3.3 3.8 4.9 1.6
Between 50 and 75% of 
follow up time  HbA1c 
values ≤ 53 mmol/mol 
(%)
15.9 3.3 0 24.4 16.5
Between 25 and 50% of 
follow up time  HbA1c 
values ≤ 53 mmol/mol 
(%)
20.1 6.7 7.7 19.5 21.1
Less than 25% of follow 
up time HbA1c values ≤ 
53 mmol/mol (%)
57.9 90.0 92.3 56. 55.3
Data represent mean ± standard deviation, proportions, or median (interquartile range). Between-cluster differences were tested with 
ANOVA and post hoc Bonferroni for mean levels, with ±² tests for proportions and Kruskal-Wallis test for median levels. Abbrevia-
tion: BMI: body mass index, SBP: systolic blood pressure, SU: sulfonylureas. * statistically significantly (p <0.05) different from class 4.
Table 1 shows the characteristics of the four 
classes determined by LCGM analysis. 
Baseline HbA1c levels of patients in class 4 were 
significantly lower than in the other classes (59 
mmol/mol vs. 67 mmol/mol, 95 mmol/mol, 89 
mmol/mol respectively).  
Table 2 shows the results of the multinomial logis-
tic regression analysis. This classifies the charac-
teristics at insulin initiation that were significantly 
associated with membership of a class (compared 
to class 4). Patients in class 2 and class 3 had sta-
tistically significant higher HbA1c levels at insulin 
initiation (class 2 OR 13.59, 95% CI 7.34 – 25.18, 
class 3 OR 9.99 (5.98 – 16.70)). Patients in class 1 
had statistically significant higher baseline HbA1c 
levels (OR 1.86, 95% CI 1.25 – 2.75), were young-
er (OR 0.93, 95% CI 0.90 – 0.98), and had higher 
total cholesterol values (OR 1.61, 95% CI 1.13 – 
2.31), compared to class 4.
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Table 2. 
Multinomial regression analyses determining characteristics of different classes, compared to class 4. 
Model OR (95% CI)
Class 1 vs. Class 4 Age 
Sex 
Cholesterol 
HbA1c 
0.93 (0.90 – 0.98)*
1.49 (0.65 – 3.40)
 1.61 (1.13 – 2.31)*
1.86 (1.25 – 2.75)*
Class 2 vs. Class 4 Age 
Sex 
HbA1c 
 0.96 (0.91 – 1.01)
0.39 (0.12 – 1.25)
13.59 (7.34 – 
25.18)*
Class 3 vs. Class 4 Age 
Sex 
HbA1c 
0.99 (0.95 – 1.04)
0.75 (0.30 – 1.84)
9.99 (5.98 – 16.70)*
Estimates are odds ratio’s with 95% confidence intervals. A * indicates a significant association (P<0.05). The model shows the final 
model including variables with  p-value <0.05, and corrected for age and sexe. 
Table 3 
Cox proportional hazard model of the time to reach and sustain the HbA1c target of ≤ 53 mmol/mol 
and sensitivity analyses with the HbA1c target of the time to reach and sustain the HbA1c target of ≤ 
58 mmol/mol.
Cox proportional 
hazard model
HR ( 95% CI) P level Sensitivity 
analyses HbA1c target 
of ≤ 58 mmol/mol.
HR (95% CI)
P level
Sex (female vs. male) 0.76 (0.55 – 1.05) 0.093 0.86 (0.70 – 1.07) 0.175
Age (yr) 1.03 (1.02 – 1.05) <0.001 1.02 (1.01 – 1.03) < 0.001
HbA1c (mmol/mol) 0.79 (0.68 – 0.92) 0.002 0.71 (0.64 – 0.79) < 0.001
Abbreviation: HR = Hazard Ratio.
Reaching and sustaining the target 
HbA1c
174 patients (21.8%) reached the target HbA1c of ≤ 
53 mmol/mol, and sustained at or below this target 
during follow up. The mean time to reach this target 
was 4.5 years (SD 3.0).  Table 3 presents the Cox 
regression model for the time to reach the target 
and for sustaining at the target HbA1c of ≤ 53 
mmol/mol. 
Lower HbA1c at baseline (HR 0.80 (95% CI 0.682 
to 0.921) and higher age (HR 1.03 (95% CI 1.015 
to 1.049) were associated with a shorter time to 
reach and sustain the target of ≤ 53 mmol/mol.  
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levels which could have influenced class member-
ship. Information on the total amount of insulin 
use was available but the proportion of patients 
using short acting insulin use was not available. 
The use of LCGM as a method to define classes 
with distinct trajectories has some limitations. The 
first limitation concerns the complexity and flex-
ibility of the model. There are numerous choices 
to make and each decision could potentially influ-
ence the final number of classes. Further, LCGM 
can lead to unbalance in the number of subjects 
in each trajectory. It should also be addressed that 
extraction of the classes is a simplification of the 
reality and is no proof for the true existence of 
multiple subgroups.14,24 However, an advantage of 
LCGM is that categorisation is not based on sub-
groups determined a-priori, but they are based 
on trajectory characteristics of HbA1c within the 
data. Further LCGM is focused on relationships 
among individuals, and creates the condition to 
categorise them in homogenous subgroups.
To our knowledge, this is the first observational 
cohort study using LCGM to define trajectories 
of HbA1c in patients initiating insulin. These tra-
jectories were revealed in a relative large popu-
lation (n = 798) of patients with T2DM. Other 
strengths of this study are the completeness of 
the measurements, the long follow up of 10 years 
and the standardized yearly measurements. Fur-
ther, there were no statistically significant differ-
ences in drop outs in the four classes. Moreover, 
in contrast to randomized trials, this observa-
tional study is representative of the patient popu-
lation in our region; this study included almost all 
T2DM patients in the region without any prior 
selection. 
Our study showed the difficulties of reaching and 
sustaining the target of  HbA1c ≤ 53 mmol/mol in 
daily practice in the majority of patients, even in 
a centrally organized managed diabetes care sys-
tem. With LCGM four classes of distinct HbA1c 
trajectories were identified. 
Conclusions
In summary, despite centrally managed diabetes 
care, only 21.8 % of the patients is achieving and 
sustaining the target of  HbA1c levels ≤ 53 mmol/
Sensitivity analyses
383 patients (48.0%) reached the less stringent 
target HbA1c, and sustained at or below the ≤ 
58 mmol/mol during follow up. The mean time to 
reach and sustain this less stringent target was 3.4 
years (SD 2.8).  Lower HbA1c (HR 0.71 (95% CI 
0.64 to 0.79)) and higher age (HR 1.02 (95% CI 
1.01 to 1.03)) at baseline were associated with a 
shorter time to reach and sustain the target of ≤ 
58 mmol/mol. 
Discussion
Four classes of trajectories of  HbA1c were 
identified. In one class (3.8%) a gradual increase 
in HbA1c over time was seen, the second class 
(3.3%) showed a decrease in HbA1c during follow 
up. The third class (5.1%) showed a good response 
to insulin treatment. The largest class (87.8 %), 
however, consisted of  T2DM patients with high 
HbA1c levels at initiation that remained high dur-
ing follow-up. Lower HbA1c levels and higher age 
at insulin initiation were associated with a short-
er time to reach and sustain the HbA1c target 
of ≤ 53 mmol/mol. In our study 21.8% reached 
and sustained the HbA1c target of 53 mmol/mol, 
with a mean time of 4.5 years. A previous study 
showed that 41 % achieved the HbA1c target of 
< 53 mmol/mol within 3-9 months after initiating 
insulin therapy.19  In agreement with our finding, 
a lower HbA1c at baseline was associated with a 
better control (HbA1c  levels < 53 mmol/mol).7,19-
22 However, the patients in these studies were fol-
lowed for a shorter period, and the target did not 
include sustained glycemic control. In the UKPDS 
study patients in the intensive treatment group 
reached a median HbA1c level over 10 years of 
53 mmol/mol.23 Nevertheless the baseline HbA1c 
values of  the 911 patients initiating insulin were 
much lower compared to the patients in our 
study due to the fact that newly diagnosed T2DM 
patients were included in the UKPDS study (43 
mmol/mol in the UKPDS vs. 63 mmol/mol in this 
study).23 
There are some limitations to consider. Data on 
the dose of insulin is lacking. Therefore we don’t 
know if the PCPs and the patients increased the 
dose of insulin in response to glucose or HbA1c 
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mol. Lower HbA1c at baseline indicates better 
glycemic response during follow up. Initiating insu-
lin earlier in the course of T2DM treatment, when 
HbA1c levels are lower, may improve glycemic 
goal attainment. 
Further studies are needed to confirm the four 
classes of distinct HbA1c trajectories, and to 
overcome the resistance of initiating insulin ear-
lier in the course of T2DM. The quality of the dia-
betes treatment may be improved and the care 
for the patient can be individualized.
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Chapter 4
Proinsulin and cancer mortality
The Hoorn Study
I Walraven, E van ’t Riet,  CDA Stehouwer,  BCP Polak, AC Moll, JM Dekker, G Nijpels
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Proinsulin is a precursor of insulin and is pro-
portionally co-secreted by the pancreatic ß-cell 
alongside insulin.9 Increased levels of proinsulin in 
the circulation are considered a signal of a defec-
tive proinsulin/insulin conversion and may reflect 
beta-cell dysfunction.10-12 Indeed, hyperproinsuli-
naemia in non-diabetic individuals is known to be 
highly predictive for T2DM.11,13 The in-vitro study 
of Malaguarnera et. al.14 recently showed that pro-
insulin binds with and activates insulin receptor 
(IR) isoforms, in particular IR-A. IR-A mediates 
effects on growth and survival15-17 and is overex-
pressed in several types of cancer, for example 
thyroid cancer.16 
None of the studies1-7 that reported on the as-
sociation between glucose metabolism and can-
cer took proinsulin into account. In the light of 
recent evidence14 for the potential link between 
proinsulin and cancer, it is hypothesized that pro-
insulin might explain part of the risk for devel-
oping cancer. To our knowledge, no other study 
has addressed the association between proinsulin 
and cancer mortality. Such data are needed since 
it might contribute to the mechanistic knowledge. 
The Hoorn study is a population-based cohort 
study with a long-term and precise follow-up of 
cause-related mortality. In a subsample of the 
Hoorn Study cohort, proinsulin concentrations 
were determined twice, on two separate days, at 
baseline in 1989.11 This paper reports on the asso-
ciation between proinsulin and cancer mortality. 
Research Design and Methods
Study population This study was conducted within 
the Hoorn Study, a population-based cohort study 
on T2DM in the Dutch population, which started 
in 1989 among 2484 participants.18 More exten-
sive measurements were performed in a stratified 
random sample of the Hoorn Study (n= 631).19 
Insulin and proinsulin levels were measured in 
individuals with normal glucose metabolism, im-
paired glucose metabolism and newly diagnosed 
T2DM not using glucose lowering therapy. Par-
ticipants with a verified history of T2DM were 
excluded from proinsulin measurements (n=56).20 
Furthermore, we excluded participants with miss-
ing values on proinsulin at one or both oral glu-
cose tolerance tests, because of missing samples 
(n=74) or for technical reasons (n= 63),20 leav-
Abstract
Aims: Proinsulin has recently been associated 
with cancer through activation of insulin receptor 
isoform A. The aim of this study was to investigate 
associations of proinsulin with 20-year cancer 
mortality.
Methods: The study was performed within the 
Hoorn Study, a population-based study of glucose 
metabolism among Caucasians aged 50-75 years. 
Fasting proinsulin levels were measured twice by 
a double-antibody radioimmunoassay. Participants 
were continuously followed to register mortality, 
causes of death were derived from medical re-
cords. Cox survival analyses were performed to 
assess the 20-year risk of cancer mortality in rela-
tion to proinsulin. All analyses were adjusted for 
age and sex, with additional adjustments for tra-
ditional risk factors. Effect modification of glucose 
metabolism and sex was tested.
Results: Proinsulin levels were measured in 438 
individuals (41% normal glucose tolerance, 35.7% 
impaired glucose metabolism and 23.3% type 2 
diabetes). Of these, 53 died from cancer. After ad-
justment for age and sex, proinsulin > 16.5 pmol/l 
(the upper tertile) was significantly associated 
with a 2-fold risk of cancer mortality [hazard ratio 
(HR) 2.01 CI 1.16, 3.46] as compared to individu-
als with lower proinsulin levels. Additional adjust-
ment for glucose metabolism, BMI and smoking 
did not substantially change the results [HR 1.91 
CI 1.04, 3.52]. No interaction with glucose me-
tabolism or sex was observed. 
Conclusion: Individuals with fasting proinsulin 
levels above 16.5 pmol/l have a twofold increased 
risk of cancer mortality over a 20-year time span. 
These findings provide population-based evidence 
for the independent association of high proinsulin 
levels with cancer mortality. 
 
Introduction
Individuals with impaired glucose metabolism 
(IGM) or type 2 diabetes (T2DM) might have an 
increased risk of cancer and cancer related mor-
tality.1-7 Insulin resistance, hyperglycaemia, high 
levels of insulin and production of insulin-like 
growth factor I and II (IGF-I and IGF-II) are sug-
gested to induce tumour cell growth and thereby 
may provide a mechanistic link between glucose 
metabolism and cancer.1,3,6,8 
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Cancer mortality follow-up The municipal regis-
ter of the city of Hoorn supplied information 
on the vital status of all participants. Causes 
of death were derived from the medical re-
cords of general practitioners and from the lo-
cal hospital. All causes of death were coded 
according to the International Classification of 
Diseases, Injuries and Causes of Death, ninth re-
vision.23 Cancer mortality was defined as ICD-9 
codes 140-239 (Neoplasms). The mortality fol-
low-up was completed until the first of January 
2009.
Statistical analysis Variables are presented as per-
centage, mean (± SD) or median ( + interquartile 
range) in case of a skewed distribution. Normality 
was tested and in case of a skewed distribution, 
log-transformation was performed. Since pro-
insulin did not exhibit a linear relationship with 
cancer mortality, despite performance of log-
transformation, the population was categorized 
into tertiles of proinsulin levels. Differences in 
baseline characteristics between different tertiles 
of proinsulin level were tested with Student’s t-
tests (continuous variables) and chi-square tests 
(categorical variables). Furthermore, differences 
in participants who did or did not have missing 
values on proinsulin were tested using Student’s 
t-tests (continuous variables) and chi-square tests 
(categorical variables).
Cumulative incidence rates of cancer and all-
cause mortality were investigated according to 
tertiles of proinsulin. The follow-up duration was 
calculated as the time between baseline examina-
tion and date of death, loss to follow-up or Janu-
ary 2009.
Kaplan-Meier survival curves for tertiles of pro-
insulin were plotted for cancer and all-cause 
mortality. Proportional hazards assumptions for 
every model were tested by interpretation of the 
survival plots. Cox proportional hazards analyses 
were performed to investigate associations be-
tween proinsulin and cancer and all-cause mor-
tality. First, we constructed a model in which we 
adjusted for age and sex. Then, we subsequently 
adjusted for possible confounding or mediating 
variables. The variables included are known to be 
associated with cancer (BMI and smoking) and/
or are closely related to proinsulin (fasting spe-
ing a cohort of 438 individuals. Written informed 
consent was obtained from all participants. The 
Ethical Review Committee of the VU University 
Medical Center in Amsterdam, The Netherlands, 
approved the Hoorn Study. 
Measurements Anthropometric measurements 
were obtained from all participants. Weight, 
height, and hip and waist circumferences were 
measured barefoot and wearing light clothes. 
Blood pressure was measured at the right upper 
arm, after 5 minutes of rest, using a random-zero 
sphygmomanometer (Hawksley-Gelman, Lancing, 
Sussex, U.K.). Mean blood pressure was then cal-
culated as the mean of two measurements.18 
Fasting plasma glucose concentration and two 
hours postload plasma glucose concentrations 
were determined by the glucose dehydrogenase 
method (Merck, Darmstadt, Germany). For the 
present analyses, the American Diabetes Asso-
ciation21 diagnostic criteria of 2011 for T2DM 
(i.e. HbA1c ≥ 6.5%/ 48 mmol/mol and/or fasting 
plasma glucose (FPG) ≥ 7.0 mmol/l and/or two 
hour plasma glucose ≥ 11.1 mmol/l) pre-diabetes 
(nondiabetic levels for all three markers of hyper-
glycaemia and at least one of: HbA1c 5.7-6.4%/ 
39-48mmol/mol, FPG 5.7-6.9 mmol/l or two hour 
plasma glucose 7.8-11.0 mmol/l) and normal glu-
cose metabolism (NGM [defined as HbA1c < 
5.7%/ 39 mmol/mol and/or FPG < 5.6 mmol/l and/
or 2-hour plasma glucose < 7.8 mmol/l])21 were 
applied. 
Insulin and proinsulin levels were measured twice 
with a two-week interval.
Immunospecific insulin was measured in serum 
by a double-antibody radio immunoassay (lot 
SP21; Linco Research, St. Louis, MO) in which 
proinsulin and 32,33 split proinsulin cross-reacts 
by 0.2%. Proinsulin was measured by a double-
antibody radioimmunoassay (Lilly Laboratory for 
Clinical Research, Indianapolis, IN) in which 31,32 
proinsulin cross-reacts by 63%. Serum total cho-
lesterol, HDL cholesterol, and triglycerides were 
measured by means of enzymatic techniques 
(Boehringer-Mannheim, Mannheim, Germany).20
Insulin resistance was estimated by homeostatic 
model assessment of insulin resistance (HOMA-
IR), calculated as (fasting insulin [µU/ml] * fasting 
glucose [mmol/l])/ 22.5.22
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0.05 were considered statistically significant. All 
analyses were performed with SPSS 20.
Results
Baseline characteristics Table 1 shows baseline 
characteristics of the participants according to 
different tertiles of proinsulin. None of the par-
ticipants with T2DM of whom proinsulin levels 
were available used glucose lowering medication. 
Compared to the lowest tertile (proinsulin ≤ 9.4 
pmol/l), participants with high levels of proinsu-
lin (> 16.5 pmol/l) had significantly higher BMIs, 
higher glucose levels and HbA1c and higher fast-
ing specific insulin concentrations. Within the 
highest tertile of proinsulin, 27 participants (18.5 
% CI 12.7, 25.9) had normal glucose metabolism, 
54 participants (37.0% CI 29.3, 45.4) had impaired 
glucose metabolism and 65 participants (44.5% CI 
36.4, 52.9) had T2DM. 
cific insulin, estimated insulin resistance (HOMA-
IR), glucose metabolism and fasting glucose). We 
constructed two different models, one in which 
we adjusted for all possible confounding variables 
and the second only adjusted for variables with 
p-values less than 0.10. To assess improvement of 
the model, changes in -2loglikelihood (-2LL) were 
tested. Furthermore, we tested for interaction 
with glucose metabolism (ADA 2011) and sex 
by adding an interaction term to the model: p-
values less than 0.10 were considered as statisti-
cally significant interactions. For a sub-population 
(N = 189) of whom we had 11-year follow-up 
information sensitivity analyses were performed 
to investigate the possible mediating effect of the 
development of T2DM in the future and possible 
use of glucose lowering medication, Data are pre-
sented as Hazard Ratios (HR) with a 95% con-
fidence interval (CI). The reported HR’s can be 
interpreted as relative risks. P-values less then 
Table 1. 
Baseline characteristics according to different tertiles of proinsulin concentration
Proinsulin (pmol/l) < 9.4 pmol/l 9.4 – 16.5 pmol/l > 16.5 pmol/l
Median 6.0 (3.8, 7.8) 12.3 (10.9, 14.2) 24.3 (19.6, 34.4)
N 146 146 146
Age (years) 63.9 (7.5) 64.0 (7.1) 65.0 (6.8)
Sex (% male) 69 (47.3) 60 (41.1) 89 (61.1)*
Fasting glucose (mmol/l) 5.7 (1.1) 5.9 (0.9) 6.7 (1.8)*
2-hour postload glucose (mmol/l) 7.2 (3.4) 8.2 (3.0)* 10.4 (4.5)*
HbA1c (%) 5.5 (0.8) 5.5 (0.6) 5.9 (1.0)*
HbA1c (mmol/mol) 37 (0.8) 37 (0.6) 41 (1.0)*
Normal glucose metabolism (N 
[%])
87 (59.6) 60 (41.1)* 27 (18.5)*
Impaired glucose metabolism (N 
[%])
41 (28.1) 57 (39.0)* 54 (37.0)*
Type 2 diabetes (N [%]) 18 (12.3) 29 (19.9)* 65 (44.5)*
Fasting specific insulin (pmol/l) 74.6 (55.4, 92.5) 81.6 (63.2, 112.2)* 120.6 (88.9, 159.7)*
HOMA-IR 2.6 (1.8, 3.3) 3.0 (2.2, 4.3)* 4.9 (3.5, 6.9)*
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ICD-9 code 150-159 (malignant neoplasm of di-
gestive organs and peritoneum). Tumour-groups 
which were also frequently present were ICD-9 
codes 235-238 (malignant neoplasm of uncer-
tain origin [31%]) and ICD-9 160-165 (malignant 
neoplasm of respiratory and intrathoracic organs 
[19%]) (data not shown). All-cause mortality was 
highest in individuals with T2DM in each tertile of 
proinsulin. Figure 1 shows proportions of cancer 
mortality according to glucose metabolism (A), 
stratified for tertiles of proinsulin(B). The propor-
tion of cancer mortality was similar among differ-
ent groups of glucose metabolism and in the first 
two tertiles of proinsulin. The highest tertile of 
proinsulin (>16.5 pmol/l) comprised the highest 
proportion of cancer mortality, with NGM con-
ferring the largest share. 
Participants with missing values of proinsulin be-
cause of missing samples (n=74) or for techni-
cal reasons (n=63) had significantly lower fasting 
specific insulin values and lower HOMA-IR. Fur-
thermore, the population with missing values of 
proinsulin comprised less individuals with T2DM. 
Cancer mortality prevalence was equal as com-
pared to the group in which proinsulin levels were 
available (12.9% versus 13.1%).  
Proinsulin and all-cause and cancer mortality Me-
dian follow-up duration was 17.3 years. At the 
end of the follow-up 196 (44.7%) of the 438 par-
ticipants had died of whom 53 participants (27%) 
died from cancer. Individuals who died from can-
cer were older and had significantly higher spe-
cific insulin and proinsulin levels at baseline (data 
not shown). One third (31%) of the participants 
who died from cancer had cancer which falls in 
Proinsulin (pmol/l) < 9.4 pmol/l 9.4 – 16.5 pmol/l > 16.5 pmol/l
BMI (kg/m2) 26.0 (3.3) 27.1 (4.0)* 28.9 (3.5)*
Physical activity (hrs per day) 1.0 (0.6, 2.0)a 1.1 (0.5, 1.8)b 1.0 (0.5, 1.8)c
Hypertension (%) 48 (33.1) 57 (39.0) 81 (55.5)*
Current smoker (%) 40 (29.4) 35 (24.3) 32 (21.9)
Smoking (pack years) 7.5 (0.0, 23.7) 4.0 (0.0, 23.2)* 14.4 (0.0, 34.9)*
20-year follow-up
All-cause death (N events [%]) 61 (41.8) 52 (35.6) 83 (56.8)*
Cancer mortality (N events [%]) 61 (41.8) 52 (35.6) 83 (56.8)*
Variables are presented as mean (± SD) or median ( + interquartile range) in case of a skewed distribution. *P < 0.05 (reference 
category proinsulin < 9.4 pmol/l) Abbreviations; HOMA-IR: homeostatic model assessment of insulin resistance, BMI: body mass index. 
Missing values (if N > 10): a:32 b:38  c:31
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and including 16.5 pmol/l) tertiles. No differences 
in HRs were observed between the first two 
tertiles and those were therefore combined and 
compared with the highest tertile (> 16.5 pmol/l). 
The survival curves in Figure 2 show that cancer 
mortality was significantly higher in the highest 
tertile of proinsulin (> 16.5 pmol/l) as compared 
to the lowest (< 9.4 pmol/l) and middle (9.4 up to 
Figure 1. 
Cancer mortality (%) according to different categories of glucose metabolism (A) and stratified for dif-
ferent tertiles of proinsulin (pmol/l [B]). 
Bars; white; normal glucose metabolism, striped; impaired glucose metabolism, black; type 2 diabetes
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Figure 2. 
Survival curve of the 20-year cancer mortality rate in tertiles of fasting proinsulin. 
Continuous line, <9.4 pmol/l; dotted line, 9.4-16.5 pmol/l; dashed and dotted line, > 16.5 pmol/l
Table 2 presents a Cox proportional hazards 
model for cancer, all-cause and all-cause except 
cancer mortality. Proinsulin levels > 16.5 pmol/l as 
compared to levels ≤16.5 pmol/l were signifi cantly 
associated with cancer mortality (HR 2.01 CI 
1.16, 3.46). Adjustment for confounding showed 
a signifi cant reduction of the -2LL, indicating a sig-
nifi cant improvement of fi t of the model. The as-
sociation was infl uenced to some extent, but not 
entirely, by other risk factors; glucose metabolism, 
BMI and smoking (pack years) were combined 
into a multivariate model, which did not signifi -
cantly infl uence the association (HR 1.91 CI 1.04, 
3.52). The highest tertile of proinsulin was asso-
ciated with all-cause mortality (HR 1.62 CI 1.18, 
2.24). After adjustment for potential confounders 
or mediating variables, the association diminished 
and did not remain signifi cant. When cancer mor-
tality was excluded from the model, we observed 
an association between proinsulin > 16.5 pmol/l 
and all-cause mortality (HR 1.45 CI 0.97, 2.17) 
not reaching statistical signifi cance. 
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To our knowledge, this is the first paper to report 
on the association between proinsulin and cancer 
mortality. The in-vitro study of Malaguarnera et. 
al.14 might provide a possible mechanistic link for 
our findings. They14 showed that proinsulin differ-
entially binds to and activates the two IR isoforms, 
with a higher affinity for IR-A than for IR-B with 
a remarkably similar behavior to that of IGF-II. 
IR-A is a low-specificity eceptor with high affinity 
not only for insulin but also for IGF-II, and it can 
also activate intracellular signalling and biological 
effects in response to IGF-I. They also showed 
that proinsulin was almost equipotent as insulin 
in inducing cell proliferation and migration in cells 
expressing various IR-A levels.14
As in other studies,12,24 proinsulin levels were as-
sociated with specific insulin levels and with insu-
lin resistance (Table 1). Therefore, fasting specific 
insulin could have mediated the association be-
tween proinsulin and cancer mortality. However, 
adjustment for specific insulin in the Cox regres-
sion analysis did not diminish the statistically 
significant association of proinsulin with cancer 
mortality. 
The association between proinsulin levels and 
cancer mortality did not significantly differ among 
Additional analyses We tested for interaction of 
proinsulin with glucose metabolism and sex, by 
adding interaction terms into the crude model. 
Both product terms for glucose metabolism (IGM 
versus NGM p-value 0.11 and T2DM versus NGM 
p-value 0.67) and sex (p-value 0.21) were not sta-
tistically significant. Furthermore, we stratified the 
analyses to visually examine whether the effect 
was different for different categories of glucose 
metabolism, and although power was weaker due 
to the smaller groups, the association of proinsu-
lin and cancer mortality was almost equal in every 
category of glucose metabolism.
Discussion
The present study shows that high proinsulin 
(>16.5 pmol/l) levels are significantly associated 
with a two-fold risk of cancer mortality over a 
20-year period as compared to proinsulin levels 
below 16.5 pmol/l. This association was inde-
pendent of glucose metabolism, fasting glucose, 
specific insulin, estimated insulin resistance, BMI 
and smoking (Table 2). Furthermore, this study 
shows that proinsulin levels were more strongly 
associated with cancer mortality as compared to 
all-cause mortality. 
Table 2. 
Cancer mortality, all-cause mortality and all-cause except cancer mortality in the group with proinsulin 
> 16.5 pmol/l versus ≤ 16.5 pmol/l (reference category)
Cancer mortality All-cause 
 mortality
All-cause mortality 
except cancer
Fasting proinsulin >  16.5 pmol/l -2LL >  16.5 pmol/l -2LL >  16.5 pmol/l -2LL
1. Model 1,  
adjusted for age 
and sex
2.01 (1.16, 3.46)* 593 1.62 (1.18, 2.24)* 1693 1.45 (0.97, 2.17) 1092
2. Model 1 +  
glucose meta-
bolism,  BMI and 
smoking
1.91 (1.04, 3.52)* 584* 1.44 (0.99, 2.09) 1624* 1.24 (0.78, 1.98) 1027*
3. Model 2 +  
insulin and 
HOMA-IR
2.08 (1.09, 3.96)* 570* 1.47 (0.99, 2.16) 1595* 1.23 (0.76, 2.01) 1014*
*P < 0.05 Abbreviations; -2LL= -2 log likelihood, HOMA-IR: homeostatic model assessment of insulin resistance, BMI: body mass index. 
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A limitation is that the radioimmunoassay used in 
this study was not able to differentiate between 
intact proinsulin and des 31-32 proinsulin. The 
inhibition of the conversion from des 31,32 pro-
insulin to insulin by hyperglycaemia,11 could there-
fore overestimate the contribution of proinsulin 
levels to some extent. Proinsulin concentrations 
are highly variable. Therefore, we measured fast-
ing proinsulin levels twice on two separate days, 
with two weeks in between, and used the mean 
to improve the precision. Furthermore, proinsulin 
levels were only measured at baseline and there 
is no indication that proinsulin levels have been in 
the same tertile during the complete follow-up 
period. Therefore we can only draw conclusions 
on the association between proinsulin measured 
at baseline and cancer mortality during a 20-year 
follow-up period. Another restriction is the rela-
tively small sample size of this study. However, the 
small sample size did not result in wide confidence 
intervals indicating that there is an apparent asso-
ciation between proinsulin and cancer mortality. 
Due to the small study population, power was 
lacking to differentiate between site-specific can-
cer mortality, therefore we can only draw conclu-
sions on the association of proinsulin with overall 
cancer mortality. Furthermore, the role of con-
founding might be an issue. Although we adjusted 
for several confounders at baseline (including 
specific insulin) there is 20 years between those 
measurements and the outcomes. Since we did 
not adjust for those potential confounders during 
this follow-up period, it does remain possible that 
other variables at follow-up might explain part of 
these observations.
To conclude, high proinsulin levels were found to 
be significantly associated with 20-year cancer 
mortality, independent of glucose metabolism and 
fasting specific insulin. These findings needs to be 
reproduced in other populations, but are in line 
with in-vitro findings.14 Additional studies with 
site-specific cancer information are warranted.
different categories of glucose metabolism (Figure 
1). The possibility exists that individuals with NGM 
and high proinsulin levels developed T2DM in the 
future, which might then mediate the association 
between high proinsulin and cancer mortality in 
individuals with NGM. Of almost half (N=189) 
of our study-population, we had access to infor-
mation about glucose metabolism 11 years later. 
From that group, 10 (11.2%) of 89 individuals with 
NGM developed T2DM, of whom only one died 
from cancer. From the 69 persons with IGM of 
whom we had follow-up information, 37 (53.6%) 
developed T2DM 11 years later, of whom no one 
died from cancer during the 20-year follow-up 
period.  Therefore, it does not seem likely that 
the development of T2DM in the future explained 
our results. None of the participants with T2DM 
in our study population used glucose lowering 
medication, which made it possible to research 
the association of proinsulin in cancer mortality. 
It was also possible that the use of glucose lower-
ing medication 11 years later biased our results. 
Therefore sensitivity analyses were performed 
and it showed that from the group of whom we 
had follow-up information (n = 189), 36 used glu-
cose lowering medication in the future of which 3 
died from cancer. 
Strengths of this study include the long and com-
plete follow-up duration (none of the participants 
in this subsample were lost to follow-up) with 
a precise cause-specific mortality registry. This 
enabled us to study a more precise association 
between proinsulin and cancer mortality. Further-
more, the Hoorn Study consists of a randomly 
selected cohort population, which limits the pos-
sibility of selection bias. Another strength of our 
study is that both fasting proinsulin and specific 
insulin were measured at baseline, in duplicate, 
which made it possible to evaluate whether the 
association of proinsulin with cancer mortality 
was independent of specific insulin. A high cor-
relation between proinsulin and specific insulin 
could cause multicollinearity within the regres-
sion model. We observed a Pearson correlation 
coefficient between proinsulin and specific insulin 
of 0.48 and the regression model did not substan-
tially change when specific insulin was added to 
the model (Table 2). 
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Chapter 5
Real world evidence of suboptimal blood 
pressure control in patients with type 2 
diabetes
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patients is associated with an increased risk of 
mortality, with eight out of ten T2DM patients dy-
ing from cardiovascular events.5
To decrease the risk of micro- and macrovascu-
lar complications, the current guidelines for blood 
pressure (BP) management in patients with T2DM 
state that systolic blood pressure (SBP) levels 
should be lowered to at least 140 mmHg.6–9 To 
further decrease the risk resulting from high BP 
levels, the initiation of antihypertensive therapy is 
indicated.6–10 
While lower SBP levels are proven to reduce the 
risk of complications.11 the idea that “the lower the 
better” is beneficial for each T2DM patient, could 
be debated.12,13 Some studies even suggest that too 
aggressive BP lowering in high-risk patients could 
do harm rather than to provide protection.12,14,15 
There are limited data from observational stud-
ies within clinical care available on the association 
between SBP levels, complications and CVD mor-
tality in T2DM patients. Therefore, little is known 
about T2DM patient heterogeneity in the course 
of SBP levels. Identifying T2DM subgroups with a 
different course of SBP levels is important in or-
der to eventually improve BP management and 
may provide more accurate insights into the rela-
tionship between SBP levels and outcomes. Latent 
class growth modelling (LCGM) is an innovative 
statistical method allowing subgroup (class) deter-
mination of T2DM patients with a distinct course 
of BP control over time.16 
The Diabetes Care System (DCS) West-Friesland 
in The Netherlands consists of a large primary 
care cohort of T2DM patients with a long-term 
follow-up and offers the unique opportunity to 
identify classes of T2DM patients with distinct SBP 
trajectories, which is the primary aim of this study. 
Subsequently, clinical characteristics and associa-
tions of class membership with outcomes were 
assessed. 
Research Design and Methods
An observational cohort study was performed 
with data from the DCS West-Friesland, described 
in detail elsewhere.17,18 Briefly, the DCS organ-
izes managed diabetes care in the region of West-
Friesland in The Netherlands, a region with about 
200,000 inhabitants, representative for a Caucasian 
population. 
Abstract
Aims: In order to eventually improve blood pres-
sure (BP) management, the aim of this study was to 
identify subgroups of T2DM patients with distinct 
trajectories of systolic BP (SBP) levels. Subgroup 
characteristics were determined and the preva-
lence of complications and mortality rates over 
time in the different subgroups was investigated.
Study Design and Setting: 5711 T2DM pa-
tients with at least two SBP follow-up measure-
ments were selected from a prospective T2DM 
cohort of 9849 T2DM patients. The mean follow-
up period was 5.7 years (range 2 - 9 years). Latent 
Class Growth Modeling was performed to identify 
subgroups of patients with distinct SBP trajecto-
ries. Subgroup characteristics were determined by 
multinomial logistic regression analyses. 
Results: Four subgroups with distinct SBP tra-
jectories were identified. The largest subgroup 
(85.6%) showed adequate SBP control (at or 
around 140 mmHg) over time. The second sub-
group (5.6%) were hypertensive in the first years, 
responded slowly to BP management and even-
tually reached SBP control. The third subgroup 
(3.4%) showed deteriorating hypertension during 
the first four years, then showed insufficient re-
sponse to BP management. The fourth subgroup 
(5.4%) showed deteriorating hypertension over 
time. Patients within subgroups 2-4 were signifi-
cantly older, comprised more women, used more 
antihypertensive medication and had a higher 
prevalence of retinopathy, microalbuminuria and 
CVD mortality. 
Conclusion: More than 85% reached and main-
tained adequate SBP control. Subgroups with a 
more unfavourable course of SBP control also 
showed higher rates of microvascular complica-
tions and CVD mortality over time. This study 
identified important subgroups to target in order 
to improve BP management in T2DM patients.
Introduction
Hypertension is present in as many as 70% of the 
patients with type 2 diabetes mellitus (T2DM).1,2 
Untreated or poorly controlled hypertension in 
patients with T2DM has an additive effect on long-
term cardiovascular risk and accelerates the risk 
of developing micro- and macrovascular compli-
cations.1,3,4 Furthermore, hypertension in T2DM 
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ing each follow-up measurement. The follow-up 
measurements from year 10 to 13 included less 
than 30% of the study population; therefore we 
included the follow-up measurements until nine 
years of follow-up. The resulting study population 
(n=5711) had a follow-up period ranging from 
two to nine years.
Measurements 
Systolic and diastolic blood pressure levels were 
measured yearly, thrice, in a sitting position after 5 
minutes of rest, using a random-zero sphygmoma-
nometer (Hawksley-Gelman, Lancing, Sussex, 
U.K.). From 2003 on, an oscillometric device was 
used (Colin Press-Mate BP-8800, Komaki City, Ja-
pan; from 2009 on, Welch Allyn ProBP 3400, Ska-
neateles Falls, NY, USA). Mean blood pressure was 
calculated as the mean of three measurements. 
The absolute change in SBP between the base-
line and the first year of follow-up was calculated. 
Pulse pressure was determined as SBP – DBP.
HbA1c level was assessed yearly with a DCCT 
standardized reversed-phase cation exchange 
chromatography (HA 8160 analyzer, Menarini, 
Florence, Italy). The HbA1c level was detected 
by a dual-wavelength colorimetric (415-500). The 
intra-assay coefficient of variation (CV) was 0.6% 
at a mean level of 4.9% and the inter-assay CV was 
0.8 % at a mean level of 5.5%.17
Weight and height were measured yearly (while 
patients were barefoot and wearing light clothing). 
BMI was calculated by weight in kilograms divided 
by the height in meters squared.
The DCS uses a managed care plan for T2DM pa-
tients with contracted health care providers in the 
region and is responsible for the quality of diabetes 
care. The diabetes care in the region encompasses 
the care provided by patients’ general practition-
ers (GPs), according to the Dutch GP treatment 
guidelines for T2DM, and annual visits as organized 
centrally by the DCS for annual review assess-
ments and patient education by the diabetes nurse 
and dietician. Results of the annual DCS visits and 
protocol driven therapeutic advices are provided 
to the patient’s GP. The DCS maintains anonymous 
computer records and patients are informed on 
the use of these records for research purposes.17
Study cohort 
Figure 1 presents a flowchart of the study popula-
tion. In the period between 1998 and 2011, 9849 
T2DM patients with different diabetes duration 
entered the DCS in different years. For each pa-
tient, the year of entry to the DCS was considered 
the baseline measurement (T1). Due to the open 
and dynamic nature of the cohort, the number of 
patients in the cohort decreased every follow-up 
year due to loss to follow-up, referral or death. In 
addition, ‘newer’ patients who entered the cohort 
at a later point in time had a shorter follow-up 
duration.17 
In order to accurately identify SBP classes, pa-
tients with a minimum follow-up of two years 
were included. Another precondition of perform-
ing LCGM is that information of at least 30% of 
the included study population is present dur-
1998-2011: 9849 T2DM patients 
5711 T2DM patients with follow-up ≥ 2 years 
 
Follow-up < 2 years; 4138 
 
 3 years 
5324 
4 years 
4747 
5 years 
4221 
6 years 
3652 
7 years 
3179 
8 years 
2764 
9 years 
2346 
Figure 1. 
Flowchart of included patients within 
the study cohort
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tribution) were tested using ANOVA (continues 
variables) and Chi-square tests (categorical vari-
ables). Overall p-values for between group differ-
ences are reported. 
Latent Class Growth Modeling (LCGM) was used 
to identify classes of patients with distinct SBP 
trajectories. LCGM is a type of cluster analysis 
used to group patients into an optimal number 
of classes, each with a unique trajectory of SBP 
over time, by modeling heterogeneity in the time 
course. Each class has its own growth parameters 
(i.e. intercept, slope) and can be characterized 
by a distinct trajectory shape. To determine the 
optimal number of classes, a stepwise forward 
approach was taken starting with a model with 
one developmental pattern. Then, one class at a 
time was added. The optimal model is a model 
where patients within a class are most similar to 
each other and most different to patients in other 
classes. The model fit was assessed by the Bayes-
ian Information Criterion (BIC) (where a lower 
BIC with a difference of at least 10 points indi-
cates a better fit) and with posterior probabili-
ties (where probabilities > 0.8 are recommended 
and a probability closer to 1 indicates a better 
classification).16,17 Also, the usefulness and clinical 
interpretation of each newly derived class were 
taken into account. The usefulness was assessed 
by considering the number of patients in each 
class (hereby rejecting small classes consisting of 
less than 1% of the total study population). The 
final number of classes was based on a low BIC 
score, good probabilities (> 0.8), usefulness, and 
clinically relevant differences between classes.17
Class characteristics were investigated with 
multinomial logistic regression analyses, using 
a backward elimination method. In this analysis, 
we assessed which available patient and disease 
determinants at baseline were associated with 
membership in classes different than the refer-
ence class. The SBP class that had the most opti-
mal SBP control was used as reference class. As-
sociations of determinants with p-values < 0.10 
were included in the final model.
Associations of class membership with the preva-
lence of retinopathy and microalbuminuria over 
time were studied using a binomial mixed mod-
eling approach, accounting for both individual 
and time levels. Two models were constructed; 
Total cholesterol level was measured yearly using 
enzymatic techniques (Boehringer Mannheim, 
Mannheim, Germany). 
Current medication use Use of cardiovascular and 
diabetes medication were obtained yearly by self-
report. 
Urinary albumin-creatinin ratio (UACR) in mg/
mmol was determined yearly in an overnight, 
first-voided urine sample. Urinary albumin was 
measured by rate nephelometry (Array Protein 
System; Beckman Coulter, Fullerton, CA) with an 
assay threshold of 2 mg/L. Urinary creatinin was 
measured using a modified Jaffé test. 
Microalbuminuria was considered present if UACR 
> 2.0 mg/mmol.17
Retinopathy From 1998 until 2000, fundus pho-
tography of both eyes was performed yearly with 
a Kowa Pro Fundus camera with a green filter 
(Kowa Optical Industry, Torrance, CA). From the 
beginning of 2000 until 2004, fundus photography 
of both eyes was performed with a nonmydriatic 
Canon CR5 camera (Canon Inc., Tokyo, Japan). 
From 2004, fundus photography of both eyes 
was performed using a nonmydriatic Topcon TRC 
NW 100 camera (Topcon, Tokyo, Japan). One 
photograph was centred on the macula and the 
other nasally with one optic disc diameter from 
the temporal side. All photographs were graded 
by an experienced ophthalmologist according to 
the EURODIAB classification score.19
Mortality Information on CVD mortality until the 
first of January 2013 was derived from the mu-
nicipal administration registries. Information on 
the cause of death was retrieved from medical re-
cords of general practitioners and from the local 
hospital. All causes of death were coded according 
to the International Classification of Diseases, In-
juries and Causes of Death, ninth revision (ICD-9). 
Cardiovascular mortality and sudden dead were 
regarded as CVD mortality and were defined as 
ICD-codes 390-459, 798, 427.4 and 427.5.
Drop-outs were identified as those who were lost 
to follow-up, e.g. due to referral to secondary 
care or migration.
Statistical analysis
Baseline characteristics were assessed and dif-
ferences between the classes (mean (± SD), pro-
portion or median in the case of a skewed dis-
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sex differences in SBP trajectories, by conducting 
LCGM and multinomial logistic regression analy-
ses stratified for sex. 
LCGM analyses were conducted with Mplus 5.21, 
binomial mixed modeling was performed with 
MLwin 2.25 and further analyses were performed 
with SPSS 20.0. 
Results 
Baseline characteristics Table 1 presents baseline 
characteristics of the included study population. A 
total of 5711 patients were included in the study 
(mean age of 60.6 years, 51% male, mean SBP 143 
mmHg) with a mean follow-up duration of 5.7 
years. 
the first model was adjusted for age, sex and 
time. The second model additionally accounted 
for confounding variables. Exponential beta’s are 
reported and can be interpreted as odds ratios 
(OR) over time. 
Cox survival analysis was performed to assess the 
risk of all-cause and CVD mortality in relation to 
class membership. All analyses were adjusted for 
age and sex, with subsequent analyses accounting 
for confounding variables. 
Associations of class membership with cardiovas-
cular medication use were studied constructing 
plots and graphically comparing differences be-
tween classes.  
Sensitivity analyses were performed to investigate 
Table 1. 
Baseline characteristics of the different classes of systolic blood pressure trajectories
Cohort Adequate 
SBP con-
trol class
Delayed 
respon-
ders class
Insufficient 
SBP con-
trol class
Non-res-
ponders 
class
Overall
P-value
N (%) 5711 4887 (85.6) 319 (5.6) 195 (3.4) 310 (5.4) -
Mean (SD)
Age (yr) 60.6 (11.6) 59.6 (11.5) 66.4 (10.4) 67.2 (10.8) 65.9 (9.4) <0.001
Follow-up  
duration (yr)
5.7 (2.3) 5.6 (2.3) 5.5 (2.3) 6.3 (2.1) 7.4 (1.1) <0.001
Diabetes 
duration (yr)
1.0 
(0.2 to 3.6)
0.9 
(0.17 to 3.3)
1.2 
(0.2 to 4.9)
1.1 
(0.2 to 5.2)
2.0 
(0.5 to 5.4)
<0.001
HbA1c (%) 7.4 (1.8) 7.4 (2.8) 7.4 (1.6) 7.5 (1.8) 7.6 (1.8) 0.207
HbA1c (mmol/
mol)
57.8 (19.7) 57.6 (19.9) 57.4 (17.4) 58.6 (19.1) 60.0 (19.3) 0.207
Entry yr 2003 (3.5) 2004 (3.5) 2004 (3.2) 2003 (2.8) 2000 (2.1) <0.001
BMI (kg/m2) 30.0 (5.4) 29.9 (5.3) 31.3 (6.0) 30.8 (6.7) 30.2 (5.3) <0.001
SBP (mmHg) 142.7 (20.9) 139.5 (17.8) 182.1 (18.2) 152.1 (23.8) 148.7 (22.2) <0.001
∆ SBP (mmHg) -1.9 (15.5) -1.5 (14.5) -15.1 (19.3) 17.8 (18.6) -2.4 (21.3) <0.001
DBP (mmHg) 81.4 (10.9) 80.5 (10.4) 92.2 (12.2) 83.2 (11.1) 83.4 (11.8) <0.001
Total choleste-
rol (mmol/L)
5.3 (1.2) 5.2 (1.2) 5.4 (1.2) 5.3 (1.1) 5.6 (1.1) <0.001
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years of follow-up, and was named the insufficient 
SBP control class. The fourth class (5.4% of the pa-
tients) showed worsening hypertension over time 
and was therefore named the non-responders class. 
Patients in the SBP control classes two to four, thus 
classes with inferior SBP control were older, were 
more often women, had a longer diabetes duration 
(except for the delayed responders class) and had 
higher BP levels at baseline (Table 1). Corresponding 
trajectories of DBP and pulse pressure levels were 
seen in all classes except for the non-responders 
class. Within the non-responders class, DBP levels 
remained stable while SBP and pulse pressure levels 
increased.
LCGM Figure 2 shows SBP trajectories of the 
identified classes. A four-class solution was found 
to be the best model according to the criteria de-
scribed in the statistical analysis section. The larg-
est class (85.6% of the patients) showed a stable 
trajectory of SBP control at or around 140 mmHg 
over time and was therefore named the adequate 
SBP control class. The second class (5.6% of the 
patients) started with hypertension (mean SBP 
182 mmHg), responded slowly to BP manage-
ment and reached SBP levels at or around 140 
mmHg within seven years of follow-up and was 
therefore named the delayed responders class. 
The third class (3.4% of the patients) showed an 
inverse U-shaped course of SBP levels during nine 
Cohort Adequate 
SBP con-
trol class
Delayed 
respon-
ders class
Insufficient 
SBP con-
trol class
Non-res-
ponders 
class
Overall
P-value
N (%)
Sex (% male) 2899 (50.8) 2589 (53.0) 144 (45.1) 63 (32.3) 103 (33.2) <0.001
Current 
smoking (% 
yes)
858 (15.0) 741 (15.2) 39 (12.2) 32 (16.4) 46 (14.8) 0.002
SBP ≤ 
140mmHg (%)
2816 (49.3) 2635 (53.9) 0 (0.0) 60 (30.8) 121 (39.0) <0.001
Prevalence of complications at baseline
Microalbumi-
nuria (%)
1102 (19.3) 852 (17.4) 106 (33.2) 65 (33.3) 79 (25.5) <0.001
Retinopathy 
(%)
429 (7.5) 339 (6.9) 28 (8.8) 23 (11.8) 39 (12.6) 0.007
Use of (any) antihypertensive and diabetes medication at baseline
Antihyperten-
sive use (%)
2757 (48.3) 2250 (46.0) 195 (61.1) 129 (66.2) 183 (59.0) <0.001
Metformin use 
(%)
2548 (44.6) 2198 (45.0) 140 (43.9) 99 (50.8) 111 (35.8) <0.001
SU use (%) 2407 (42.1) 2052 (42.0) 126 (39.5) 79 (40.5) 150 (48.4) 0.001
Insulin use (%) 473 (8.3) 396 (8.1) 26 (8.2) 25 (12.8) 26 (8.2) 0.102
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higher SBP levels and of higher BMI levels com-
pared to patients within the adequate SBP control 
class. Patients within the non-responders class 
had a statistically signifi cantly higher likelihood of 
being female, of advanced age, had higher SBP lev-
els and had a longer diabetes duration compared 
to patients within the adequate SBP control class.
Class characteristics Table 2 shows the results of 
the multinomial logistic regression analysis. Pa-
tients within the delayed responders class had 
signifi cantly higher baseline BMI levels and higher 
baseline SBP levels compared to the adequate SBP 
control class. Patients within the insuffi cient SBP 
control class had a statistically signifi cantly higher 
likelihood of being women, of advanced age, of 
Figure 2. 
Classes of systolic blood pressure trajectories
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Table 2. 
Multinomial logistic regression analyses associated with membership of different classes, compared to 
class 1 (adequate blood pressure control)
Model 1
Odds Ratio +  95% confi dence interval
Delayed responders class versus adequate control class
Sex 0.75 (0.53 to 1.05)
Systolic blood pressure (mmHg) 1.11 (1.10 to 1.13)*
Body mass index (g/m2) 1.05 (1.02 to 1.08)*
Insuffi cient SBP control class versus adequate control class
Sex 2.03 (1.43 to 2.90)*
Age (years) 1.04 (1.01 to 1.08)*
Systolic blood pressure (mmHg) 1.02 (1.01 to 1.03)*
Cholesterol (%) 0.86 (0.74 to 1.00)
Body mass index (g/m2) 1.05 (1.03 to 1.07)*
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Microvascular complications At baseline, classes 
with SBP control other than the adequate SBP 
control class had a significantly higher prevalence 
of microalbuminuria, compared to the adequate 
SBP control class (Table 1).  Table 3 presents asso-
ciations of class membership with retinopathy and 
microalbuminuria over time. Adjusted for con-
Model 1
Non-responders class versus adequate control class
Sex 1.97 (1.52 to 2.55)*
Age (years) 1.14 (1.05 to 1.23)*
Diabetes duration (years) 1.03 (1.02 to 1.05)*
Systolic blood pressure (mmHg) 1.02 (1.01 to 1.03)*
Multivariate analyses, corrected for age and sex showing determinants with p-values <0.10 
* indicates a p-value < 0.05
Table 3. 
Associations of class membership with retinopathy and microalbuminuria 
Delayed 
responders class
Insufficient SBP 
control class
Non-responders 
class
1. Retinopathy Model 1,  
adjusted for age, 
sex and time
1.16 (0.86 to 1.57) 1.84 (1.32 to 2.57)* 1.63 (1.28 to 2.08)*
Model 1 + BMI, 
diabetes duration 
and HbA1c
1.26 (0.94 to 1.69) 1.68 (1.18 to 2.37)* 1.62 (1.28 to 2.05)*
2. Microalbuminuria Model 1,  
adjusted for age, 
sex and time
1.31 (1.05 to 1.63) 1.86 (1.46 to 2.35)* 2.04 (1.68 to 2.46)*
Model 1 + BMI, 
diabetes duration 
and HbA1c
1.59 (1.27 to 2.00)* 1.86 (1.46 to 2.37)* 1.79 (1.47 to 2.18)*
The reference group is the Adequate SBP control group
*P < 0.05
founding, the insufficient SBP control (OR 1.68 CI 
1.18 to 2.37) and the non-responders class (OR 
1.62 CI 1.28 to 2.05) showed a significantly in-
creased risk of retinopathy over time. Microalbu-
minuria was significantly more present in all other 
classes, compared to the adequate SBP control 
class (Table 3).
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control class was signifi cantly associated with an al-
most twofold risk of cardiovascular mortality (HR 
1.80 CI 1.10 to 2.96). The delayed responders class 
and the non-responders class had a similar car-
diovascular mortality risk as compared to the ad-
equate SBP control class. Accounting for confound-
ing variables did not alter the results (Table 4). 
All-cause and cardiovascular mortality Table 4 presents 
a cox proportional hazards model for all-cause and 
cardiovascular mortality. The non-responders class 
had a signifi cantly lower risk of all-cause mortality 
(HR 0.67 CI 0.48 to 0.95) compared to the ad-
equate SBP control class. Adjustment for potential 
confounders did not alter the results (HR 0.69 CI 
0.48 to 0.98). Membership of the insuffi cient SBP 
Table 4. 
Cardiovascular mortality risk according to different subgroups compared to the Adequate SBP control 
group
Adequate SBP control Delayed 
responders class
Insuffi cient SBP 
control class
Non-responders 
class
1. Model 1, adjusted for age and sex 1.02 (0.64 to 1.76) 1.72 (1.05 to 2.81)* 0.78 (0.50 to 1.22)
2. Model 1 + diabetes duration, BMI and 
HbA1c
0.98 (0.57 to 1.67) 1.80 (1.10 to 2.96)* 0.78 (0.49 to 1.24)
Cardiovascular mortality
1. Model 1, adjusted for age and sex 1.02 (0.64 to 1.76) 1.72 (1.05 to 2.81)* 0.78 (0.50 to 1.22)
2. Model 1 + diabetes duration, BMI and 
HbA1c
0.98 (0.57 to 1.67) 1.80 (1.10 to 2.96)* 0.78 (0.49 to 1.24)
The reference group is the Adequate SBP control group
*P < 0.05, DBP; diastolic blood pressure
Within the insuffi cient SBP control class, the 
course of SBP levels over time did not differ be-
tween those who died from cardiovascular events 
and those who did not (Figure 3).
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Cardiovascular mortality rates increased stead-
ily over time, with a slightly steeper increase in 
mortality from the sixth year of follow-up (data 
not shown). 
Figure 3. 
Systolic blood pressure levels of the insuffi cient SBP control class, stratifi ed for cardiovascular mortality.
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ies when providing BP management recommen-
dations for clinical practice.
In our study, classes with suboptimal SBP con-
trol were significantly older (mean age 66 years), 
more likely to be female and had higher BP levels 
at baseline. Particularly older T2DM patients are 
mainly not included in RCTs. Older T2DM pa-
tients with uncontrolled hypertension represent 
an important subgroup to target in order to im-
prove SBP control within primary care. 
The delayed responders class and the insufficient 
SBP control class steadily used more antihyper-
tensive drugs as compared to the adequate SBP 
control class. Although the use of antihyperten-
sive drugs has a beneficial effect on BP control, 
it is often difficult to control BP levels using a 
single drug. Therefore, combination therapy is ad-
vocated in T2DM patients with uncontrolled SBP 
levels.6,8–10,20 Classes with inferior control indeed 
used combination therapy more often, indicating 
that clinical efforts were made to improve BP 
control. However, at nine years a maximum of 
30% of the patients with inferior SBP control used 
three or more antihypertensive drugs. Because of 
the observational nature of the study, we cannot 
identify underlying reasons for the potential re-
luctance to initiate a third antihypertensive drug. 
More research is needed to identify reasons for 
not initiating a third antihypertensive drug.
The insufficient SBP control class showed an al-
most twofold increased risk of cardiovascular re-
lated mortality. This subgroup typically showed an 
inverse U-shaped course of SBP levels and mor-
tality rates increased more steeply after SBP levels 
started to decline. Within this class, the course of 
SBP levels over time did not differ between those 
who died from cardiovascular events and those 
who did not; thereby reducing the likelihood that 
selective dropouts influenced the observed asso-
ciation. There is some validating evidence for our 
findings. Analysis of a T2DM cohort showed that 
the risk of death in elderly patients with T2DM 
increased by 15% for every 10 mmHg decrease 
in systolic BP.25 Another study investigated blood 
pressure trajectories before death and showed 
that mean SBP levels declined in the years before 
death in patients with T2DM. This annual rate of 
Medication use In all classes, use of any cardiovas-
cular medication increased over time. Classes with 
inferior BP control had the highest utilization of 
(any) antihypertensive drug. Use of two and three 
or more antihypertensive drugs was most com-
mon within the delayed responders class and the 
insufficient SBP control class with ±30% of the pa-
tients using three or more antihypertensive drugs 
at nine years (data not shown).
Sensitivity analyses LCGM analyses stratified for 
sex showed no differences in SBP trajectories 
among men and women and did not materi-
ally change the results of the analyses (data not 
shown). 
Discussion 
In the current study, we identified four T2DM 
classes with distinct trajectories of SBP control 
during a mean follow-up period of 5.7 years; an 
adequate SBP control class, a delayed respond-
ers class, an insufficient SBP control class and a 
non-responders class. Patients within SBP control 
classes other than the adequate SBP control class 
were older, comprised more women, had higher 
BMI en SBP levels and had a higher prevalence 
of microvascular complications over time. The 
insufficient SBP control class showed an almost 
twofold increased risk of cardiovascular related 
mortality over time. 
To our knowledge, we are the first to show T2DM 
patient heterogeneity in the course of SBP levels 
and to provide long-term proof of the real world 
effectiveness of the current BP guidelines in T2DM 
patients. Although more than 85% reached stable 
levels of SBP control at or around 140 mmHg, we 
also showed that there are certain groups that 
have insufficiently controlled SBP levels over time 
and for whom the current guidelines might not 
provide the best treatment strategy. The current 
guidelines are merely based on outcomes of rand-
omized clinical trials (RCTs).6,9,20 Patients included 
in RCTs generally do not reflect the clinical T2DM 
population and represent only a highly selected 
patient group defined with detailed in- and exclu-
sion criteria. Our results complement the results 
of several cross-sectional studies within clinical 
practice showing suboptimal BP control21–24 and 
urge the need to consider real world clinical stud-
71
5
indicate that arterial stiffness is the reason for un-
controlled BP levels within this group. 
A limitation of our study is that we had neither 
information on treatment intensification nor on 
treatment adherence. Furthermore, the associa-
tions of class membership with the proportion of 
medication use might have been underestimated, 
since this information was obtained by self-report. 
Additionally, because of the observational nature 
of this study, our findings do not imply causality 
and we cannot explain the mechanisms underlying 
the observed associations.
Finally, the extraction of the classes from the data 
by using LCGM is no proof for the true exist-
ence of multiple subgroups. However, an advan-
tage of LCGM is that categorisation is not based 
on subgroups determined a-priori on theoretical 
knowledge, but they are based on comparable 
trajectory characteristics within the data. Moreo-
ver, LCGM takes sensoring into account, thereby 
eliminating the chance that selective dropouts in-
fluenced the construction of classes.16
Strengths of this study include its observational 
prospective design, its large sample size with 
standardized measurements of T2DM related risk 
factors and complications. Further, the availabil-
ity of multiple measurements of SBP from each 
participant allowed identification of SBP control 
trajectories. 
To conclude, we showed that, under the current 
guidelines, long-term SBP control is still subop-
timal in T2DM patients treated within primary 
care. Even though more than 85% of the T2DM 
patients reached and maintained stable SBP levels 
at or around 140 mmHg during an average of 5.7 
years of follow-up, classes with a more unfavora-
ble course of SBP control showed higher rates of 
complications. The insufficient SBP control class 
showed an increased risk of cardiovascular re-
lated mortality over time. 
We emphasize that more research needs to be 
performed to unravel underlying causes for the 
existence of classes with suboptimal SBP control 
within clinical practice in order to eventually im-
prove SBP control and thereby decrease the risk 
of complications. 
decline was significantly higher than in the pa-
tients who remained alive.26
Surprisingly, the non-responders class exhibited a 
higher risk profile and had a lower all-cause and 
cardiovascular mortality risk compared to the ad-
equate SBP control class. The lower cardiovascu-
lar mortality risk in the non-responders class is 
contra-intuitive and could have been influenced 
by competing mortality risks. To exclude bias by 
selective loss to follow-up, the number of drop-
outs was compared in all subgroups and no statis-
tically significant differences were seen. Based on 
these outcomes, we cannot exclude the risk that 
competing mortality risks biased our results. Fur-
thermore, this finding remains contra-intuitive and 
more research needs to be performed to unravel 
underlying causes for this lower mortality risk.
Enrolment of patients was carried out between 
1998 and 2011, a period in which SBP targets 
were more rigorous than nowadays (<130mmHg). 
This might have caused an overestimation of the 
finding that a very high proportion of the patients 
achieved adequate SBP control during follow-up. 
These proportions might not reflect current BP 
control in T2DM patients. Nonetheless, charac-
teristics of T2DM patients with inferior SBP con-
trol are probably comparable.
The adequate SBP control class showed stable 
SBP control at or around 140 mmHg and showed 
a beneficial effect in terms of microvascular com-
plications and cardiovascular mortality risk. These 
results are in line with large RCTs. The UKPDS 
study found that lowering SBP levels to a mean 
of 144 mmHg markedly reduced the incidence 
of micro- and macrovascular complications com-
pared to the group that achieved mean SBP levels 
of 154 mmHg during follow-up.1 A retrospective 
subgroup analysis of the HOT trial showed a 
large reduction in CVD complications in T2DM 
patients with a mean achieved blood pressure of 
140/81 mmHg.27 
The non-responders class showed deteriorating 
SBP levels over time, while DBP levels remained 
stable. Consequently the pulse pressure within 
this class increased over time as well. This might 
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Retinopathy and left ventricular dysfunction 
The Hoorn Study
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The presence of retinopathy is associated with an 
increased risk of LV dysfunction and HF.3,4 How-
ever, it is still unclear how retinopathy signifies an 
increased risk of HF. One suggested pathway is 
that micro- and macrovascular complications in 
individuals with type 2 diabetes mellitus (T2DM) 
share common pathogenic mechanisms , such as 
systemic low-grade inflammation (LGI) and mi-
cro- or macrovascular endothelial dysfunction 
(ED).5-8 
Studies on the association between retinopathy 
and LV function in which objective measures like 
echocardiography are used, are rare and exist 
on a cross-sectional base only.3,9 Furthermore, 
the potential confounding role of LGI and mi-
cro- or macrovascular ED dysfunction has, to our 
knowledge, not yet been investigated. Therefore, 
we prospectively investigated the association be-
tween retinopathy and changes in LV function in 
a cohort of individuals with impaired glucose me-
tabolism and T2DM. Second, we assessed whether 
LGI and micro- or macrovascular ED explained 
(part of) the association between retinopathy and 
LV function. 
Research Design and Methods
Study population 
The present study was conducted among 147 
individuals with impaired glucose metabolism (n 
= 34) and T2DM (n = 113) who participated in 
2000-2001 (baseline) and 2008 (follow-up) ex-
aminations of the Hoorn Study10 and the Hoorn 
Screening Study.11 The design of the Hoorn Study 
and the Hoorn Screening Study have been de-
scribed previously.10,11 In short, the Hoorn study 
is a population based cohort study on T2DM and 
its complications. It started in 1989 among 2484 
Caucasians between 50-75 years of age. From 
1998 to 2000, another T2DM population based 
cohort study (Hoorn Screening Study) was per-
formed and 88 individuals with newly detected 
T2DM from the Hoorn Screening Study were 
added to the initial Hoorn Study cohort. In the 
year 2000, follow-up measurements were per-
formed among 648 individuals. Echocardiography 
and fundus photography were performed among 
324 individuals with impaired glucose metabo-
lism (IGM) (n =67) and T2DM (n =257). In 2008 
(follow-up), 147 (IGM n = 34, T2DM n = 113) 
Abstract
Aims: The aim of this study was to prospectively 
investigate the association of retinopathy with 
changes in left ventricular (LV) function.
Methods: Within the Hoorn Study, a popula-
tion-based cohort study of diabetes in The Neth-
erlands, retinal photography and echocardiogra-
phy were performed in the year 2000 (baseline) 
and 2008 (follow-up). Retinopathy was graded 
according to the Eurodiab classification and fur-
ther defined as absent or present retinopathy. 
LV systolic and diastolic function were assessed 
by LV ejection fraction (%), LV mass (g/m2.7) and 
left atrial (LA) volume indices and the ratio of 
LV inflow (E) and early diastolic lengthening (e’) 
velocities. Linear regression analyses stratified for 
sex were completed to investigate associations of 
retinopathy with changes in LV function in partici-
pants with impaired glucose metabolism and type 
2 diabetes. 
Results: 147 participants (58% men, mean age 
66) were included in the study, of whom 13.6% 
were present with retinopathy at baseline. LV ejec-
tion fraction was similar among participants with 
and without retinopathy (60.2% versus 60.7%) at 
baseline. Eight years later, retinopathy was signifi-
cantly associated with a lower LV ejection fraction 
(β 8.0 95% CI -15.37 to -0.68) in men , independ-
ent of risk factors. Microvascular endothelial dys-
function ([ED] β 4.87 95% CI -13.40 to 3.67) and 
low-grade inflammation ([LGI] β -5.30 95% CI 
-13.72 to 3.12) both diminished the association. 
No significant associations between retinopathy 
and other LV function parameters were observed. 
Conclusion: Retinopathy was significantly as-
sociated with a lower LV ejection fraction in men 
but not in women. LGI and ED might explain the 
observed association.
Introduction
Heart failure (HF) often develops progressively, 
with a preceding (asymptomatic) period of left 
ventricular (LV) systolic or diastolic dysfunction.1 
Lifestyle and drug interventions in individuals with 
LV systolic and diastolic dysfunction have shown 
to be effective in preventing or delaying the onset 
of HF.2 Therefore, early detection of individuals at 
risk for LV systolic and diastolic dysfunction might 
be useful to prevent HF in individuals with T2DM.
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nificantly worse LV function at baseline. The study 
complied with the Declaration of Helsinki, the 
Ethical Review Committee of the VU University 
medical center (VUmc) in Amsterdam, approved 
the Hoorn Study and written informed consent 
was obtained from all participants.
of the 324 individuals participated in follow-up 
measurements (including echocardiography) and 
are therefore referred to as the current study 
population (Figure 1). Participants who were lost 
to follow-up (n = 177) were significantly older, 
had a higher body mass index (BMI) and had sig-
Figure 1. 
Hoorn Study population at baseline and follow-up examinations. 
T2DM = Type 2 Diabetes
1999-2001: 648 participated follow-up Hoorn Study 
-Baseline echocardiography 
1999-2001: 324 (IGM n=67 T2DM n= 257) of the 648 participants  
underwent ophthalmological examinations 
2007-2009: 328 participated in  
follow-up measurements of the Hoorn Study 
-Follow-up echocardiography 
 
-107 died 
-36 excluded 
-177 refused to/could not partcipate 
 
2007-2009: 147 (IGM n = 34, type 2 diabetes n = 113)  
of the 324 participants underwent ophthalmological examinations  
in 1999-2000 
Measurements 
Retinopathy To assess the presence of retinopa-
thy, fundus photography was performed with my-
driasis of both eyes with 0.5% tropicamide and 
2.5% phenylephrine eye drops. One photograph 
was centred on the macula and the other with 
the optic disc one diameter from the temporal 
edge. A 45 degrees CR5 nonmydriatic retinal 
camera (Canon, Tokyo, Japan) was used.11,12 All 
photographs were graded according to the Euro-
diab classification score,13 in which grade 0 is “no 
retinopathy,” grade 1 is “minimal nonproliferative 
retinopathy,” grade 2 is “moderate nonprolifera-
tive retinopathy,” grade 3 is “severe nonprolifera-
tive or preproliferative retinopathy,” grade 4 is 
“photocoagulated retinopathy” and grade 5 is 
“proliferative retinopathy”. In each subject the 
‘worst’ eye was graded for retinopathy.12
LV function Echocardiography was performed at 
baseline and follow-up with the use of an HP SO-
NOS 5500 echocardiography system (2-4 MHz 
transducer, Andover, Massachusetts, USA) accord-
ing to a standardized protocol consisting of 2D, 
M-mode and pulsed wave Doppler assessments as 
previously described.14 At follow-up, this protocol 
was expanded with tissue Doppler assessments 
of LV annular myocardial lengthening velocities. LV 
systolic dysfunction was determined by measur-
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a supine position (room temperature 23°C). Pe-
ripheral vascular disease, ischemic heart disease 
and history of stroke were considered as prior 
CVD and were assessed at baseline and follow-
up. Peripheral vascular disease was defined as 
intermittent claudication assessed with the Rose 
questionnaire, Ankle Brachial Index ≤0.9, history 
of surgery or endovascular treatment for arterial 
disease, or lower limb amputation. Ischemic heart 
disease was defined as Minnesota Code 1.1–1.3, 
4.1–4.3, 5.1–5.3, or 7.1 on the electrocardiogram 
or self-reported history of myocardial infarction. 
A history of stroke was based on self-report.18
Statistical analysis 
Baseline characteristics of participants are pre-
sented as mean ± SD, percentage or median with 
interquartile range in case of a skewed distribu-
tion. Differences between individuals with and 
without retinopathy were tested using Chi-square 
tests for categorical variables and Student’s t-
tests for continuous variables. In case of a skewed 
distribution, the Student’s t- test was performed 
on log-transformed data. Overall z-scores of bio-
markers of LGI and microvascular ED were cre-
ated. The overall z-scores were created by first 
calculating the individual z-score of each biomark-
er by; [(individual value/population mean)/popu-
lation standard deviation]. Second, the individual 
z-scores were averaged into an overall z-score 
for LGI and microvascular ED. The Z-score for 
microvascular ED was calculated twice, including 
and excluding UACR. 
Linear regression models were constructed to in-
vestigate associations of retinopathy with markers 
of LV systolic and diastolic function at follow-up. 
Unstandardized regression coefficients (β) and 
95% confidence intervals (CI) are reported. Lin-
earity was tested with P-P plots and residual his-
tograms. Since all cases of retinopathy were grade 
1 (non-proliferative) retinopathy, a dichotomous 
variable (absence or presence of (grade 1) retin-
opathy) was created. All analyses were adjusted 
for age. Since it is known that men and women 
possess different risks of developing LV systolic or 
diastolic dysfunction, all analyses were stratified 
for sex.19 To investigate the association between 
ing LV ejection fraction. A set of three markers 
of LV diastolic dysfunction were determined: LA 
volume index, LV mass indexed to height2.7 and 
(at follow-up only) the ratio of early (E) mitral 
valve flow to early (e’) diastolic lengthening veloc-
ity (E/e’) using tissue and pulsed wave Doppler 
assessments.1,15
Measurements Participants underwent risk fac-
tor assessment, including measurements of body 
mass index, blood pressure, hypertension, glycat-
ed hemoglobin level (HbA1c), total cholesterol, 
presence of type 2 diabetes mellitus, smoking and 
eGFR as previously described.11
Biomarkers of LGI (C-reactive protein [CRP], se-
rum amyloid A, interleukin 6, interleukin 8, tumor 
necrosis factor-α, and sICAM-1) and biomarkers 
of microvascular ED (soluble intercellular adhe-
sion molecule 1 [sICAM-1], soluble vascular cell 
adhesion molecule 1 [sVCAM-1], soluble en-
dothelial selectin, soluble thrombomodulin and 
von Willebrand factor [vWF]) were assessed by 
a multi-array detection system based on electro-
chemiluminicence technology (SECTOR Imager 
2400, Meso Scale Discovery, USA), which has 
been described in detail previously.16 
Urinary albumin-creatinin ratio (UACR, as a sur-
rogate of microvascular ED) was determined in 
an overnight first-voided urine sample. Urinary al-
bumin was measured by rate nephelometry (Ar-
ray Protein System; Beckman Coulter, Fullerton, 
CA) with an assay threshold of 2 mg/L. Urinary 
creatinin was measured by a modified Jaffé test. 
To include patients (n = 86) with an albuminuria 
level below the assay threshold, UACR was calcu-
lated with albumin concentration set at 1.9 mg/L 
divided by the urinary creatinin concentration.17 
Intima-media thickness (IMT), Ankle-Brachial In-
dex (ABI) and prior cardiovascular disease (CVD) 
were considered markers for macrovascular ED. 
IMT was measured with carotid ultrasonogra-
phy, as described earlier.14 To measure the ABI, 
Doppler-assisted systolic blood pressure meas-
urements were taken from the brachial and pos-
terior tibial arteries on both sides using 12-cm 
cuffs (Medasonics Vasculab, Mountainview, CA). 
Recording started after a 15-min resting period in 
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To investigate whether participants with IGM in-
fluenced the association between retinopathy and 
LV function, we performed sensitivity analyses in-
cluding only patients with T2DM (n=113). 
All p-values less than 0.05 were considered statis-
tically significant, except for interaction analyses 
where p-values less than 0.10 were considered 
statistically significant. All analyses were per-
formed with SPSS 20.0. 
Results
Baseline characteristics At baseline, 20 (13.6%) in-
dividuals had retinopathy of whom 11 (55%) were 
male. Individuals with retinopathy were slightly 
older, had significantly higher glucose levels, used 
more diabetes medication and the prevalence of 
prior CVD was higher. Diabetes duration was not 
significantly different in patients with and without 
diabetic retinopathy at baseline (Table 1). 
retinopathy and changes in LV systolic and diastol-
ic function, all models were additionally adjusted 
for the baseline value of these markers (models 
of E/e’ were adjusted for baseline LA volume 
index since E/e’ was not measured at baseline). 
Confounding by traditional risk factors of HF (i.e. 
cholesterol, HbA1c, diabetes duration, cigarette 
smoking, systolic and diastolic blood pressure, 
hypertension, prior CVD, UACR, eGFR, BMI and 
use of glucose-, blood pressure-, and lipid lower-
ing medication) was investigated by adding those 
variables one by one to the model. 
To assess whether LGI and micro- or macro-
vascular ED explained the association between 
retinopathy and LV function, those variables were 
entered separately to the model. 
Additional analyses Product terms were entered 
to test for effect modification of T2DM (ADA 
2011, yes/no) or hypertension in the association 
between retinopathy and LV function.
Table 1. 
Baseline characteristics of individuals with and without retinopathy
No retinopathy Retinopathy
Baseline
Total N (%) 127 (86.5) 20 (13.6)
Age 65.3  (7.7) 66.3 (8.8)
Sex (% male) 74 (58.3) 11 (55.0)
Current smoker (% yes) 14 (11.0) 0 (0.0)
Systolic blood pressure (mmHg) 142.5 (17.9) 143.9 (21.2)
Diastolic blood pressure (mmHg) 85.5 (10.7) 86.1 (8.3)
Blood pressure lowering medication 51 (40.2) 8 (38.1)
Total cholesterol (mmol/L) 5.7 (1.1) 5.6 (0.9)
HDL cholesterol (mmol/L) 1.3 (0.3) 1.3 (0.4)
Use of lipid lowering medication 25 (19.7) 5 (23.8)
Waist circumference 99.2 (9.6) 102.0 (14.0)
BMI 28.1 (3.4) 29.2 (4.7)
IGM (%) 32 (25.2) 2 (10.0)
T2DM (%) 95 (74.8) 18 (90.0)
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No retinopathy Retinopathy
HbA1c 6.3 (0.9) 6.8 (6.2 to 7.8)*
Fasting glucose 7.0 (1.3) 8.0 (2.2)*
Glucose postload 8.5 (2.8) 10.9 (2.1)*
Diabetes duration 0.0 (0.0 to 0.0) 0.0 (0.0 to 2.7)
Use of diabetes medication 22 (17.3) 6 (28.6)
Albumin/creatinine ratio (mg/mmol) 0.6 (0.4 to 1.4) 0.7 (0.5 to 2.3)
eGFR 84.0 (16.1) 84.5 (20.1)
Hypertension (% yes) 97 (77.0) 17 (81.0)
Prior cardiovascular disease (% yes)a 57 (45.2) 16 (76.2)*
Intima-media thickness 0.85 (0.16) 0.85 (0.14)
Ankle-brachial index 1.16 (0.14) 1.15 (0.14)
Low-grade inflammation -0.09 (0.56) 0.09 (0.49)
Microvascular endothelial dysfunction -0.08 (0.65) -0.11 (0.5)
LV ejection fraction (%) 60.9 (8.1) 59.6 (9.7)
LV mass index (g/m2.7) 40.9 (12.3) 44.4 (12.8)
LA volume index (mL/m2) 23.8 (20.4 to 29.0) 21.6 (20.4 to 31.4)
Follow-up
Impaired glucose metabolism (%) 32 (25.2) 2 (13.6)
Type 2 diabetes (%) 95 (74.8) 18 (90.0)
LV ejection fraction (%) 52.1 (9.2) 46.3 (15.3)*
LA volume index (mL/m2) 23.4 (19.3 to 31.8) 25.1 (22.3 to 43.1)
LV mass index (g/m2.7) 44.2 (11.6) 47.2 (11.4)*
E/e’ 9.0 (7.9 to 11.1) 9.1 (8.4 to 13.0)
Data are presented as mean ± standard deviation, median (interquartile range) in case of a skewed distribution, or n (%) in case of propor-
tions. * = P-value < 0.05. Abbreviations; NGM=normal glucose metabolism, IGM=impaired glucose metabolism, LV= left ventricular, LA=left 
atrial, E/e’=ratio of early (E) mitral valve flow to early (e’) diastolic lengthening velocity.
Women At baseline, LV function was similar in 
women with and without retinopathy. Eight years 
later, LV mass index2.7 was significantly higher in 
women with retinopathy (46.2 g/m2.7 versus 54.6 
g/m2.7). After adjustment for baseline LV function, 
no significant associations of retinopathy with 
changes in LV systolic or diastolic function were 
observed (Table 2). 
81
6
cation (data not shown) as well as eGFR and hy-
pertension (Table 3) did not materially affect the 
association between retinopathy and LV ejection 
fraction. The association between retinopathy and 
LV ejection fraction was however attenuated and 
no longer significant after adjustment for micro-
vascular ED (explained 39% of the association), 
LGI (explained 34% of the association) or both 
Men LV function at baseline was similar in men 
with and without retinopathy (data not shown). 
Eight years later, the presence of retinopathy at 
baseline was significantly associated with an 8.0% 
(95% CI -15.4 to -0.7) lower LV ejection frac-
tion at follow-up. Further adjustment for HbA1c, 
smoking, UACR, diabetes duration and use of li-
pid-, glucose- and blood pressure lowering medi-
Table 2. 
Association between retinopathy and LV function eight years later in women
Women LV ejection 
fraction
LV mass index LA volume index E/e
Model 1,  
adjusted for 
age 
0.33 (-9.36 to 10.01) 7.05 (-5.13 to 19.22) -1.38 (-11.28 to 11.53) -1.05 (-4.39 to 2.84)
Model 2,  
model 1 + 
baseline LV 
function 
5.38 (-4.11 to 14.86) 4.82 (-6.39 to 16.04) -2.30 (-11.38 to 6.78) -0.82 (-4.42 to 2.78)
Traditional risk factors
Model 2 +  
Hypertension
5.39 (-4.66 to 15.44) 5.42 (-6.04 to 16.88) -2.39 (-11.5 to 6.73) -0.87 (-4.50 to 2.78)
Model 2 + 
eGFR
5.70 (-3.98 to 15.36) 5.31 (-6.24 to 16.86) -2.41 (-11.42 to 6.6) -0.71 (-4.38 to 2.97)
Markers of macrovascular endothelial dysfunction
Model 2 +  
prior CVD
5.58 (-4.49 to 15.64) 2.69 (-9.23 to 14.61) -1.14 (-10.61 to 8.34) -1.06 (-5.01 to 2.90)
Model 2 + 
IMT
5.08 (-4.35 to 14.51) 8.72 (-3.03 to 20.46) -2.36 (-11.45 to 6.72) -0.93 (-4.11 to 2.24)
Model 2 + 
ABI
3.95 (-8.11 to 16.03) 6.41 (-6.12 to 18.96) -3.48 (-13.53 to 6.58) -0.90 (-4.88 to 3.07)
Low-grade inflammation or microvascular endothelial dysfunction 
Model 2 +  
microvascular 
ED
4.44 (-7.54 to 16.42) 8.06 (-4.83 to 20.96) -1.22 (-11.65 to 9.21) -0.24 (-3.63 to 3.15)
Model 2 + 
LGI
6.27 (-5.91 to 18.44) 8.61 (-4.61 to 28.81) -1.77 (-12.82 to 9.28) -0.25 (-3.75 to 3.25)
Model 2 +  
ED & LGI
6.71 (-5.70 to 19.12) 9.17 (-4.08 to 22.42) -1.39 (-12.41 to 9.64) -0.13 (-3.58 – 3.32)
* P-value < 0.05. Abbreviations; LV= left ventricular, LA=left atrial, E/e’=ratio of early (E) mitral valve flow to early (e’) diastolic length-
ening velocity, CVD= cardiovascular disease, IMT= intima-media thickness, ABI= Ankle-brachial index, ED= endothelial dysfunction, 
LGI= low-grade inflammation. Bold= statistically significant (p < 0.05)
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tion. No significant associations of retinopathy 
with other LV function parameters in men were 
observed (Table 3). 
(explained 34% of the association). Markers of 
macrovascular ED did not influence the associa-
tion between retinopathy and LV ejection frac-
more, exclusion of IGM in the linear regression 
analyses did not change the observed associa-
tion between retinopathy and LV ejection frac-
tion in men.
Additional analyses No effect modification of hy-
pertension or glucose tolerance status (IGM or 
T2DM) was observed in the association between 
retinopathy and markers of LV function. Further-
Table 3. 
Association between retinopathy and LV function eight years later in men
Men LV ejection 
fraction
LV mass index LA volume 
index
E/e
Model 1, adjusted 
for age
-7.29 
(-15.59 to 1.50)
1.15 
(-7.75 to 10.04)
4.50 
(-3.65 to 12.65)
0.85 
(-0.84 to 2.54)
Model 2, model 1 + 
baseline LV function 
-8.02 
(-15.37 to -0.68)*
-1.12 
(-9.05 to 6.81)
5.29 
(-2.02 to 12.59)
0.85 
(-0.87 to 2.57)
Traditional risk factors
Model 2 + Hyper-
tension
-8.10 
(-15.51 to -0.69)*
-0.74 
(-8.72 to 7.25)
4.99 
(-2.27 to 12.27)
0.86 
(-0.87 to 2.59)
Model 2 + eGFR -8.12 
(-15.52 to -0.73)*
-1.60
(-9.40 to 6.20)
5.28 
(-1.92 to 12.48)
0.88 
(-0.83 to 2.59)
Markers of macrovascular endothelial dysfunction 
Model 2 + prior 
CVD
-7.30 
(-14.77 to 0.18)
-1.23 
(-9.20 to 6.74)
5.41 
(-2.05 to 12.87)
0.97 
(-0.75 to 2.69)
Model 2 + IMT -7.69 
(-14.80 to -0.57)*
-1.23 
(-9.36 to 6.89)
5.21 
(-1.61 to 12.02)
0.59 
(-1.21 to 2.38)
Model 2 + ABI -8.90 
(-21.47 to 3.67)
-5.32 
(-18.03 to 7.40)
7.01 
(-5.61 to 19.64)
0.66 
(-2.55 to 3.88)
Low-grade inflammation or microvascular endothelial dysfunction 
Model 2 + micro-
vascular ED
-4.87 
(-13.40 to 3.67)
-4.50 
(-12.74 to 3.74)
3.67 
(-4.97 to 12.31)
0.23 
(-1.65 to 2.10)
Model 2 + LGI -5.30 
(-13.72 to 3.12)
-3.97 
(-12.27 to 4.33)
3.11 
(-5.57 to 11.80)
0.21 
(-1.68 to 2.11)
Model 2 + ED & 
LGI
-5.30 
(-13.82 to 3.23)
-4.24 
(-12.56 to 4.08)
3.13 
(-5.66 to 11.92)
0.13 
(-1.79 to 2.04)
P-value < 0.05. Abbreviations; LV= left ventricular, LA=left atrial, E/e’=ratio of early (E) mitral valve flow to early (e’) diastolic length-
ening velocity, CVD= cardiovascular disease, IMT= intima-media thickness, ABI= Ankle-brachial index,  ED= endothelial dysfunction, 
LGI= low-grade inflammation. Bold= statistically significant (p < 0.05)
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about the underlying mechanism between retin-
opathy and LV ejection fraction in men. 
None of the previous studies9,21-23 stratified for 
sex and to our knowledge, there is no other 
literature describing sex differences in the as-
sociation between retinopathy and LV function. 
Although (predominantly) not significant, we 
showed that the association between retinopathy 
and LV function differed among sexes. Further-
more, adjustment for LGI and microvascular ED 
weakened the association between retinopathy 
and LV systolic dysfunction in men while it aug-
mented the association between retinopathy and 
LV diastolic dysfunction in women. Our findings 
correspond with a current review19 on sex dif-
ferences in the aetiology of HF in which women 
were described to be at higher risk of developing 
HF with preserved LV ejection fraction and men 
are more likely to develop LV systolic dysfunc-
tion. More research is needed to further eluci-
date the mechanism behind sex differences in the 
association between retinopathy and LV function. 
Some important limitations of this study need to 
be mentioned. The sample size was small, resulting 
in wide confidence intervals. The power problem 
also prevented multivariable adjustment for con-
founding. Furthermore, since the measurements 
of our study were performed at two points in 
time only, with a similar time interval for all par-
ticipants, we were not able to perform survival 
analyses. Another limitation of the study is the se-
lective non-response at follow-up. Individuals who 
were lost to follow-up had worse LV function at 
baseline, which likely led to an underestimation 
of the observed association between retinopathy 
and LV function. 
To conclude, this study shows that the presence 
of retinopathy is significantly associated with low-
er LV ejection fraction in men but not in women. 
LGI and ED explained more than 30% of the as-
sociation between retinopathy and LV ejection 
fraction. It remains unclear what exact mechanism 
explains the association between retinopathy and 
reduced LV ejection fraction and more research 
behind this mechanism is warranted.
Discussion
In this prospective cohort study, retinopathy was 
significantly associated with an 8% reduced LV 
ejection fraction after eight years in men. Adjust-
ment for traditional cardiovascular risk factors 
did not influence the association. However, ad-
justment for microvascular ED and/or low-grade 
inflammation explained more than 30% of the 
association between retinopathy and LV ejection 
fraction in men. No significant associations be-
tween retinopathy and (changes in) LV function in 
women were found.
To our knowledge, this is the first study to pro-
spectively investigate the association between 
retinopathy and changes in LV function in a popu-
lation with impaired glucose metabolism and 
T2DM. Strengths of this study include its pro-
spective design and comprehensive assessment 
of LV systolic and diastolic function. Furthermore, 
the availability of biomarkers of LGI, micro- and 
macrovascular ED made it possible to investi-
gate whether those mechanisms explained (part 
of) the association between retinopathy and LV 
function. In addition, our study consisted mainly 
of newly diagnosed T2DM patients, therefore we 
were able to exclude the possible confounding ef-
fect of diabetes duration in our hypotheses.  
Our findings extend previous studies which re-
ported significant associations of retinopathy with 
LV dysfunction,3,9 coronary heart disease4 or HF.7,20 
As in those studies,9,21-23 adjustment for classical 
cardiovascular risk factors in our analyses did 
not influence the observed association between 
retinopathy and LV function. Most studies suggest 
that LGI, macro- or microvascular ED could be 
underlying mechanisms to both retinopathy and 
heart disease. Only one study20 actually adjusted 
for microvascular ED (i.e. von Willebrand Factor 
and Factor VII) within the multivariate model and 
observed a weaker but significant association. We 
adjusted for a broader range of biomarkers of mi-
crovascular ED, perhaps representing microvascu-
lar ED more accurately. However, LGI and micro-
vascular ED at baseline were used and therefore 
serve as a proxy for LGI and microvascular ED at 
follow-up. This prevents us from being conclusive 
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Retinopathy and cognition
The Hoorn Study
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Research Design and Methods
Participants 315 participants (mean age 72.9±5.6 
years, 52% male) from the population-based Hoorn 
cohort were included. Detailed information on this 
study has been reported before.6,7 All participants 
underwent ophthalmological and neuropsycho-
logical examination between 2005 and 2008. The 
Hoorn Study was approved by the medical ethics 
committee of the VU University Medical Center 
and was performed in accordance with the guide-
lines of the Helsinki Declaration. Written informed 
consent was obtained from all participants.
Measurements Participants underwent physical 
examination, including measurements of body 
mass index (BMI; calculated as weight divided 
by squared height), hypertension (systolic blood 
pressure ≥ 140 mm Hg, diastolic blood pressure 
≥ 90 mm Hg or use of blood pressure-lowering 
medication), glycated hemoglobin level (HbA1c, 
%), and total cholesterol. Presence of type 2 diabe-
tes mellitus was based on WHO criteria (WHO 
1999). History of cardiovascular disease was de-
fined as self-reported intermittent claudication, 
angina pectoris, possible myocardial infarction, 
amputation, stroke, or transient ischemic attack.
Ophthalmological examination The retina was ex-
amined with fundus photography after mydriasis. 
Methods were similar to those reported earlier 
in the Hoorn Study.8 All photographs were graded 
by an experienced ophthalmologist. Retinopathy 
was defined as the presence in at least one eye of 
hypertensive retinopathy, sclerotic vessel changes, 
hemorrhages/microaneurysms, preretinal hem-
orrhages, vitreous hemorrhages, flame shaped 
hemorrhages, hard exudates, cotton wool spots, 
intraretinal microvascular abnormalities, venous 
beading, areas of neovascularization, fibrous pro-
liferation and/or laser coagulation scars, focal ar-
teriolar narrowing, arteriovenous nicking, venous 
or arteriolar occlusion, arterial narrowing, and/or 
a clinical diagnosis of  diabetic retinopathy (based 
on EURODIAB 9). Severe retinopathy was defined 
as the presence of  hemorrhages, microaneu-
rysms, cotton wool spots, intraretinal microvas-
cular abnormalities, areas of neovascularization, 
fibrous proliferation, laser coagulation scars, and/
or diabetic retinopathy.
Abstract
The retinal vasculature is strongly related to that 
of the brain and as such may be a marker of late-
life cognitive impairment of vascular origin. We 
hypothesized that older persons with vascular 
retinopathy signs had worse cognitive function-
ing than persons without. In 315 participants of 
the population-based Hoorn Study (age 72.9±5.6 
years), fundus photographs were graded elabo-
rately for any or severe retinopathy, and cognitive 
functioning was assessed on six domains. Results 
show that severe retinopathy may mark aging-
related cognitive impairment, but retinopathy has 
limited value as a population screening tool.
Introduction 
Cognitive impairment and dementia are impor-
tant health problems and are partly attributable 
to vascular risk factors and vascular damage in 
the brain.1 The cerebral vasculature is anatomi-
cally, embryologically, and physiologically related 
to that of the retina, and both are sensitive to 
exposure to vascular risk factors.2,3 Furthermore, 
vascular damage to the retina is easy to measure 
noninvasively. Thus, visualization of the retina may 
offer insight into the status of the vessels in the 
brain, and examining the relation between vascu-
lar changes in the brain and cognitive functioning 
can provide insight into vascular causes of late-life 
cognitive impairment.
Previous studies on the relation between retinal 
vascular changes and dementia or cognitive func-
tioning show small but consistent effects, most 
pronounced for relatively severe retinal vascular 
abnormalities. Community-dwelling persons with 
retinopathy have an increased risk for cognitive 
impairment or dementia, although associations 
with continuous domains of cognitive function-
ing are inconsistent.4,5 We aimed to extend these 
findings, in an older population-based sample with 
detailed retinal evaluation and comprehensive 
neuropsychological data. In the current study, we 
examined whether older persons with any sign of 
retinopathy had worse cognitive functioning than 
persons without retinopathy. 
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persons with and without severe retinopathy.
Results
Any retinopathy sign in at least one eye was 
present in 74 participants (24.1%). This group in-
cluded persons with a clinical diagnosis of hyper-
tensive retinopathy (54 participants, 17.1% of the 
sample), and/or diabetic retinopathy (5 partici-
pants, 1.6%). The most common retinopathy sign 
was sclerotic vessel changes (n=15, 4.8%). Other 
signs were less common: arteriovenous nicking 
(n=4, 1.3%), venous occlusion (n=3, 1.0%), or mi-
croaneurysms (n=2, 0.6%). Hard exudates, venous 
beading, and focal narrowing were each present 
in one individual (0.3%). None of the participants 
had cotton wool spots, intraretinal microvascular 
abnormalities, areas of neovascularization, fibrous 
proliferation, arteriolar occlusion, photocoagula-
tion scars, preretinal hemorrhages, vitreous hem-
orrhages, flame shaped hemorrhages, or narrow 
arteries.
Population characteristics are shown in Table 1. 
Participants with retinopathy were older than 
those without retinopathy (74.0±5.6 versus 
72.5±5.6 years), were slightly less often male 
(43% versus 55%), and had higher HbA1c levels 
(6.0±0.6% versus 5.7±0.6%). None of the partici-
pants had cognitive dysfunction severe enough to 
disturb day to day functioning.
Cognitive assessment All participants performed 
an extensive neuropsychological examination 
measuring 6 cognitive domains: abstract reason-
ing, memory, information processing speed, atten-
tion and executive function, visuoconstruction, 
and language.7 Raw test scores were standardized 
into z-scores per test and subsequently averaged 
per domain. A sum score was also calculated. The 
Dutch version of the National Adult Reading Test 
was used as an estimation of the premorbid level 
of intellectual functioning. Educational level was 
recorded (7 categories). Depressive symptoms 
were assessed with the validated Dutch version 
of the 20-item Centre for Epidemiologic Studies 
Depression Scale (CES-D; possible range 0–60). A 
score ≥16 was considered an indicator of possible 
depression.
Statistical analysis
Between-group differences in population charac-
teristics were analyzed with analysis of variance 
for continuous variables, Mann-Whitney U tests 
for non-parametric data and chi-square tests for 
proportions. Between-group differences in cog-
nitive functioning  were examined with analysis 
of covariance, with sex, age, and estimated pre-
morbid IQ as covariates. In separate analyses, we 
added as covariates hypertension, diabetes, car-
diovascular disease, and depression. Furthermore, 
we performed sensitivity analyses by comparing 
Table 1. 
Characteristics of participants
With 
retinopathy
Without 
retinopathy
P-value
Participants 76 (24%) 239 (76%)
Age (years) 74.0 ± 5.6 72.5 ± 5.6 0.04*
Male 33 (43%) 131 (55%) 0.06
Education, median (IQR)a 4 (4 – 5) 4 (4 – 5) 0.24
Estimated premorbid IQ 98 ± 13 98 ± 13 0.96
Type 2 diabetes 17 (23%) 49 (21%) 0.44
Hypertension 56 (74%) 168 (70%) 0.34
 HbA1c (%) 6.0 ± 0.6 5.7 ± 0.6 <0.01*
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Table 2. 
Comparison of cognitive functioning between participants with and without (severe) retinopathy (no 
retinopathy = reference)
Mean difference in z-scores1, beta with 95% CI
Any (n=76) versus no 
(n=239) retinopathy
Severe (n=8) versus no 
(n=239) retinopathy
Abstract reasoning 0.06 (-0.18 to 0.30) -0.10 (-0.82 to 0.62)
Memory 0.07 (-0.04 to 0.18) -0.07 (-0.38 to 0.25)
Information processing speed -0.06 (-0.24 to 0.12) -0.45 (-0.95 to 0.04)
Attention and executive functioning -0.02 (-0.17 to 0.13) -0.40 (-0.80 to -0.002)*
Visuoconstruction 0.09 (-0.14 to 0.31) -0.21 (-0.85 to 0.43)
Language 0.08 (-0.13 to 0.29) -0.34 (-0.91 to 0.24)
Sum score 0.03 (-0.07 to 0.14) -0.27 (-0.56 to 0.03)
1Adjusted for sex, age and estimated premorbid IQ.
out retinopathy (75.6±6.5 versus 72.5±5.6 years, 
p=0.12). Importantly however, the groups did not 
differ regarding sex, blood pressure, or BMI (all 
p>0.05). On all cognitive domains, participants 
with severe retinopathy performed worse than 
those without retinopathy (Table 2). Effect sizes 
were larger than for any retinopathy (between 
-0.45 and -0.07), but reached statistical significance 
only for attention and executive functioning (mean 
difference in z-score -0.40, CI -0.80 to -0.002).
There were no differences in cognitive functioning 
between participants with and without retinopa-
thy (Table 2). Mean differences in z-scores ranged 
from -0.07 to 0.09, all p>0.05. Additional adjust-
ment for depressive symptoms, hypertension, 
cardiovascular disease, or diabetes did not change 
the results (data not shown). 
Eight participants (2.5%) had severe retinopathy. 
They tended to be older than participants with-
With 
retinopathy
Without 
retinopathy
P-value
Total cholesterol (mmol/L) 5.4 ± 1.1 5.3 ± 1.1 0.94
Systolic blood pressure (mm Hg) 149 ± 20 146 ± 21 0.35
Diastolic blood pressure (mm Hg) 73 ± 9 75 ± 11 0.28
Body mass index 28 ± 4 27 ± 4 0.13
History of cardiovascular diseasec 17 (22%) 40 (17%) 0.17
Current smokers 13 (17%) 31 (13%) 0.09
Depressive symptoms (CES-D ≥ 
16)
10 (13%) 20 (8%) 0.16
Data are presented as means ± SD , n (%), or median (range), unless otherwise specified. 
* p ≤ 0.05, with versus without retinopathy. aSeven categories. bDefined as systolic blood pressure ≥140 mm Hg, diastolic blood pres-
sure ≥90 mm Hg or use of blood pressure-lowering medication. cDefined as self-reported history of claudicatio intermittens, angina 
pectoris, possible myocardial infarction, amputation (Rose questionnaire (Rose 1982)), stroke, or transient ischemic attack.
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thy – was related to worse cognitive functioning. 
Because associations are detectable only in cases 
of severe retinal or cognitive pathology, the popu-
lation risk of cognitive impairment attributable 
to retinal damage is likely to be low. Therefore, 
the relevance and usefulness of retinopathy as a 
marker of cognitive impairment is limited. Only 
presence of severe retinopathy can be used to 
identify a very small group of individuals at ele-
vated risk for cognitive impairment. Nevertheless, 
our findings do convey an etiological message. 
Microvascular damage in the retina and the brain 
may develop side by side and reflect exposure to 
vascular risk factors such as hypertension, diabe-
tes, or hypercholesterolemia, and susceptibility to 
microvascular damage. 
Strengths of the present study include the detailed 
recording of vascular and retinal determinants 
and extensive neuropsychological assessment in 
a well-defined population-based cohort of older 
participants. Our study also some limitations. 
First, because of the observational cross-sectional 
design, it could not be determined whether retin-
opathy may predict cognitive decline in the years 
to come. Second, a possible selection bias may 
have occurred due to attrition of this elderly pop-
ulation during follow-up, since persons with a less 
favorable vascular risk factor profile at baseline 
(1989) or severe cognitive dysfunction are more 
likely to be lost to follow-up. Third, visual impair-
ment due to retinal vascular changes may have 
confounded performance on cognitive tests.11 Vis-
ual acuity was not formally tested, therefore we 
cannot rule out the possibility that persons with 
(severe) retinopathy have encountered difficulties 
during cognitive assessment due to poorer vision. 
However, only persons with sufficient vision to 
complete the neuropsychological examination 
were included in this study.
In conclusion, in our population of older individu-
als, any retinopathy was unrelated to cognitive 
functioning. Severe retinopathy, present only in 
very a small subset, was associated with moderate 
cognitive decrements. In the general population, 
retinopathy has limited value as a screening tool 
for aging-related cognitive impairment.
Discussion
The present study shows that in a population-
based sample of older persons participating in 
the Hoorn Study, any retinopathy was unrelated 
to cognitive functioning. However, a small subset 
of participants with severe retinopathy had worse 
cognitive functioning than participants without se-
vere retinopathy.
Our study sample permitted us to detect dif-
ferences between persons with any retinopathy 
versus without with effect sizes as small as ~0.30 
(power 0.80, alpha 0.05). Thus, statistical power 
was sufficient to detect decrements in cognitive 
performance that are relevant for daily function-
ing.10 The observed differences between partici-
pants with and without any retinopathy were very 
small, with point estimates for effect sizes below 
0.10 with narrow 95% CIs. This indicates that the 
absence of an association was true and not due to 
low statistical power. For severe retinopathy, on 
the other hand, statistical power was considerably 
lower because of the small number of participants 
showing this pathology. The obtained differences 
in cognitive functioning between participants with 
severe versus no retinopathy were of moderate 
effect sizes and are therefore potentially clinically 
relevant. 
A limited number of studies have investigated 
the relation between retinopathy and cognitive 
functioning in the general population. Generally, 
neuropsychological examinations in these stud-
ies were less elaborate than in the current study. 
A recent systematic review4 shows effect sizes 
for any retinopathy in the range of -0.25 to 0.03 
that are fully in line with the present results. Tak-
ing into account a possible publication bias, even 
more studies may have been performed that failed 
to obtain significant associations. Taken together, 
these findings show that in non-demented indi-
viduals in the general population, there is no clini-
cal relevant relation between the presence of any 
retinopathy and cognitive performance. Never-
theless, people with any retinopathy are at risk for 
performing at the extreme end of the spectrum 
of cognitive functioning, in particular dementia.4,5 
In a similar fashion, in our study, the extreme end 
of retinal damage – defined as severe retinopa-
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program which is usually integrated within regular 
diabetes care.2-5 Nevertheless, a ‘one size fits all’ 
approach is costly and time consuming as only a 
minority of the T2DM patients eventually devel-
ops sight threatening retinopathy (STR) which 
is mainly dependent of several well-known risk 
factors such as diabetes duration, HbA1c, blood 
pressure and early stages of retinopathy.6-9 Conse-
quently, patients at low risk for STR might be over 
screened with a predefined screening interval, 
while patients at high risk for developing STR may 
be missed. Therefore, a personalized screening 
interval in which the individual risk of developing 
STR is taken into account might be a more appro-
priate or cost-effective method to screen for STR 
in T2DM patients.2,3,10-16 Aspelund et al recently 
developed a model, based on diabetes related risk 
factors, in which they aim to reach a more person-
alized approach to screen for STR in diabetes.17 
However, assessment of the accuracy and validity 
of a model should be performed before generaliz-
ing it to other populations. The Diabetes Care Sys-
tem West-Friesland (DCS) is a large prospective 
T2DM cohort in which diabetes related risk fac-
tors and complications are extensively measured, 
which offers a unique opportunity to validate the 
model. Therefore, the aim of this study was to vali-
date the personalized screening model of Aspe-
lund17 by assessing the accuracy of predicting STR.
Research Design and Methods
Study population Data of T2DM patients includ-
ed in the dynamic cohort of the Diabetes Care 
System West-Friesland (DCS) were used. The 
DCS coordinates regional care for T2DM using 
a centrally organized database available to all in-
volved caregivers. Diabetes nurses and dieticians 
perform annual follow-up examinations, including 
glucose control, cardiovascular risk profiling and 
identifying the presence of micro- and macrovas-
cular complications.18 
In the study period between 1998 and 2010, the 
DCS cohort consisted of 8,308 T2DM patients. 
The cohort is dynamic, meaning that each year 
newly diagnosed diabetes patients as well as pa-
tients with a longer duration of diabetes enter 
the DCS cohort. For each patient, the year of en-
try was considered as baseline. Because current 
T2DM guidelines recommend annual or biannual 
Abstract
Aims: To validate a model for determination of 
a personalized screening frequency for diabetic 
retinopathy.
Methods: A model calculating a personalized 
screening interval for monitoring retinopathy 
based on patients risk profile was validated using 
data of 3,319 type 2 diabetes patients of the Dia-
betes Care System West-Friesland, The Nether-
lands. Two-field fundus photographs were graded 
according to the EURODIAB coding system. Sight 
threatening retinopathy (STR) was considered 
grade 3 to 5. Validity of the model was assessed 
using calibration and discrimination measures. We 
compared model-based time of screening with 
time of STR diagnosis and calculated differences 
in number of fundus photographs using the model 
compared to annual or biannual screening.
Results: During a mean of 53 months of follow-
up, 76 (2.3%) patients developed STR. Using the 
model, mean screening interval was 31 months, 
leading to a reduced screening frequency of 61% 
compared to annual screening and 23% compared 
to biannual screening. STR incidence occurred af-
ter a mean of 26 months after the model-based 
time of screening in 67 patients (88.2%). In 9 
patients (11.8%) STR had developed before the 
model-based time of screening. Discriminatory 
ability of the model was good (C-statistic: 0.83, 
95% CI 0.74 to 0.92). Calibration showed that the 
model overestimated STR risk.
Conclusion: A large reduction in retinopathy 
screening was achieved using the model in this 
population with a very low incidence of retinopa-
thy. Considering the number of potentially missed 
cases of STR, there is room for improvement of 
the model. Use of the model for personalized 
screening may eventually help reducing health 
care use and costs of diabetes care.
Introduction
With the growing prevalence of type 2 diabetes 
mellitus (T2DM), diabetic retinopathy (DR) is 
thought to become the leading cause of visual im-
pairment and blindness.1 Screening for DR among 
diabetes patients is an effective method to de-
crease the disease burden by early diagnosis and 
timely medical treatment.1 Therefore, many coun-
tries have adopted an annual or biannual screening 
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occasions (fasting glucose ≥7.0 mmol/l or random 
plasma glucose ≥ 11.1 mmol/l) in the absence of 
symptoms.19 Diabetes duration was calculated 
from the date of diabetes diagnosis until the date 
of the baseline measurement.
Measurements Annual physical examinations were 
performed following a standardized protocol. 
Weight and height were measured with patients 
barefoot and wearing light clothes. HbA1c was 
measured with high-performance liquid chroma-
tography. Fasting plasma glucose was measured 
by means of a hexokinase method (Roche Diag-
nostics GmbH, Mannheim, Germany). Levels of 
total cholesterol, HDL cholesterol, and triglycer-
ides were measured with enzymatic techniques 
(Boehringer-Mannheim, Mannheim, Germany). 
Systolic and diastolic blood pressure were meas-
ured on the right arm after 5 minutes resting in 
a seated position using a random-zero sphygo-
momanometer (Hawksley-Gelman, Lancing, Sus-
sex, UK). Year of onset of diabetes and informa-
tion on country of birth of the patient and his 
parents was obtained by self-report.9 Patients 
were categorized into two ethnic groups: West-
ern (European countries (except for Turkey), 
Indonesia, USA and Oceania) and non-Western 
(Turkey, Morocco, Surinam, Aruba, Netherlands 
Antilles, Africa, Asia and Latin-America).
Diabetic retinopathy From 1998 until 2000, fundus 
photography of both eyes was performed with a 
Kowa Pro Fundus camera with green filter (Kowa 
Optical Industry, Torrance, CA). From the begin-
ning of 2000 till 2004, fundus photography of both 
eyes was performed with a nonmydriatic Canon 
CR5 camera (Canon Inc., Tokyo, Japan). From 2004, 
fundus photography of both eyes was performed 
with a nonmydriatic Topcon TRC NW 100 camera 
(Topcon, Tokyo, Japan).9 All participants were ex-
amined with 45 degrees fundus photographs. One 
photograph was centered on the macula and the 
other nasally with the optic disc one disc diam-
eter from the temporal edge. Mydriasis with 0.5% 
tropicamide and 2.5% phenylephrine eye drops 
was performed when the nonmydriatic photo-
graph was not gradable. All photographs were 
graded by an experienced ophthalmologist who is 
trained as a retinal specialist. Each patients grade 
screening for retinopathy,2-5 in most patients di-
agnostic fundus photography was performed 
within two years after baseline. Therefore, we 
included patients in whom results of graded fun-
dus photographs and variables used to estimate 
screening frequency were present at baseline 
(n=5,483). In patients with missing fundus pho-
tograph results at baseline but in whom fundus 
photograph results were present one or two year 
after baseline (n=1,030), the measurement one 
or two years after baseline was considered the 
baseline measurement. Of the 6,513 patients, we 
excluded patients in whom the STR was already 
present at baseline (EURODIAB grade 3, 4 or 5) 
(n=61). For 3,133 subjects, no graded fundus pho-
tographs within one year after model-based time 
of screening were available. Patients that had no 
graded fundus photographs available within one 
year after model-based time of screening had a 
significantly higher age (+1.4 years), shorter dia-
betes duration (-0.3 years), lower HbA1c (-0.7%), 
lower systolic blood pressure (-5.5mmHg) and 
a lower diastolic blood pressure (-5.1mmHg) at 
baseline. Furthermore, those patients had a sig-
nificantly lower prevalence of grade 1 retinopathy 
(3.5%) and a comparable prevalence of grade 2 
retinopathy (1.4%, respectively) at baseline and 
were appointed a significantly longer (+9 months) 
screening interval as compared to those included 
for the current analyses.
Thus, 3,319 T2DM patients remained for the cur-
rent analyses. Patients that were included but were 
censored due to incomplete follow-up (n=991) 
had a significantly higher age (+6.5 years), long-
er diabetes duration (+2.4 years), lower HbA1c 
(-0.21%) and diastolic blood pressure (-3.7mmHg) 
as compared to patients with complete 60-month 
follow-up data. Mortality rates did not significantly 
differ between patients with complete (17.5%) 
and incomplete (16.3%) follow-up (p=0.2).
Confirmation of diabetes and diabetes duration 
T2DM was considered confirmed if at least one 
of the following was reported by patients’ general 
practitioner: 1) one or more classic symptoms 
(excessive thirst, polyuria, weight loss, hunger or 
pruritis) and fasting plasma glucose ≥ 7.0 mmol/l) 
or random plasma glucose 11.1 mmol/l; 2) at least 
two elevated plasma glucose levels on different 
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during follow-up and was visually checked by plot-
ting the predicted risk to develop STR against 
the observed incidence of STR. Participants were 
grouped into quintiles of predicted STR risk dur-
ing 60 months of follow-up, which was calculated 
in the first step of the model. Using Poisson re-
gression for survival data, the observed incidence 
of STR was calculated within each quintile, taking 
into account censored data.21 Within each quin-
tile, observed STR incidence was plotted against 
the predicted risk. Discrimination is the ability to 
distinguish between those who develop STR dur-
ing follow-up from those who do not. Discrimi-
natory ability was estimated by calculating the 
Harrell’s C-statistic (similar to the area under the 
receiver operating characteristic (ROC) curve), 
censoring missing data from patients who did not 
have complete 60 month follow-up data.22 
The discriminatory power is graded as poor for a 
C-statistic below 0.6, moderate between 0.6 and 
0.8, and good if  > 0.8. 
Finally, we investigated whether updating the 
model to the observed risk of developing STR 
within our study population improved calibration 
and discrimination of the model. Updating the 
model was performed by calculating the calibra-
tion factor; ([1- the proportion of patients with-
out STR after 60 months]/mean risk calculated by 
the model). Then, the calibration factor was used 
to update the risk function as calculated by the 
model; (calibration factor*mean risk calculated by 
the model). 
All statistical analyses were conducted using SPSS 
version 20 (SPSS, Chicago, IL) and R version 3.0.2 
(Vienna, Austria) for Windows.
Results
A total of 3,319 T2DM patients were included in 
the study, of whom 339 (10.2%) presented grade 
1 or 2 retinopathy at baseline, mostly mild non-
proliferative retinopathy (grade 1) (9.1%). During 
a mean of 53 months of follow-up, 76 patients 
(2.3%) developed STR. 
Patients with prevalent grade 1 or 2 retinopathy 
at baseline were significantly older, had a longer 
diabetes duration and had higher HbA1c levels as 
compared to individuals without retinopathy at 
baseline (Table 1). 
of retinopathy was based on the grading of the 
worst eye. All photographs were graded according 
to the EURODIAB classification score, in which 
grade 0 is “no retinopathy,” grade 1 is “minimal 
non-proliferative retinopathy (one or few scat-
tered hemorrhages or microaneurysms),” grade 2 
is “moderate non-proliferative retinopathy,” grade 
3 is “severe non-proliferative or preproliferative 
retinopathy,” grade 4 is “photocoagulated retinop-
athy,” and grade 5 is “proliferative retinopathy”.20 
Because patients with grade 3 to 5 retinopathy 
are usually referred to an ophthalmologist for 
assessment and/or treatment, grade 3 to 5 were 
included in the outcome measure and considered 
as ‘STR’. If abnormalities were seen near to the 
macula and maculopathy was suspected, the EU-
RODIAB grading is minimally set on 3 and the pa-
tient was referred to an ophthalmologist.
Statistical analyses
Variables are presented as percentage, mean (± 
standard deviation (SD)) or median (interquartile 
range) in case of a skewed distribution. Differ-
ences in baseline characteristics between patients 
with and without grade 1-2 retinopathy at base-
line were tested with Student’s t-test for normal 
distributed variables and by Mann-Whitney’s U 
test for variables with a skewed distribution. Dif-
ferences in proportions were tested by the Chi-
square test. 
Using the model of Aspelund et al, STR risk and 
an accompanying screening interval ranging from 
6 to 60 months were calculated for each patient 
based on sex, HbA1c, systolic blood pressure, 
presence of retinopathy and diabetes duration.17 
In patients with incident STR during follow-up, we 
checked whether STR occurred before or after 
the model-based time of screening. Outcomes 
of omitted fundus photographs according to the 
model and potentially missed cases of retinopathy 
grade 3 to 5 were checked. For the total popula-
tion, we calculated the reduction in screening fre-
quency by comparing the mean screening interval 
of the population assigned by the model to annual 
and biannual screening. 
The predictive accuracy of the model was esti-
mated using calibration and discrimination tech-
niques. Calibration is the ability of the model to 
predict the number of observed cases of STR 
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Table 1. 
Baseline characteristics of type 2 diabetes patients population stratified by retinopathy grade (EURO-
DIAB) at baseline
No 
retinopathy
Grade 1 
retinopathy
Grade 2 
retinopathy
N (%) 2,980 (89.8) 302 (9.1) 37 (1.1)
Age (years) 60.3 (11.3) 62.6 (12.0) a 62.4 (10.2)
Men (%) 53.7 57.6 67.6
Ethnicity (% Western) 91.4 87.6 85.7
BMI (kg/m2) 30.2 (5.4) 29.3 (5.1) a 30.1 (5.0)
Diabetes duration (years) 1.1 (0.3 to 3.7) 2.8 (0.9 to 8.5) a 9.6 (2.7 to 14.4) a
 HbA1c (%) 7.6 (2.0) 7.8 (1.8) 8.4 (1.7) a
HbA1c (mmol/mol) 60 (21) 61 (20) 68 (18) a
Systolic blood pressure (mmHg) 145.3 (22.0) 146.5 (22.5) 148.8 (18.3)
Diastolic blood pressure (mmHg) 83.2 (10.8) 83.6 (11.7) 82.3 (10.8)
Total cholesterol (mmol/l) 5.3 (1.2) 5.3 (1.0) 5.7 (1.1)
LDL cholesterol (mmol/l) 3.2 (1.3) 3.3 (0.9) 3.5 (0.9)
HDL cholesterol (mmol/l) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3)
Triacylglycerol (mmol/l) 2.1 (1.7) 1.9 (1.0) 2.7 (2.3)
aSignificantly (p-value < 0.05) different from reference category (no retinopathy).
Data are presented as proportions, means (SD) or median (interquartile range) in case of a skewed distribution.
Using the model, 2,468 (74.4%) patients were 
appointed a screening interval longer than 12 
months and 1,755 (52.9%) patients were assigned 
a screening interval longer than 24 months. When 
using the model, screening frequency could be re-
duced with 23% compared to biannual screening 
and a reduction of 61% could be achieved com-
pared to annual screening.
Table 2 shows the model-based screening interval 
for the total population (mean (SD): 31.0 (20.0) 
months) and stratified for patients with different 
grades of retinopathy at baseline. With progress-
ing grades of retinopathy at baseline, the model-
based screening interval shortened and the inci-
dence of STR increased. 
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in Figure 1A. It shows the observed incidence of 
STR within each quintile of the predicted risk of 
developing STR. The model overestimates the risk 
of developing grade 3 to 5 retinopathy.  
Figure 1B shows the calibration plot of the ob-
served incidence of STR against the predicted in-
cidence of STR after updating of the model to the 
observed risk in our study population. Compared 
to the initial calibration plot, the observed inci-
dence within quintiles of the updated predicted 
risk lies closer to the diagonal line meaning that 
updating the model improved calibration of the 
model in our study population. When using the 
updated model, screening frequency could be re-
duced with 29% compared to biannual screening 
and a reduction of 65% could be achieved com-
pared to annual screening. Of all patients who 
developed STR during a mean of 53 months of 
follow-up, 13 patients developed STR before the 
updated model-based time of screening (mean 
(SD): 25.5 (14.3) months) which is later than the 
current care.
A total of 76 patients developed STR during follow-
up. Of these, 67 patients (88,2%) developed STR 
after the model-based time of screening (mean 
(SD):25.5 (22.2 months), meaning that the model-
based screening interval was safe in these patients. 
Of these, 5 patients (7.5%) developed STR within 
1 year after baseline and screening should already 
have been performed after 6 months according 
to the model. Of all patients who developed STR 
during a mean of 53 months of follow-up, 9 pa-
tients (11.8%) developed STR before the model-
based time of screening (mean (SD): 24.3 (13.2) 
months) which is later than the current care. Pa-
tients who were potentially missed by the model 
had significantly lower systolic blood pressure 
levels (127 mmHg versus 146 mmHg) at baseline 
compared to patients screened in time. HbA1c 
level was not significantly different between the 
two patient groups.
The C-statistic of the personalized screening 
model was 0.83 (95% CI 0.74 to 0.92), indicat-
ing that the discriminatory power of the model is 
of good fit. Calibration of the model is depicted 
Table 2. 
Model-based screening interval and cases of STR for the total population and stratified by grade of 
retinopathy (EURODIAB) at baseline
Retinopathy grade at baseline
Total population 0 1 2
N 3,319 2,980 (89.8%) 302 (9.1%) 37 (1.1%)
Incidence of STR during a 
mean of 53 months of 
follow-up (%)
76 (2.3) 31 (1.5) 27 (13) 18 (72)
Screening interval (months) 31.0 (20.0) 32.8 (19.8) 15.9 (14.4) 10.9 (10.2)
Screening interval (median  
(interquartile range))
26 (12-53) 29 (15-56) 10 (6-19) 6 (6-11)
Cases of STR missed if the  
model was applieda
9 (0.3) 9 (0.3) 0 0
Data are presented as proportions, means (SD) or median (interquartile range). STR: Sight threatening retinopathy; a STR incidence 
before model-based time of screening.
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Figure 1. 
Observed incidence of sight threatening retinopathy (STR: EURODIAB grade 3 to 5) within quintiles of 
predicted risk of STR according to the model (a) and according to the updated model based on STR 
incidence in the study population (b). 
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less precise due to the relatively low incidence 
of grade 3 to 5 retinopathy (2.3%). Updating the 
model to the observed risk of STR in our popu-
lation improved calibration of the model, but 
did not lead to an increased predictive accuracy. 
Therefore, updating the model before using it in 
populations with a different prevalence of STR is 
not recommended. 
Patients who developed STR during follow-up and 
were missed by the model had significantly lower 
baseline systolic blood pressure levels, which led 
to an underestimation of STR risk. Taking into ac-
count previous trends in risk factors, medication 
use, and more specific information on presence 
of early stages of retinopathy (grade 1 to 2) might 
increase the accuracy of the model in estimating a 
patients risk of STR. 
In the present analyses, the development of STR 
was determined using the follow-up data until the 
first fundus photograph after the model-based 
screening interval. This might have led to a less 
precise estimation of the predictive accuracy of 
the model. However, the time between model-
based time of screening and actual fundus photo-
graph results was restricted to a maximum of one 
year and the patients included had a less favorable 
risk profile compared to patients who were ex-
cluded because they had no fundus photograph 
within one after the model-based time of screen-
ing.
Mainly due to large model-based screening in-
tervals and the dynamic nature of the cohort, a 
considerable number of patients had incomplete 
follow-up. Estimated risk of STR of patients with 
incomplete follow-up was lower compared to pa-
tients with 5 years of follow-up. The predictive ac-
curacy of the model was determined by estimating 
calibration and discrimination of the model while 
censoring patients with incomplete follow-up. Tak-
ing into account patients with incomplete follow-
up, may have led to a more precise estimate of the 
accuracy of the model. 
We validated the model in a mainly Caucasian 
population. Before extrapolation of the results to 
Discussion
This study is the first to validate the model for 
personalized screening of diabetic retinopathy of 
Aspelund et al.17 Compared to the conventional 
annual or biannual screening intervals, use of the 
personalized screening model can attain a sub-
stantial reduction in the number of screenings, 
while safety and efficacy are hardly compromised. 
Furthermore, we showed that the model is of 
good fit and that it overestimates the risk of de-
veloping STR. 
Strengths of the present study include the large 
sample size and its long-term follow-up with 
measurements of T2DM related risk factors and 
complications. Furthermore, fundus photographs 
were graded using the internationally accepted 
EURODIAB classification system,20 which en-
hances generalizability of our results to other 
populations. 
Using the model, a reduction in screening frequen-
cy ranging from 23% to 61% could be achieved, 
compared to biannual or annual screening respec-
tively. This number is comparable to that of Aspe-
lund et al,17 who showed in a Danish population 
used to test the fit of the model, that 59% of the 
screenings could be safely omitted. Other stud-
ies already showed that annual screening intervals 
can be safely prolonged for individuals at low risk 
of developing STR.2,3,10-16 The model of Aspelund 
also integrated a shorter (< 12 months) screening 
interval for patients at high risk of STR, perhaps 
diminishing the time to diagnosis of STR.
We showed that the model overestimates the risk 
of developing retinopathy in the present study co-
hort, which was also true in the Danish cohort 
used to test the fit of the model.17 Overestimation 
of the model may be caused by several reasons. 
First, the present study cohort consists of a well 
treated group of T2DM patients, in whom glucose 
and blood pressure control are very well main-
tained. This may result in less precise estimates of 
the relative contribution of the independent risk 
factors in the model. Second, baseline prevalence 
of grade 1-2 retinopathy in our cohort is lower 
as compared to the cohorts used by Aspelund et 
al.17 Third, estimation of the risk could have been 
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patients of other ethnic origins, the model should 
be validated in these patients.
The current study was performed in a real-life setting 
and the fundus photographs were graded by only 
one grader. Therefore, we have no information on 
inter- and intrarater reliability. The fundus photo-
graphs were graded by an experienced ophthal-
mologist who was trained as a retinal specialist, 
enhancing reliable grading in a real-life setting.23 
Still, some cases of STR might have been misclas-
sified by the grader, due to the possibility of over 
grading background retinopathy as pre-prolifera-
tive retinopathy and due to the enhanced possibil-
ity of missing fine exudates by retinal specialists.24 
Differences in grading protocols may also affect 
the validity of the personalized screening model. 
Therefore, validation before implementing the 
model in populations were other grading proto-
cols are used, is recommendable.
A limitation of personalized screening is that it 
is dependent of the accuracy and punctuality of 
the care system and care professionals. The use 
of personalized screening intervals makes the sys-
tem more prone to errors, for example missing a 
fundus screening. Therefore, it is recommendable 
to make use of a computerized system when ap-
plying the model in clinical care so that reminders 
for screening are automatically generated to en-
sure safe follow-up procedures. 
To conclude, we validated a new model for per-
sonalized diabetic retinopathy screening and dem-
onstrated that a large reduction in screenings for 
retinopathy was achieved in this well-managed 
population with relatively short duration of diabe-
tes and an extremely  low incidence of STR. Fur-
ther improvement of the model might decrease 
the number of missed cases of STR. Use of the 
model for personalized screening may eventually 
help to reduce health care use and costs of dia-
betes care. 
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Chapter 9
General discussion 
From the real world to research
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sponders,” “reduced glycemic control,” and 
“non-responders.” There were 83.1%, 8.2%, 
5.2%, and 3.4% in each subgroup, respectively. 
The good glycemic control subgroup maintained 
HbA1c levels at or around the target through-
out follow-up. Patients within the fast responders 
group experienced a rapid drop in HbA1c in the 
first 2 years of treatment, and then maintained 
adequate glycemic control for the duration of 
follow-up. Patients with reduced glycemic control 
exhibited an initial HbA1c decrease very close to 
target, but the HbA1c subsequently increased fur-
ther away from the target during follow-up, and 
the non-responders failed to achieve glycemic 
control throughout the course of their treatment. 
Higher HbA1c levels; a longer diabetes duration 
and younger age at baseline were associated with 
a more unfavorable course of glycemic control 
over time (Chapter 2).
In terms of treatment, most patients were doing 
well on metformin alone, sulfonylureas, or on both 
of those, with about a quarter of them using or ini-
tiating insulin during follow-up. T2DM patients on 
insulin were typically less controlled as compared 
to patients with good glycemic control on met-
formin and/or sulfonylureas alone.1,2 For clinical 
practice it is important to understand which fac-
tors influence the effectiveness of insulin therapy. 
Therefore we selected patients who initiated insu-
lin and studied the course of HbA1c levels within 
identified subgroups of this specific subset of 
T2DM patients. One of the major findings was that, 
even within centrally organized diabetes care, none 
of the identified subgroups reached stable levels at 
or around the target HbA1c level (≤ 53 mmol/mol) 
after the initiation of insulin. The largest subgroup 
(88.7%) did show a stable course of glycemic con-
trol over time, but HbA1c levels remained elevated 
and the target was not reached in 60.9% of the 
patients (Chapter 3). 
Four subgroups of patients with a distinct SBP 
course over time were identified. While the ma-
jority (85.6%) of patients fell into the “adequate 
SBP control” group and achieved SBP levels at 
or around the SBP target (≤ 140 mmHg), three 
subgroups with inferior SBP control were also 
identified; 5.6% were “delayed responders,” 3.4% 
Main findings and summary of 
results
The research underlying this thesis has been car-
ried out to reach a greater understanding of the 
variation in current glucose and BP goal attain-
ment rates and its association with risk factors on 
diabetic retinopathy and other complications of 
T2DM in a real-world setting. 
T2DM patients are at increased risk for both mi-
cro- and macrovascular complications. However, 
not every T2DM patient has the same risk profile. 
Guidelines do not take individual characteristics 
into account and recommend fixed targets for 
both blood glucose and BP levels. These targets 
are based on outcomes of RCTs, which do not 
always reflect real world clinical practice. Since 
T2DM is a heterogeneous disease, and evidently 
“one size does not fit all” T2DM patients, there 
was a need to look at subgroups with distinct 
trajectories of both blood glucose (Chapter 2 
& 3) and BP control (Chapter 5), to investigate 
if there were any changes over time and to help 
identify patients at high or at low risk of devel-
oping complications. Furthermore, we evaluated 
whether high proinsulin levels could identify pa-
tients at high risk of cancer mortality (Chapter 4) 
and if retinopathy could be a useful risk marker 
to identify patients at high risk of left ventricular 
dysfunction (Chapter 6) or cognitive impairment 
(Chapter 7). Finally, we evaluated whether use of 
a personalized screening model for retinopathy 
could be of help to reduce screening frequency in 
clinical practice(Chapter 8).
Long-term blood glucose and blood 
pressure control in real world T2DM 
patients
Most T2DM patients within our study population 
were well controlled, with 83.1% having stable 
HbA1c levels at or around the target (7%/53 mmol/
mol [Chapter 2]) and 86% showing adequate SBP 
control (at or around 140 mmHg [Chapter 5]), 
both after a mean follow-up of 5.7 years. 
By using Latent Class Growth Modeling, an in-
novative statistical technique, four subgroups 
based on glycemic control were identified 
and labeled; “good glycemic control,” “fast re-
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fore a patient is actually diagnosed with T2DM.3,4 
Retinopathy at the time of diagnosis could be due 
to longstanding periods of mostly symptomless 
hyperglycemia (the “legacy effect” as outlined in 
Chapter 1). Therefore, retinopathy may as well 
contribute to personalized care as it might stratify 
between those patients at risk for other compli-
cations. Consequently, we studied whether retin-
opathy was associated with the development of 
left ventricular (LV) systolic and diastolic dysfunc-
tion after 8 years (Chapter 6) and with cognitive 
dysfunction (Chapter 7). 
We observed that retinopathy was significantly 
associated with an 8% reduced LV ejection frac-
tion in men. However, no significant associations 
between retinopathy and changes in LV function 
in women were found (Chapter 6). Furthermore, 
retinopathy was unrelated to cognitive functioning. 
However, a small subset of patients with severe 
retinopathy had worse cognitive functioning than 
patients without severe retinopathy (Chapter 7). 
Personalized screening for retinopathy in 
the real world 
Many countries have adopted an annual or bian-
nual screening program for retinopathy, which is 
usually integrated within regular diabetes care.5–8 
However, as only a minority of the T2DM patients 
eventually develops sight threatening retinopathy 
(STR) this “one size fits all” approach is costly and 
time consuming. A more personalized screen-
ing frequency, taking into account individual risk 
factors, might be a more appropriate method to 
screen for STR. Therefore, we validated a new 
model for personalized retinopathy screening 
and demonstrated that a reduction in screening 
frequency ranging from 23% to 61% could be 
achieved, compared to biannual or annual screen-
ing, respectively (Chapter 8). 
Methodological considerations
RCT versus Observational Study Design
RCTs count as the golden standard to prove ef-
fectiveness for interventions because the strict 
selection criteria and the randomization proce-
dure minimize the risk that confounding factors 
influence the results.9 Therefore, the outcomes 
of RCTs are considered to be close to the true 
effect. However, patients enrolled in RCT’s are 
were “insufficient responders” and 3.4% were 
“non-responders.” Subgroups with inferior SBP 
control were significantly older, comprised more 
women and used more antihypertensive medica-
tions as compared to the adequate SBP control 
group (Chapter 5). 
Subgroups in the real world at increased 
risk of developing complications
After having identified subgroups of T2DM patients 
with insufficient glycemic and BP control, the ques-
tion remained what the consequences of those 
subgroups within clinical practice were. Were the 
identified subgroups also at increased risk of mi-
crovascular complications and of mortality? 
For glycemic control, we found that both retinop-
athy and microalbuminuria over time were statis-
tically significantly more prevalent in all subgroups 
with insufficient glycemic control as compared to 
the good glycemic control subgroup. The non-re-
sponders subgroup further showed an increasing 
prevalence of microalbuminuria over time, while 
other subgroups either showed a stable or dimin-
ishing prevalence over time (Chapter 2). 
Within the subgroups of patients who initiated in-
sulin, only those with the highest baseline HbA1c 
(>80 mmol/mol) level had a significantly increased 
risk of retinopathy and of microalbuminuria 
(Chapter 3). 
As for BP control, microalbuminuria was signifi-
cantly more present in all other subgroups, com-
pared to the adequate SBP control group. The 
insufficient SBP control and the non-responders 
subgroup showed a significantly increased risk 
of retinopathy over time. Furthermore, patients 
within the insufficient SBP control group had an 
almost twofold risk of cardiovascular mortality 
(Chapter 5). 
Retinopathy as a risk marker to stratify 
patients at risk for other diabetic 
complications 
With the shift from “one size fits all” towards per-
sonalized diabetes care, it is necessary to be able 
to stratify patients at risk of developing irrevers-
ible and progressive complications. Retinopathy 
is an early microvascular complication of T2DM 
and might even be developing 4 to 7 years be-
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lesser extent. Nonetheless, clinical characteristics 
of patients who reached the recommended tar-
gets are comparable to other observational stud-
ies, as were the clinical characteristics of those 
patients that were of increased risk of complica-
tions.11–16 
It is likely that the identified subgroups also exist 
in other T2DM populations, probably with dissimi-
lar proportions across subgroups. Nonetheless, 
our findings need to be confirmed in other long-
term, real world study populations. 
Furthermore, the DCS consists of a mainly Cau-
casian population. Before extrapolation of the 
results to patients of other ethnic origins, they 
should be validated in such patients first. Another 
limitation of the DCS is that the proportion of 
medication use might be an underestimation, since 
information about medication use was obtained 
via self-reporting. However, comparison of the di-
abetes medication with data from the PHARMO 
network, showed an almost complete agreement. 
The PHARMO network is a comprehensive re-
cord linkage system in which drug-dispensing data 
in a regional/national catchment area are linked 
to a registry of hospital discharge diagnoses and 
other registries. Therefore the degree of under-
estimation is probably negligible. Nonetheless, 
information on intensified treatment was lacking, 
hampering the possibility to study whether treat-
ment intensification influenced our results. 
Hoorn Study 
The Hoorn Study is a population-based study on 
the prevalence and determinants of diabetes and 
outcomes. Since study participants were selected 
from the municipal registry, the study population 
is likely to be representative of the general popu-
lation. 
Strengths of the Hoorn Study include the detailed 
recording of vascular and retinal determinants 
and extensive neuropsychological assessment.
In the ageing population of the Hoorn Study, 879 
(35.4%) of the 2484 original participants had died 
in 2009.17 As in the real world, mortality also oc-
curs in an observational cohort study. Therefore, 
dropouts due to mortality does not necessarily 
influence the representativeness of the Hoorn 
study18. Furthermore, selective non-response 
in cohort studies does not influence the direc-
typically not representative for the actual patient 
population within clinical practice. For example, 
RCTs exclude patients with comorbidities as well 
as patients of higher age. Moreover, standardized 
RCT protocols do not reflect usual care, where 
physicians usually make numerous individualized 
treatment decisions according to clinical, psycho-
social, patient preference, and economical factors. 
Observational studies have the potential to pro-
vide more relevant and realistic information on 
the true effectiveness of the guidelines within 
clinical practice. However, using real world obser-
vational data comes along with its own challenges. 
Firstly, because of the observational nature, the 
results from observational studies do not neces-
sarily imply causality and therefore cannot prove 
the mechanisms underlying the observed associa-
tions. Secondly, small sample sizes and measure-
ment errors might influence the precision of the 
reported data. Nonetheless, observational studies 
are necessary to test the validity of RCT out-
comes in the real world. For this PhD thesis, we 
used two specific observational studies; the Dia-
betes Care System (DCS) and the Hoorn Study. 
Within the next paragraphs, methodological con-
siderations for the specific studies are described. 
Diabetes Care System
The DCS consists of a well-controlled group of 
T2DM patients, who were treated according to a 
managed care plan. Starting at diagnosis, patients 
receive an annual extended diabetes assessment 
at the DCS in addition to the diabetes care of-
fered by the patients’ GPs. Patients have a central 
role in their own care and self-management is 
stimulated by providing education and informa-
tion programs. Moreover, individual care plans 
are discussed with the patient and patients are 
encouraged to make their own choices with re-
spect to treatment options and lifestyle behav-
ior.10 The highly protocolized organization of care 
within the DCS may be an important reason why 
the studied patients are so well controlled. Fur-
thermore, probably because of the particularly 
well-controlled population, the incidence of sight 
threatening retinopathy and kidney dysfunction 
was low. Therefore, these results might not be 
generalizable to other clinical populations where 
blood glucose and BP levels are controlled to a 
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The use of Latent Class Growth Modeling as a 
method to define subgroups has some limita-
tions. The first limitation concerns the complex-
ity and flexibility of the model. There are numer-
ous, somewhat arbitrary, choices to make and 
each decision could potentially influence the final 
number of subgroups. Furthermore, the extrac-
tion of the subgroups from the data does not 
prove the existence of multiple subgroups, but is 
a simplification of reality. However, an advantage 
is that categorization is not based on subgroups 
determined a-priori, but on trajectory charac-
teristics derived from the data. Further, LCGM 
is focused on relationships among individuals, and 
makes it possible to categorize them in statisti-
cally homogenous subgroups.20
Interpretation of results and 
comparison with existing 
literature
In this thesis, we showed that the majority of the 
T2DM patients reached adequate glycemic and/
or BP control. However, we also showed that 
there are certain groups that have insufficiently 
controlled blood glucose and/or SBP levels over 
time. Our results complement the results of sev-
eral cross-sectional studies within clinical practice 
showing suboptimal glycemic14–16,21 and BP con-
trol11,22,23 and urge the need to consider long-term 
real world studies within the T2D guidelines.
Yet, how could the results of this thesis be used to 
complement the current guidelines? And, did we 
find proof for the existence of the concepts on 
which the current guidelines are heavily grounded? 
The lower, the better
The adequate SBP control subgroup showed 
stable SBP levels at or around 140 mmHg and 
showed lower rates of microvascular complica-
tions and a decreased cardiovascular mortality 
risk as compared to patients with inferior SBP 
control. These results are in line with the UKPDS 
study in which lowering SBP levels to a mean of 
144 mmHg markedly reduced the incidence of 
micro- and macrovascular complications com-
pared to the group that achieved mean SBP lev-
els of 154 mmHg during follow-up.24 Therefore, 
these results may favor the concept “the lower, 
tion, but does lead to an underestimation of the 
true effect.19 Therefore, the association between 
retinopathy and LV dysfunction and cognitive im-
pairment is probably an underestimation of the 
true effect. Furthermore, the number of patients 
in each follow-up measurement decreased, re-
sulting in small sample sizes and wide confidence 
intervals in the association between retinopathy 
and left ventricular dysfunction (Chapter 6). The 
small study population also hampered the possi-
bility to differentiate between site-specific cancer 
mortality (Chapter 4). 
Statistical methods
Several statistical techniques were used in this 
thesis, all chosen on their specific advantages. 
Thereby we sought to answer the studied re-
search question in an optimal manner. Associa-
tions between determinants and outcomes were 
studied using linear (Chapter 6) and (multivariate) 
logistic regression (Chapter 2, 3 and 5) analyses. 
Associations between determinants and mortal-
ity (Chapter 4 and 5) were studied using Cox 
proportional hazards analyses. Subgroups were 
identified using Latent Class Growth Modeling 
(Chapters 2, 3 and 5). Associations of subgroups 
with long-term microvascular complications were 
analyzed using binomial mixed modeling (Chap-
ter 2, 3 and 5). Lastly, the predictive accuracy of 
the personalized screening model was performed 
using calibration (Poisson regression for survival 
data) and discrimination (Harrell’s C-statistic) 
techniques (Chapter 8).
Many patients in both the DCS as the Hoorn study 
had incomplete follow-up data. In each chapter, we 
dealt with missing data in a different way, accord-
ing to the statistical method used. Latent Class 
Growth Modeling takes censoring into account, 
thereby decreasing the chance that dropouts in-
fluenced the construction of subgroups (Chapter 
2, 3 and 5). Using Cox proportional hazard analy-
sis (Chapter 4 and 5) and Poisson survival analysis 
(Chapter 8), patients with incomplete follow-up 
were taken into account, which may have led to 
more precise estimates of the researched effect. 
Furthermore, in almost all chapters, we compared 
patients with incomplete follow-up with those 
with complete follow-up data, in order to predict 
the influence of selective dropouts. 
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the better.” However, as the adequate SBP con-
trol group had the “best” controlled SBP levels 
and showed a mean SBP of 140 mmHg over time, 
we did not study whether SBP levels were linear-
ly associated with a decreased risk of complica-
tions. Recently, a retrospective cohort study from 
the Kaiser Permanente health system25 showed 
that both higher and lower achieved SBP levels 
compared with 130-139 mmHg were associated 
with an increased risk of mortality in both dia-
betic and non-diabetic patients, thereby validating 
the evidence from the ADVANCE26 and the AC-
CORD27 studies that “lower SBP levels are not 
always better.” 
The earlier, the better
Longer diabetes duration with accompanying high 
levels of glycemia at the start of diabetes treat-
ment was associated with worse glycemic control 
during follow-up and with an increased risk of 
retinopathy and other microvascular complica-
tions (Chapter 2 and 3). In comparison, the fast 
responders subgroup consisting mainly of newly 
diagnosed T2DM patients, showed a fast response 
to diabetic treatment and the prevalence of mi-
crovascular complications immediately decreased 
following tight glycemic control (Chapter 2). These 
findings confirm that strict glycemic control in 
newly diagnosed T2DM patients has a beneficial 
effect on glycemic control risk and developing mi-
crovascular complications. Our results are in line 
with the UKPDS28–30 and favor the concept “The 
earlier, the better”. How periods of hyperglycemia 
impact on the vascular fate of diabetic subjects re-
mains to be elucidated. Mechanisms may include 
hemodynamic anomalies or be more biochemi-
cal in nature. It may be that hyperglycemia alters 
function and perhaps structure of the vascular 
endothelium, and that periods of hyperglycemia af-
fect the genome, leaving an imprint on the future 
of organisms, especially regarding vasculature. 
Personalized care
Which subgroups may be entitled to 
receive, more intensive, personalized 
diabetes care?
Higher HbA1c levels, a longer diabetes duration 
and younger age at baseline were associated with 
a more unfavorable course of glycemic control 
over time in patients entering the DCS (Chapter 
2) and those initiating insulin (Chapter 3). Fur-
thermore, these subgroups showed a higher risk 
of microvascular complications. A recent study31 
showed similar results and observed that the 
greatest risks of microvascular complications oc-
cur in the group with the youngest age at diagno-
sis (<50 years) and with the longest diabetes du-
ration (>10 years). Further, glycemic control was 
less often achieved in the younger age groups.31 
It could be that patients who develop T2DM at a 
younger age have a different, more aggressive phe-
notype than those who develop T2DM at a more 
advanced age, so that worse glycemic control 
and a greater microvascular risk are experienced. 
These results may indicate that younger patients 
need to receive more intensive, diabetes care in 
order to achieve glycemic control and to prevent 
microvascular complications. 
Subgroups with suboptimal SBP control were sig-
nificantly older (mean age 66 years), more likely 
to be female and had higher BP levels at base-
line (Chapter 5). Particularly older T2DM pa-
tients are mainly not included in RCTs and have 
an increased risk of vascular complications and 
death. Older T2DM patients with uncontrolled 
hypertension represent an important subgroup to 
target in order to improve SBP control and to 
minimize the excessive risk of vascular complica-
tions and death. 
Is retinopathy useful as a risk marker for 
other complications?
Retinopathy has been associated with an in-
creased risk of CVD complications.32–34 In our 
study, any retinopathy was associated with a sig-
nificantly reduced LV ejection fraction. Since this 
effect was only observed in men and in one aspect 
of LV dysfunction only, using retinopathy as a risk 
marker for LV dysfunction does not seem useful. 
However, the small sample size and selection that 
occurred most likely led to an underestimation 
of the observed association between retinopathy 
and LV function. Therefore, and considering other 
studies that did show convincing results,32–34 we 
cannot exclude the possibility that retinopathy 
might be a useful risk marker to identify patients 
at risk for CVD complications. 
Retinopathy and cognitive functioning were unre-
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Physicians make treatment decisions that are as 
relevant as possible to the individual patient. In 
doing so, they balance their own skills with the 
treatment of T2DM and supplement this with the 
T2DM guidelines and evidence from scientific re-
search.  Currently, this type of personalized care 
may lead to a large variety of T2DM treatment 
policies, largely depending on a physician’s own ex-
perience with T2DM. Use of personalized screen-
ing models for T2DM and its complications as a 
whole, such as the screening tool for retinopathy, 
will probably decrease treatment variation across 
clinical practices. However, a limitation of person-
alized screening is that it is dependent of the ac-
curacy and punctuality of the care system and care 
professionals, making the system more prone to 
errors. Therefore, computerized medical systems 
that send automatically generated reminders for 
screening might ensure safe follow-up procedures 
whilst using personalized care strategies. 
The increasing number of T2DM patients has driv-
en the development of several sorts of glucose 
lowering medications that may ultimately result in 
increased glycemic control among T2DM patients, 
thereby reducing the risk of developing compli-
cations.40 Because of the numerous availability of 
glucose lowering medications, one of the major 
challenges for clinicians currently is to choose the 
therapy that fits best and has the highest chance 
of achieving glycemic control in a specific patient, 
taking into account individual characteristics. 
However, few studies examined which patients do 
better or worse with specific medications. As a 
result, T2DM patients are currently treated with-
out taking into account individual characteristics 
that might influence the effectiveness of a particu-
lar therapy. Therefore, improved understanding of 
environmental, phenotypic and genotypic aspects 
that may influence the response to glucose lower-
ing medications is important in order to reduce 
the chance of treatment failure.41 Comparative 
effectiveness research (CER) holds a promise to 
identify the best strategies towards personaliza-
tion by reaching a better understanding of the 
question “What works for whom and in what 
context?” In CER, groups of real world patients 
are analyzed to compare the effectiveness of 
for example, glucose lowering medications, with 
the intent to more precisely match the optimal 
lated in our study population. A recent systematic 
review35 showed that any retinopathy was asso-
ciated with cognitive changes with effect sizes 
ranging from -0.25 to 0.03. Although severe retin-
opathy was associated with worse cognitive func-
tioning within our study, these findings show that 
in non-demented patients, retinopathy has limited 
value to be used as a screening tool for deterio-
rating cognitive functioning. 
Can personalized screening reduce 
screening frequency for retinopathy?
Using the personalized screening model for retin-
opathy, a reduction in screening frequency ranging 
from 23% to 61% could be achieved, compared 
to biannual or annual screening respectively. This 
number is comparable to a Danish population 
used to test the fit of the model, where 59% of the 
screenings could be safely omitted.36 Other stud-
ies already showed that annual screening intervals 
could be safely prolonged for individuals at low 
risk of developing STR.5,6,37 Use of a personalized 
screening showed to be safe and also increases the 
likelihood to diminish the time to detect STR, by 
also integrating shorter (< 12 months) screening 
intervals for patients at high risk of STR. If this is 
also the case for ethnic groups with a much higher 
risk of developing diabetes and its complications, 
must still be evaluated. Momentarily, our group 
is validating the personalized screening model in 
small ethnic groups in a secondary care unit.  
Perspectives of Type 2 Diabetes
An increasing number of people is being diag-
nosed with T2DM, with the greatest number of 
patients nowadays aged between 40 years and 59 
years.38 Given the shifting age distribution among 
T2DM patients and the accompanying increase 
in costs of diabetes care, there is a need to re-
form care for T2DM patients. A refocus towards 
intensive management of hyperglycemia at diag-
nosis, particularly in younger people, seems useful 
to minimize the long-term risk of complications. 
On the other hand, patients with consistently 
well-controlled glucose and BP levels might are 
currently over screened by the “one size fits all” 
guidelines. In those patients, lowering of the moni-
toring frequency might be cost-effective while not 
hampering glycemic control.39 
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therapy with the individual patient.42 By doing so, 
more dynamic statistical models might be used, 
such as marginal structural models, which allows 
adjustment for time-dependent confounders. By 
adjusting for time-dependent confounding more 
valid results on the real world effectiveness of 
several treatment strategies for long-term glyce-
mic and BP control in T2DM patients might be 
achieved.43–45
Conclusions
This thesis provides long-term proof for the clini-
cal effectiveness of the current T2DM guidelines. 
Although most patients reached glycemic and/or 
BP control, we also identified subgroups of pa-
tients with insufficient glycemic and/or BP con-
trol over time. For those patients, the current 
guidelines might not provide the best treatment 
strategy and personalized care strategies may be 
required to achieve glycemic and/or BP control 
and thereby prevent complications. 
We showed that younger age groups might need 
to receive more intensive diabetes care in order 
to achieve glycemic control and to prevent mi-
crovascular complications. Personalized screening 
for retinopathy could reduce costs and screening 
frequency by up to 61% whilst still ensuring safety. 
Evidence-based personalized screening schemes 
might be the next step to improve T2DM care in 
the real world. 
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Lange termijn glucose –en 
bloeddrukregulatie in klinische T2DM 
patiënten. 
Het merendeel (83%) van de T2DM patiënten 
in onze studiepopulatie had een goed gecon-
troleerde glucoseregulatie over een gemiddelde 
periode van 5.7 jaar, met stabiele HbA1c waarden 
onder of nabij de streefwaarde (7%/53 mmol/
mol [Hoofdstuk 2]).  De bloeddrukregulatie was 
bij 86% van de patiënten adequaat gecontroleerd 
(bloeddrukwaarden op of onder 140mmHg 
[Hoofdstuk 5]). 
Met behulp van latente klasse analyse, een in-
novatieve statistische methode, hebben we vier 
subgroepen kunnen onderscheiden die ieder een 
verschillende glucoseregulatie over de tijd heb-
ben; een goede glucoseregulatie groep, een snelle 
responders groep, een matige glucoseregulatie 
groep en een non-responders groep, met respec-
tievelijk 83.1%, 8.2%, 5.2% en 3.4% patiënten in 
de verschillende subgroepen. De goede glucos-
eregulatie subgroep had goed gecontroleerde en 
stabiele HbA1c waarden gedurende de gehele fol-
low-up periode. Patiënten in de snelle responders 
groep initieerden zeer hyperglycaemisch, maar 
reageerden goed op glucose verlagende medi-
catie en behaalden de streefwaarde binnen twee 
jaar. Patiënten met een matige glucoseregulatie 
vertoonden in eerste instantie een goede respons 
op glucose verlagende medicatie, dit hield echter 
geen stand en na verloop van tijd verslechterde 
de glucoseregulatie. De non-responders subgroep 
had een suboptimale glucoseregulatie gedurende 
de gehele follow-up periode. Hogere HbA1c 
waarden, een langere diabetesduur en een lagere 
leeftijd bij diagnose waren geassocieerd met een 
minder gunstig verloop van de glucoseregulatie 
(Hoofdstuk 2). 
De meeste patiënten behaalden een goede glu-
coseregulatie bij het gebruik van metformine, 
sulfonylureas of een combinatie van beiden. Een 
kwart van de patiënten startte met het gebruik 
van insuline gedurende follow-up. T2DM patiënt-
Nederlandse samenvatting
Patiënten met type 2 diabetes mellitus (T2DM) 
hebben een verhoogd risico op de ontwikkeling 
van microvasculaire en macrovasculaire com-
plicaties. Echter, niet iedere T2DM patiënt loopt 
hetzelfde risico om bovengenoemde complicaties 
te ontwikkelen. Het risico op de ontwikkeling 
van complicaties is afhankelijk van verscheidene, 
individuele risicofactoren. De huidige richtlijnen 
houden geen rekening met deze individuele risi-
cofactoren en de aanbevelingen voor het aantal 
controles en de te behalen glucose –en bloed-
drukstreefwaarden zijn dan ook voor iedere 
patiënt gelijk. De richtlijnen zijn met name ge-
baseerd op uitkomsten van klinisch gerandomis-
eerde studies (RCT’s). Echter, de patiënten die in 
aanmerking komen voor deelname aan RCT’s re-
flecteren niet altijd de werkelijke T2DM populatie. 
De werkelijke T2DM populatie is ouder en heeft 
meer comorbiditeiten. Het blijkt dan ook dat op 
dit moment meer dan 50% van de T2DM patiënt-
en de glucose -en/of bloeddrukstreefwaarde niet 
behaalt. 
De huidige “one size fits all” richtlijnen passen dus 
niet bij iedere T2DM patiënt. Daarom hebben wij 
onderzocht of er in de klinische T2DM populatie 
subgroepen te onderscheiden zijn met een ver-
schillend verloop in glucoseregulatie (Hoofdstuk 
2 en 3) en bloeddrukregulatie (Hoofdstuk 5) en 
een hiermee gepaard gaand hoger dan wel lager 
risico op de ontwikkeling van complicaties. Daar-
naast hebben we onderzocht of hoge proinsuline 
waarden geassocieerd zijn met een verhoogd 
risico op kankermortaliteit (Hoofdstuk 4) en of 
de aanwezigheid van retinopathie een risicofac-
tor is voor de ontwikkeling van linker ventrikel 
dysfunctie (Hoofdstuk 6) en cognitieve dysfunctie 
(Hoofdstuk 7). Als laatste hebben we een geper-
sonaliseerd screeningsmodel voor retinopathie 
gevalideerd, welke mogelijk kan leiden tot een 
veilige reductie van de screeningsfrequentie voor 
retinopathie. 
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bestaan van deze subgroepen voor de klinische 
praktijk zijn. Is het erg dat verschillende sub-
groepen zijn en hebben deze groepen ook een 
verhoogd risico op microvasculaire complicaties 
en/of overlijden? 
In de subgroepen met een suboptimale glucos-
eregulatie kwamen zowel retinopathie als mi-
croalbuminurie significant vaker voor. De non-
responders subgroep had tevens een stijgende 
prevalentie van microalbuminurie, terwijl de 
prevalentie in de andere subgroepen stabiel bleef 
of zelfs een dalende trend liet zien (Hoofdstuk 
2). Bij patiënten die insuline gingen gebruiken 
gedurende follow-up, hadden patiënten met de 
hoogste HbA1c waarden (>80 mmol/mol) bij aan-
vang een significant verhoogd risico op het krijgen 
van retinopathie en microalbuminurie (Hoofdstuk 
3). In de subgroepen met een suboptimale bloed-
drukregulatie was microalbuminurie tevens sig-
nificant vaker aanwezig. De subgroepen met een 
onvoldoende of geen respons op antihypertensiva 
hadden tevens een verhoogd risico op het krij-
gen van retinopathie. Daarnaast hadden patiënten 
met een onvoldoende respons een bijna tweemaal 
verhoogd risico eerder te overlijden, al dan niet 
ten gevolge van cardiovasculaire aandoeningen 
(Hoofdstuk 5). 
Retinopathie als een risicofactor voor de 
ontwikkeling van andere diabetes gerela-
teerde complicaties 
Met de trend gaande van een ‘one size fits all’ 
zorgmodel richting meer gepersonaliseerde 
zorg is het nodig om T2DM patiënten te kun-
nen stratificeren op hun individuele risico op het 
ontwikkelen van onomkeerbare en progressieve 
complicaties. Retinopathie is een van de eerste 
complicaties die optreedt bij T2DM en kan zelfs 
al vier tot zeven jaar aanwezig zijn voordat een 
patiënt daadwerkelijk gediagnosticeerd wordt 
met T2DM. De aanwezigheid van retinopathie 
op het moment van diagnose zou kunnen komen 
door langere perioden van, meestal symptoom-
vrije, hyperglycaemie (het ‘legacy effect’ zoals be-
en die insuline gebruiken hebben over het alge-
meen een slechtere glucoseregulatie dan patiënt-
en die een goede glucoseregulatie bereiken met 
alleen metformine en/of sulfonylureas, zelfs na 
initiatie van insulinetherapie. Om de effectiviteit 
van insuline op de glucoseregulatie te vergroten, 
is het belangrijk te weten welke factoren van inv-
loed zijn op de effectiviteit van insuline. Om deze 
reden zijn patiënten geselecteerd die insuline gin-
gen gebruiken gedurende de follow-up periode. 
Binnen deze groep hebben we tevens subgroepen 
geïdentificeerd die een verschillend verloop in 
glucoseregulatie hadden na de start van insuline. 
Een van de belangrijkste bevindingen was dat geen 
van de geïdentificeerde subgroepen een goede 
glucoseregulatie wist te bereiken na de initiatie 
van insuline. De grootste subgroep (88.7%) liet 
wel een stabiele glucoseregulatie over de tijd zien, 
echter de HbA1c waarden bleven verhoogd en de 
streefwaarde werd niet bereikt in 60.1% van de 
patiënten (Hoofdstuk 3). 
Vier subgroepen met een verschillende bloed-
drukregulatie zijn geïdentificeerd. Alhoewel de 
grootste subgroep (85.6%) een adequate bloed-
drukregulatie had met bloeddrukwaarden op of 
onder de streefwaarde (≤ 140 mmHg), zijn er 
ook drie subgroepen geïdentificeerd met een 
verslechterde bloeddrukregulatie; 5.6% van de 
patiënten had een verlate respons op antihyper-
tensiva, 3.4% had een onvoldoende respons en 
nog eens 3.4% vertoonde geen respons op an-
tihypertensiva. Subgroepen met een slechtere 
bloeddrukregulatie waren significant ouder, waren 
vaker van het vrouwelijke geslacht en gebruikten 
vaker antihypertensiva in vergelijking met patiënt-
en die een adequate bloeddrukregulatie hadden 
(Hoofdstuk 5). 
Klinische subgroepen met een 
verhoogd risico op de ontwikkeling van 
complicaties 
Nadat subgroepen met een suboptimale glucose 
-en/of bloeddrukregulatie waren geïdentificeerd, 
bleef de vraag wat de consequenties van het 
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Conclusie
Dit proefschrift levert lange-termijn bewijs voor 
de klinische effectiviteit van de huidige T2DM 
richtlijnen in ‘the Real World’. Alhoewel de 
meeste patiënten een goede glucose -en/of bloed-
drukregulatie behaalden, hebben we ook groepen 
geïdentificeerd met een suboptimale glucose –
en/of bloeddrukregulatie. Voor deze patiënten 
verschaffen de huidige richtlijnen mogelijk niet 
de beste behandelingsstrategieën en zou geper-
sonaliseerde zorg ervoor kunnen zorgen dat de 
glucose -en bloeddrukwaarden beter gereguleerd 
worden om zo de ontwikkeling van complicaties 
te verminderen. 
We hebben laten zien dat met name jongere 
patiënten baat zouden kunnen hebben bij meer 
gepersonaliseerde diabetes zorg om zo een ver-
beterde glucoseregulatie te bereiken en, mogelijk, 
te beschermen tegen de ontwikkeling van (mi-
crovasculaire) complicaties. Met behulp van ge-
personaliseerde screening voor retinopathie kan 
het aantal screenings veilig verminderd worden 
tot wel 61%. Evidence-based gepersonaliseerde 
zorgmodellen voor T2DM als geheel kunnen de 
volgende stap zijn om de zorg voor T2DM in ‘the 
Real World’ te verbeteren. 
schreven in Hoofdstuk 1). Omdat hyperglycaemie 
een verhoogd risico geeft op de ontwikkeling van 
diabetes gerelateerde complicaties, zou de aan-
wezigheid van retinopathie op het moment van 
diagnose patiënten met een verhoogd risico op 
andere complicaties kunnen identificeren. Om 
deze reden hebben we onderzocht of de aan-
wezigheid van retinopathie geassocieerd was met 
de ontwikkeling van linker ventrikel systolische en 
diastolische dysfunctie acht jaar later (Hoofdstuk 
6) en met cognitieve dysfunctie (Hoofdstuk 7). 
We vonden dat retinopathie inderdaad geasso-
cieerd was met een 8% verlaagde linker ventrikel 
ejectiefractie in mannen. Echter, we vonden geen 
significante associaties tussen retinopathie en ve-
randeringen in linker ventrikelfunctie in vrouwen 
(Hoofdstuk 6). Ook konden we geen significante 
associatie tussen de aanwezigheid van retinopa-
thie en cognitieve dysfunctie aantonen. Patiënten 
met visus-bedreigende retinopathie hadden wel 
een slechtere cognitieve functie dan patiënten 
zonder visus-bedreigende retinopathie (Hoofd-
stuk 7). 
Gepersonaliseerde screening voor  
retinopathie in de klinische praktijk 
Veel landen hanteren een jaarlijks of tweejaarli-
jks screeningprogramma om te controleren op 
de aanwezigheid van retinopathie, welke over het 
algemeen ingebed is in de reguliere diabeteszorg. 
Slechts een klein deel van de patiënten ontwikkelt 
uiteindelijk visus bedreigende retinopathie. Daar-
om is de ‘one size fits all’ aanpak te duur en tijdrov-
end. Een meer gepersonaliseerd screeningsmodel, 
gebaseerd op individuele risicofactoren, zou een 
meer efficiënte methode kunnen zijn om op de 
aanwezigheid van retinopathie te controleren. 
Om deze reden hebben we een nieuw, geperson-
aliseerd screeningsmodel gevalideerd. We vonden 
dat, bij gebruik van het gepersonaliseerde model, 
een reductie in het aantal screenings kan worden 
behaald variërend van 23% tot 61%, wanneer re-
spectievelijk wordt vergeleken met jaarlijkse of 
tweejaarlijkse screening (Hoofdstuk 8). 
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leren kennen tijdens ons congresbezoek in Padua 
en uitstapje naar Venetië, wat heel gezellig was! 
Daarnaast was u altijd bereid om af te spreken 
of richting het VUmc te komen, ondanks de lange 
reistijd, waarvoor veel dank. Door de vele plan-
ningen die ik heb moeten maken, zorgde u voor 
de nodige stok achter de deur. 
Jacqueline, dank voor de kans die je me hebt 
geboden om dit promotieonderzoek te mogen 
doen. Ondanks je drukke schema deed je je uit-
erste best om mij zo goed mogelijk te helpen. 
Hopelijk vind je je passie in het dermatologie vak 
en kun je met de combinatie diabetes en derma-
tologie een nieuw onderzoeksveld aanboren!
Esther, als eerste promovendus heb ik het je 
niet bepaald makkelijk gemaakt, sorry….! Ik heb 
veel gehad aan je nuchterheid en open houding. 
Jouw ogen leken soms door me heen te kijken, 1 
blik was voor jou al voldoende om te zien hoe het 
ervoor stond. Bedankt voor al je hulp. Ik ben blij 
dat je helemaal op je plek zit in Deventer en dat 
het goed met je gaat! 
Annette, door jou heb ik diabetische retinopa-
thie in the Real World gezien. Ik heb ontzettend 
veel geleerd en genoten van de meeloopoch-
tenden op de poli Oogheelkunde, waarvoor heel 
veel dank. Je bereidheid en enthousiasme om 
alles uit te leggen zijn zeer speciaal. Bedankt dat 
je plaats wilde nemen in mijn promotiecommissie!
Petra, een huisarts pur sang met een echte 
onderzoeksgeest! Patiënten die bij jou in de prak-
tijk komen, mogen in hun handjes knijpen. Jouw 
invalshoek was altijd net even anders, wat voor 
goede discussies heeft gezorgd. Ik waardeer het 
enorm dat je plaats wilt in de promotiecommissie.
De leden van de leescommissie; profes-
sor Romijn, professor Tack, professor 
Keunen, professor Tan, professor Moll 
en dr Elders, hartelijk dank voor de bereidheid 
dit proefschrift te lezen en beoordelen. 
Dankwoord
Hier zit ik dan, te broeden op het dankwoord. Het 
meest gelezen onderdeel van het proefschrift maar 
toch ook het stuk waar je op het laatste tegenaan 
zit te hikken want ‘ohja, het dankwoord moet ook 
nog….’. Al meerdere malen heb ik het document 
geopend om het een paar uur later weer te slu-
iten zonder een letter getypt te hebben. Want, 
hoe breng je onder woorden wat je in vier jaar 
tijd hebt geleerd? En, waar wil ik wie precies voor 
bedanken? Hierbij een poging van mijn kant!
Allereerst wil ik het internet bedanken. Hotmail, 
Facebook, Google, de achterklap sectie van nu.nl, 
vakantie aanbiedingen, als ik een (niet zeldzame) 
inspiratieloze dag had boden jullie ware afleiding. 
Door mijn enorm gestegen kennis van celebrities, 
heb ik eindelijk ook een bijdrage kunnen leveren 
aan pubquizzen! 
Alle deelnemers van de Hoorn Studie en de 
patiënten van het Diabetes Zorg Systeem 
West-Friesland, zonder jullie deelname aan 
het onderzoek was het niet mogelijk geweest dit 
proefschrift te schrijven. 
Uiteraard wil ik mijn promotoren bedanken 
voor de kansen en alle hulp die ik heb gekregen 
tijdens mijn onderzoek.  
Giel, we zijn een ‘promotiehuwelijk’ aangegaan en 
zonder ons huwelijk zou dit proefschrift er nooit 
zijn gekomen, dat weet jij ook. Jouw enthousiasme 
en manier van motiveren hebben me heel erg 
geholpen en daar ben ik je ontzettend dankbaar 
voor. Door jou heb ik veel geleerd, vooral over 
mezelf. Daarnaast heb ik genoten van onze brain-
stormsessies waarbij je vaak even ging lopen om 
na te denken en ik op de gang allerlei onbestemde 
kreten hoorde. Nu komt er een einde aan dit hu-
welijk maar we gaan als goede vrienden uit elkaar 
en ik hoop in de toekomst nog eens met je te kun-
nen samenwerken! 
Professor Polak, dank voor al uw hulp om 
mijn promotieonderzoek te laten slagen. Ik be-
wonder uw inzet voor het onderzoek en de zorg 
rondom diabetische retinopathie. Ik heb u beter 
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Ruth, naast onze gezamenlijke promotiefrustra-
ties was het met name heel gezellig. Als een van 
de weinigen op de VU deel je mijn niet aflatende 
interesse in kleding, zorg jij ervoor dat de diabe-
tesgroep er een beetje hip blijft uitzien? We heb-
ben veel samengewerkt, wat in een aantal mooie 
artikelen en publicaties heeft geleid! Eigenlijk kun-
nen we wel elkaars copromotor zijn ;).
Simone, met jou erbij was ons ‘hok’ compleet. 
Ik zal de “enter enter backspace type yes space 
space” uitspraken missen! Je bent heel eerlijk en 
oprecht en dat is echt een kwaliteit van je. 
Eva Stokx, het was altijd een welkome afleiding 
wanneer je weer eens een praatje kwam maken. 
Inmiddels ken ik alle ins en outs van je familie en 
welke gekke avonturen je nu weer mee hebt ge-
maakt! Bedankt ook dat je hebt gezocht naar een 
suède jas voor me! 
Jet en Janneke, zonder jullie geen proefschrift! 
Super bedankt voor jullie hulp bij het ontwerpen 
van de cover en layout, het ziet er echt super tof 
uit!
Op de VU had ik ook nog een aantal neventaken. 
Zo dank ik mijn mede bestuursleden van ProVU, 
Willem van Willigen, Laurens Robbers, 
Suzanne Roth en Caroline Kampshoff 
voor de leuke tijd en de lange doch interessante 
vergaderavonden, sciencequizzen en borrels. Met 
name Caroline wil ik bedanken, ik heb altijd 
zeer genoten van onze koffiemeetings. Ook de 
PakEmgo collega’s bedankt voor de leuke tijd, 
mede door jullie heb ik geleerd dat mijn expertise 
vooral ligt bij het maken van rebussen…. 
Naast mijn promotie op de VU heb ik er meerdere 
‘baantjes’ bij gehad. Wendy, Anouk, Jantine 
en Anne, leuk dat we de borrelavondjes erin 
houden, altijd gezellig en ook smeuïg om de laatste 
roddels weer te horen! Anne, een betere gast-
mama in spe kan ik me niet wensen!
Alle coauteurs van de verschillende artikelen, 
hartelijk dank voor de snelle, kritische en motiver-
ende commentaren. 
Collega’s van de afdeling Oogheelkunde. 
Als ‘buitenpromovendus’ van de afdeling voelde ik 
me toch altijd welkom en onderdeel van de afde-
ling, dank ook voor jullie interesse in mijn onder-
zoek. Hilde, wij gingen ongeveer gelijk op, heel fijn 
om promotiefrustraties met je te kunnen delen. 
Hata, mijn retinopathie voorgangster van de dia-
betesgroep. Je hebt het me wel moeilijk gemaakt; 
dacht ik weer met een origineel idee te komen, 
was het antwoord ‘nee, dat heeft Hata al gedaan’. 
Maar ik heb mooi kunnen voortborduren op jouw 
werk en daarnaast kon ik altijd met vragen bij je 
terecht! Nanja, de afdeling Oogheelkunde is niet 
compleet zonder jou. Altijd gezellig om even bij 
je te komen kletsen wanneer ik weer eens lang-
skwam op de afdeling. Bedankt ook voor je luis-
terend oor. Annie, ook bij jou kon ik altijd even 
komen kletsen. Na een gezellig gesprekje met jou, 
over de laatste nieuwtjes of kookflaters, was de 
dag een stuk zonniger!
Alle medeonderzoekers van de Diabe-
tesgroep. Dank voor jullie waardevolle input en 
gezellige avonden tijdens congressen. Danielle, 
dank dat je mee hebt willen denken met een aantal 
artikelen. Je bent niet alleen een hele goede onder-
zoekster, je bent ook erg betrokken wat ik erg in 
je waardeer. Trynke, het clusteren was niet al-
leen voor mijn promotie heel goed maar de lange 
rekentijd die de computer nodig had maakte het 
ook heel gezellig!
Mijn kamergenootjes op de VU; Katja, jij zorgde 
er voor dat ik me direct thuis voelde in ons ‘hok’ 
op de VU! Ook al had je het heel druk met het 
einde van je promotie, het was altijd super gezellig. 
Gelukkig zijn we nu weer buren, dus kunnen we de 
kletsuurtjes voortzetten! Ohja, sorry dat ik Noes 
bijna heb vermoord …. 
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vriend, ook van mij en straks ben je natuurlijk onze 
ideale oppas! Marieke, al sinds het begin van 
mijn promotie zit ik bij je op naailes, helaas ben 
ik nog steeds geen steek verder en moet je me 
nog steeds alles uitleggen! Gelukkig is het wel altijd 
zeer gezellig! 
Lieve Schoonfamilie, bedankt dat jullie me zo 
open en hartelijk hebben opgenomen, altijd leuk 
om richting Twente/Wijchen te komen! Nu ik het 
minder druk heb, zullen we dat ook zeker proberen 
vaker te doen! Jan en Annelies,  jullie gastvrij-
heid is onovertroffen! Mijke en Robbert, heel 
handig dat we het komende ouderschap al bij jullie 
hebben kunnen afkijken, jullie zijn topouders!
Lieve Papa en Mama, bedankt voor jullie on-
voorwaardelijke liefde en steun, die werkelijk heel 
bijzonder is. Het is zo fijn om te weten dat wat ik 
ook doe, jullie altijd achter me zullen staan! Door 
jullie heb ik geleerd mijn eigen keuzes te maken en 
me niet te laten leiden door wat anderen vinden, 
en daar ben ik trots op! En nu ik geen proefschrift 
meer heb om te schrijven staat het boek ‘mijn 
ouders, de hippies’ op de planning! Lieve Merel, 
als jongere zus heb ik het makkelijk. Ik hoef eigen-
lijk alleen maar jouw voorbeeld te volgen en dan 
komt het allemaal goed! Dus dat doe ik dan ook 
maar; jij promoveren, ik promoveren, jij een kind, 
ik een kind. ;-) Ik ben trots op de sterke band die 
we hebben en ben blij dat je tijdens mijn promo-
tie naast me staat! Joep, je bent een aanwinst 
voor onze familie! Eigenlijk lijken we best wel op 
elkaar en mede daarom voel je voor mij al lang 
niet meer als schoonbroer maar ben je een echte 
broer. Melliebellie, jij bent de liefste en meest 
oprechte persoon die ik ken! Ik kan me geen beter 
broertje wensen, ook al had jij misschien wel liever 
een andere zus gewild als ik je weer eens een jurk 
aantrok of staartjes in je haar maakte. Ik ben er 
trots op hoe zelfstandig je bent geworden en zie 
je nog iedere keer groeien! Lieve Oma, wat een 
sterke en onafhankelijke vrouw ben je! Ik vind het 
heel knap hoe je alles nog steeds zelfstandig doet 
en organiseert. Ik ben blij dat we al zo lang van je 
HIN –en GHOR-collega’s, een andere tak 
van sport maar ook erg leuk! Mede dankzij jul-
lie weet ik nu meer over de rampenbestrijding en 
(denk ik te weten) wat ik moet doen tijdens een 
ramp! Ook heb ik veel geleerd van de vele scrip-
tiebeoordelingen op de Fontys Hogeschool, 
altijd leuk om alle docenten weer te spreken en de 
bijzonder goede sfeer te proeven. 
AvL collega’s, wat een warm bad om weer 
op de afdeling Radiotherapie werkzaam te zijn! 
Jullie enthousiasme over mijn terugkomst maakt 
dat ik me zeer welkom voel. Jose, bedankt dat 
je mij deze kans hebt gegeven. Margriet, je bent 
niet alleen een goede vriendin maar ook een heel 
goede collega! Sinds onze eerste ontmoeting kun-
nen we het goed met elkaar vinden en hebben we 
zeer memorabele stapavonden, uitjes naar Parijs 
en vakanties meegemaakt. Door jou heb ik de kans 
gekregen om weer in het AvL te kunnen werken 
en daar ben ik je zeer dankbaar voor. Jij gaat echt 
voor mensen door het vuur en dat is een eigensc-
hap die weinig mensen bezitten. 
Ronald Damhuis, ik heb erg veel aan onze 
samenwerking! Hopelijk voldoet de resolutie van 
dit proefschrift ook aan jouw wensen…
Lieve vrienden, dank voor de oh zo nodige af-
leiding, gezellige etentjes, uitstapjes, reizen, borrels 
en ook jullie begrip wanneer ik weer eens niet 
kon, moe was of het om een andere reden liet 
afweten! Annikki, Margriet, Lilian en Ma-
rielle, de oude Afrika gang! Onze etentjes, die 
steevast eindigen in verhalen over in broeken en 
slaapzakken poepen, zijn altijd erg gezellig! Indra 
en Marlies, mijn oudste vriendinnen, fijn dat de 
band nog altijd overeind blijft. Mede door jullie 
voelt Vlissingen nog altijd als thuiskomen. Marjet 
en Joep, badders, blij om jullie nog steeds zo nu 
en dan te zien en te horen hoe het jullie nu vergaat 
maar ook oude herinneringen op te halen aan ‘die 
zwangere’ ed! Simone, nog nooit heb ik zo lang 
met iemand samengewoond, knap dat je mij zo 
lang hebt verdragen! Nu geen huisgenootjes meer 
maar nog steeds vriendinnen! Arend, onze beste 
huisgenoot! Niet alleen van Bart ben je een goede 
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mogen genieten, van het vroeger bij oma logeren, 
kroketjes eten met Ome Wout tot persoonlijke 
gesprekken nu, en ik hoop dat nog heel lang te 
kunnen doen.
Lieve Bart, jij bent mijn man en ik ben ontzet-
tend gek op je! Als partner in crime heb jij nog wel 
het meeste gezeur moeten aanhoren over de ups 
en downs van het schrijven van een proefschrift. 
Jouw rust en relaxte instelling zorgden ervoor dat 
ik  het allemaal wat beter kon en kan relativeren. 
Met jou naast me voel ik me sterk en ik ben dan 
ook heel blij dat je ook tijdens mijn promotie naast 
me staat. Ik geniet van het leven samen met jou 
en ik weet zeker dat je een straks een super lieve 
papa zal zijn!
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